US007943551B2

(12) **United States Patent**
Ahrens et al.

(10) **Patent No.: US 7,943,551 B2**
(45) **Date of Patent: May 17, 2011**

(54) **3-CYCLOPROPYL-4-(3-THIOBENZOYL) PYRAZOLES AND THEIR USE AS HERBICIDES**

(75) Inventors: **Hartmut Ahrens**, Egelsbach (DE); **Andreas van Almsick**, Karben (DE); **Stefan Lehr**, Liederbach (DE); **Monika Schmitt**, Frankfurt a. M. (DE); **Jan Dittgen**, Frankfurt a. M. (DE); **Dieter Feucht**, Eschborn (DE); **Martin Hills**, Idstein (DE); **Heinz Kehne**, Hofheim (DE); **Christopher Rosinger**, Hofheim (DE)

(73) Assignee: **Bayer Cropscience AG**, Monheim (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 383 days.

(21) Appl. No.: **12/135,602**

(22) Filed: **Jun. 9, 2008**

(65) **Prior Publication Data**

US 2008/0305956 A1 Dec. 11, 2008

(30) **Foreign Application Priority Data**

Jun. 11, 2007 (DE) 10 2007 026 875

(51) **Int. Cl.**

A01N 43/56	(2006.01)
C07D 231/20	(2006.01)
C07C 317/14	(2006.01)

(52) **U.S. Cl.** **504/282**; 548/369.4; 568/37

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,013,659	A	5/1991	Bedbrook et al.	
7,396,939	B2 *	7/2008	Schmitt et al.	548/369.4
2009/0069184	A1 *	3/2009	Ahrens et al.	504/282

FOREIGN PATENT DOCUMENTS

DE	25 13 750		10/1975
DE	100 39 723		7/2001
EP	0 142 924		5/1985
EP	0 186 117		7/1986
EP	0 193 259		9/1986
EP	0 221 044		5/1987
EP	0 240 001		10/1987
EP	0 242 236		10/1987
EP	0 242 246		10/1987
EP	0 257 993		3/1988
EP	0 527 036		2/1993
EP	0580439	A1	1/1994
EP	0 352 543		9/1994
GB	1447032	A	8/1976
WO	WO 84/02919		8/1984
WO	WO 91/13972		9/1991
WO	WO 91/19806		12/1991
WO	WO 92/00377		1/1992
WO	WO 92/11376		7/1992
WO	WO 92/14827		9/1992
WO	94/02465	A1	2/1994
WO	94/18179	A1	8/1994
WO	WO 97/41106		11/1997
WO	WO 98/42648		10/1998
WO	WO 98/42678		10/1998
WO	WO 00/03993		1/2000
WO	WO 03/014071		2/2003

OTHER PUBLICATIONS

International Search Report for PCT/EP2008/004262, mailed Jun. 5, 2009.

Isogai, A. et al., "New 3-cyclopropyl-4-carbonyl-5-hydroxypyrazole Derivatives Are Herbicides Useful for Wheat, Corn or Paddy Fields," Database WPI / Thompson, doc. No. XP-002500085.

Master, H.E. et al., "Preparation of 4'-amino-3-carboxy-6-methoxydiphenyl Sulfide and Its Derivatives," Journal of the Indian Chemical Society, 1978, Database CA, doc. No. XP-002500081.

Goghari, M.H. et al., "Fries Reaction. XV. Preparation of Hydroxydiaryl Sulfones," University Dep. Chem., Bhavnagar, India, Database CA, doc. No. XP-002500082.

Patwa, B.S. et al., "Fries Reaction—Part XI, Preparation of Hydroxydiarysulphones," J. Inst. Chemists (India), vol. VLVI, Jul. 1974, doc. No. XP-000600341, pp. 140-142.

Database Registry, Chemical Library, Mar. 7, 2001, doc. No. XP-002500083.

Database Registry, Chemical Library, Mar. 5, 2001, doc. No. XP-002500084.

Database Registry, Chemical Library, May 12, 2002, doc. No. XP-002524369.

Braun, H., et al. "The general mitochondrial processing peptidase from potato is an integral part of cytochrome c reductase of the respiratory chain." EMBO Journal. vol. 11 No. 9. pp. 3219-3227. 1992. Browning, JE. "Agglomeration:Growing Larger in Applications and Technologies." Chemical Engineering, 1967, p. 147-170.

Christou, P. "Transformation technology," Trends in Plant Science, Dec. 1996, vol. 1, No. 12, pp. 423-431.

Jensen, BS. "The synthesis of 1-Phenyl-3-methyl-4-acyl-pyrazolones-5." Acta Chem. Scan. 13 (1959) No. 8, pp. 1668-1670.

Siddall, T. et. al. "Synthesis and herbicidal activity of phenyl-substituted benzoylpyrazoles." Pest Management Science (2002),58(12):1175-1186.

Sonnewald, U. et al. "Transgenic tobacco plants expressing yeast-derived invertase in either the cytosol, vacuole, or apoplast: a powerful tool for studying sucrose metabolism and sink/source interactions." The Plant Journal (1991), 1 (1), p. 95-106.

Freyer, JD et. al. "Weed Control Handbook," 5th edition, Blackwell Scientific Publications, Oxfor, 1968, p. 101-103.

Klingman, GC. "Weed Control as a Science," John Wiley and Sonce, New York, 1961, pp. 81-96.

Wolter, F. "rbcS genes in *Solanum tuberosum*: Conservation of transit peptide and exon shuffling during evolution," PNAS, vol. 85, pp. 846-850, Feb. 1988.

Weed Research, 1986, vol. 26, pp. 441-445.

* cited by examiner

Primary Examiner — Kamal A Saeed

(74) *Attorney, Agent, or Firm* — Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

(57) **ABSTRACT**

What is described are 3-cyclopropyl-4-(3-thiobenzoyl)pyrazoles of the general formula (I) and their use as herbicides

(I)



In this formula (I), R^1, R^2, R^3, X and Y are radicals such as hydrogen and organic radicals, such as alkyl. R^4 is hydrogen or a protective group, such as tosyl.

9 Claims, No Drawings

3-CYCLOPROPYL-4-(3-THIOBENZOYL) PYRAZOLES AND THEIR USE AS HERBICIDES

CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from DE 10 2007 026 875.2 filed Jun. 11, 2007, the content of which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to the technical field of the herbicides, in particular that of the herbicides for the selective control of broad-leaved weeds and weed grasses in crops of useful plants.

2. Description of Related Art

From various publications, it is already known that certain 4-benzoylpyrazoles have herbicidal properties. Thus, EP 0 352 543 A1 mentions 4-benzoylpyrazoles which may be substituted in the phenyl ring, inter alia by a thio radical. WO 97/41106 and WO 00/03993 mention 3-cyclopropyl-4-benzoylpyrazoles which may be substituted in the phenyl ring, inter alia by a thio radical. The publications mentioned above do not disclose any embodiments of a substitution of the phenyl ring in the meta-position by a thio radical.

However, the herbicidal activity of the compounds known from these publications is frequently insufficient. It is therefore an object of the present invention to provide herbicidally active compounds having herbicidal properties which are better than those of the compounds disclosed in the prior art.

SUMMARY OF THE INVENTION

It has now been found that certain 4-benzoylpyrazoles which are substituted in the 3-position by a cyclopropyl group and whose phenyl ring carries a substituted sulfenyl, sulfynyl or sulfonyl group in the 3-position are particularly suitable for use as herbicides. Part of the subject matter of the present invention are 3-cyclopropyl-4-(3-thiobenzoyl)pyrazoles of the formula (I) or salts thereof



(I)

in which

R^1 is $(C_1$-$C_4)$-alkyl,

R^2 is halogen or $(C_1$-$C_4)$-alkyl,

R^3 is $(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkyl-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-C_6-alkynyl, $(C_1$-$C_6)$-haloalkyl, $(C_3$-$C_8)$-halocycloalkyl-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkenyl, $(C_2$-$C_6)$-haloalkynyl, $(C_2$-$C_6)$-nitroalkyl, phenyl, $(C_3$-$C_8)$-cycloalkoxy-$(C_1$-$C_9)$-alkyl, $(C_3$-$C_8)$-cycloalkyl-$(C_1$-$C_9)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_1$-$C_6)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkenyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkynyloxy-$(C_1$-$C_9)$-alkyl, $(C_1$-$C_6)$-haloalkoxy-$(C_1$-$C_9)$-alkyl, $(C_3$-$C_8)$-halocycloalkyl-$(C_1$-$C_9)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkenyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkynyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-nitroalkoxy-$(C_1$-$C_9)$-alkyl, phenyloxy-$(C_1$-$C_9)$-alkyl, where the phenyl group may in each case be substituted by m identical or different radicals from the group consisting of $(C_1$-$C_3)$-alkyl, halogen, nitro, $(C_1$-$C_3)$-alkoxy,

R^4 is hydrogen, $(C_1$-$C_6)$-alkylsulfonyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_6)$-alkylsulfonyl, or is phenylsulfonyl, thien-2-ylsulfonyl, benzoyl, (ethylthio)carbonyl, benzoyl-$(C_1$-$C_6)$-alkyl or benzyl, each of which is substituted by m identical or different radicals from the group consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkoxy,

X and Y independently of one another are hydrogen, mercapto, nitro, halogen, cyano, thiocyanato, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-haloalkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-haloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_6)$-haloalkynyl, $(C_3$-$C_6)$-cycloalkyl, OR^5, methylsulfonylethoxymethyl, methylsulfonylethylsulfonylmethyl, methoxyethylsulfonylmethyl, $OCOR^5$, OSO_2R^5, $S(O)_nR^5$, SO_2OR^5, $SO_2N(R^5)_2$, $(C_1$-$C_3)$-alkoxy-$(C_1$-$C_3)$-alkoxy-$(C_1$-$C_3)$-alkyl, $NR^5SO_2R^5$, NR^5COR^5, $(C_1$-$C_6)$-alkyl-$S(O)_nR^5$, $(C_1$-$C_6)$-alkyl-OR^5, $(C_1$-$C_6)$-alkyl-$OCOR^5$, $(C_1$-$C_6)$-alkyl-OSO_2R^5, $(C_1$-$C_6)$-alkyl-SO_2OR^5, $(C_1$-$C_6)$-alkyl-$SO_2N(R^5)_2$ or $(C_1$-$C_6)$-alkyl-NR^5COR^5;

R^5 is hydrogen, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_6)$-cycloalkyl, phenyl or phenyl-$(C_1$-$C_6)$-alkyl, where the six last mentioned radicals are substituted by s radicals from the group consisting of hydroxyl, mercapto, amino, cyano, nitro, thiocyanato, OR^6, SR^6, $N(R^6)_2$, NOR^6, $OCOR^6$, $SCOR^6$, NR^6COR^6, CO_2R^6, $COSR^6$, $CON(R^6)_2$, $(C_1$-$C_4)$-alkyliminooxy, $(C_1$-$C_4)$-alkoxyamino, $(C_1$-$C_4)$-alkylcarbonyl, $(C_1$-$C_4)$-alkoxy-$(C_2$-$C_6)$-alkoxycarbonyl and $(C_1$-$C_4)$-alkylsulfonyl;

R^6 is hydrogen, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl or $(C_2$-$C_6)$-alkynyl,

m is 0, 1, 2, 3, 4 or 5,

n is 0, 1 or 2,

q is 0, 1, 2, 3, 4 or 5,

s is 0, 1, 2 or 3,

with the proviso that R^3 is not $(C_1$-$C_6)$-haloalkyl if n is 0.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

Where R^4 is hydrogen, the compounds of the formula (I) according to the invention, depending on external conditions, such as solvent and pH, may occur in different tautomeric structures:



-continued







Depending on the nature of the substituents, the compounds of the general formula (I) contain an acidic proton which may be removed by reaction with a base. Suitable bases are, for example, hydrides, hydroxides and carbonates of lithium, sodium, potassium, magnesium and calcium, and also ammonia and organic amines, such as triethylamine and pyridine. It is also possible to form salts by forming adducts with organic acids, such as formic acid or acetic acid, and inorganic acids, such as phosphoric acid, hydrochloric acid or sulfuric acid. Such salts also form part of the subject matter of the invention.

In formula (I) and all subsequent formulae, alkyl radicals with more than two carbon atoms can be straight-chain or branched. Alkyl radicals are, for example, methyl, ethyl, n- or i-propyl, n-, i-, t- or 2-butyl, pentyls, hexyls, such as n-hexyl, i-hexyl and 1,3-dimethylbutyl. Halogen is fluorine, chlorine, bromine or iodine. Tosyl is 4-methylphenylsulfonyl.

If a group is polysubstituted by radicals, this is to be understood as meaning that this group is substituted by one or more identical or different of the radicals mentioned.

Depending on the type and the linkage of the substituents, the compounds of the general formula (I) can exist as stereoisomers. If, for example, one or more asymmetric carbon atoms are present, enantiomers and diastereomers may occur. Stereoisomers may also occur when n is 1. Stereoisomers can be obtained from the mixtures resulting from the preparation by means of customary separation methods, for example by chromatographic separation methods. Likewise, stereoisomers may be prepared selectively by using stereoselective reactions employing optically active starting materials and/or auxiliaries. The invention also relates to all stereoisomers and their mixtures which are encompassed by the general formula (I), but not defined specifically.

Preference is given to compounds of the general formula (I) in which:

R^1 is $(C_1$-$C_4)$-alkyl,

R^2 is halogen, methyl or ethyl,

R^3 is cyclopropyl, cyclopropylmethyl, cyclopropylmethoxyethyl, methoxyethyl, methoxypropyl, ethoxyethyl,

R^4 is hydrogen, n-propylsulfonyl, phenylsulfonyl, methoxyethylsulfonyl, benzoylmethyl, benzoyl, 4-methylbenzoylmethyl, (ethylthio)carbonyl, 4-methylphenylsulfonyl, thien-2-ylsulfonyl,

X is nitro, halogen, $(C_1$-$C_4)$-alkyl, trifluoromethyl, $(C_1$-$C_4)$-alkoxy, methylsulfonyl, methoxymethyl, methoxymethoxymethyl, ethoxyethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, methoxypropoxymethyl, methylsulfonylmethyl, methylsulfonylethoxymethyl, methoxyethylsulfonylmethyl, methylsulfonylethylsulfonylmethyl,

Y is halogen, trifluoromethyl, $(C_1$-$C_4)$-alkoxy, methylsulfonyl or ethylsulfonyl,

n is 0, 1 or 2,

q is 0, 1 or 2.

Particular preference is given to compounds of the general formula (I) in which

R^1 is methyl or ethyl,

R^3 is cyclopropyl, cyclopropylmethyl, cyclopropylmethoxyethyl, methoxyethyl, methoxypropyl, ethoxyethyl,

R^4 is hydrogen, n-propylsulfonyl, phenylsulfonyl, methoxyethylsulfonyl, benzoylmethyl, benzoyl, 4-methylbenzoylmethyl, (ethylthio)carbonyl, 4-methylphenylsulfonyl, thien-2-ylsulfonyl,

X is nitro, bromine, chlorine, fluorine, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methylsulfonyl, methoxymethyl, methoxymethoxymethyl, ethoxyethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, methoxypropoxymethyl, methylsulfonylmethyl, methylsulfonylethoxymethyl, methoxyethylsulfonylmethyl, methylsulfonylethylsulfonylmethyl,

Y is bromine, chlorine, fluorine, trifluoromethyl, methoxy, methylsulfonyl or ethylsulfonyl,

n is 0, 1 or 2,

q is 0.

In all the formulae given below, the substituents and symbols have the same meaning as described under formula (I), unless defined otherwise.

Compounds according to the invention in which R^4 is hydrogen can be prepared, for example, by the process shown in scheme 1 and known from B. S. Jensen (Acta Chemica Scandinavica 13 (1959), 1668-1670) by base-catalyzed reaction of a benzoyl halide (III) with a pyrazolone (II), or by the process shown in scheme 2 and known, for example, from EP-A 0 186 117 by base-catalyzed reaction of a benzoyl halide (III) with a pyrazolone (II) and subsequent rearrangement.

Scheme 1



(II)



(III)



(I*)

Scheme 3



(I*) (V)



(I)

Compounds according to the invention can also be prepared according to the process shown in scheme 4 and known from WO 98/42678 by reacting a pyrazolone(II) with a halobenzoyl chloride (IIIa), subsequent nucleophilic aromatic substitution with a thio compound HS—R^3 and, if

Scheme 2



(II) (III) (IV)



(I*)

According to scheme 3, compounds according to the invention in which R^4 has a meaning different from hydrogen are expediently prepared from the compounds obtainable according to scheme 1 or 2, by base-catalyzed reaction with a suitable acylating agent R^4—Z of formula (V) in which Z is a leaving group, such as halogen. Such methods are known in principle to the person skilled in the art and described, for example, in DE-A 25 13 750.

appropriate, oxidation of the thio group. Here, L is, for example, chlorine, bromine, iodine or trifluoromethylsulfonyl. Such substitution reactions are known to the person skilled in the art and described, for example, in Houben-Weyl, Methoden der Organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag Stuttgart, Vol. E 11, additional and supplementary volumes to the fourth edition 1985, p. 174 et seq.

Scheme 4



The compounds of the formula (III) mentioned above can be prepared, for example, from the corresponding benzoic acids of the formula (IIIb) by reaction with acid chlorides, such as thionyl chloride, according to methods known to the person skilled in the art.



(IIIb)

Compounds of the formula (IIIb) can be prepared, for example, according to scheme 6: to this end, in a first step, the 3-amino derivative of the formula (IIIc) is diazotized and then converted with potassium ethyl xanthogenate and subsequent hydrolysis into a 3-thio derivative of the formula (IIId). Such reactions are described, for example, in Houben-Weyl, Methoden der Organischen Chemie, Georg Thieme Verlag Stuttgart, Vol. E 9, fourth edition 1955, p. 12 et seq.

In a second step, the 3-thio derivatives of the formula (IIId) can be alkylated with alkylating agents by nucleophilic substitution on a saturated carbon atom or by a conjugated addition to an acceptor-substituted olefin, to give a derivative of the formula (IIIe). Such reactions are described, for example, in Houben-Weyl, Methoden der Organischen Chemie, Georg Thieme Verlag Stuttgart, Vol. E 11, additional and supplementary volumes to the fourth edition 1985, p. 165 ff. Subsequent oxidation of the compounds of the formula (IIIe) gives compounds of the formula (IIIb) in which n is 1 or 2.

Scheme 6



Compounds of the formulae (III) and (IIIb) in which X, Y and n are as defined for formula (I) are novel and also form part of the subject matter of the present application.

The starting materials used in the above schemes are either commercially available or can be prepared by methods known per se. Thus, the pyrazolones of the formula (II) can be prepared, for example, by the methods described in EP-A 0 240 001 and J. Prakt. Chem. 315, 382, (1973), and the benzoic acids of the formula (III) and the benzoyl chlorides of the formula (IIIa) can be prepared by the methods described in EP-A 0 527 036 and WO 03/014071.

The compounds of the formula (I) according to the invention have an excellent herbicidal activity against a broad range of economically important monocotyledonous and dicotyledonous harmful plants. The active substances control perennial weeds equally well which produce shoots from rhizomes, root stocks or other perennial organs and which cannot be easily controlled. In this context, it generally does not matter whether the substances are applied before sowing, pre-emergence or post-emergence. Some representatives of the monocotyledonous and dicotyledonous weed flora which can be controlled by the compounds according to the inven-

tion may be mentioned individually as examples, but this is not to be taken to mean a restriction to certain species. The monocotyledonous weed species which are controlled well are, for example, *Avena, Lolium, Alopecurus, Phalaris, Echinochloa, Digitaria, Setaria* and *Cyperus* species from the annual group, and *Agropyron, Cynodon, Imperata* and *Sorghum* or else perennial *Cyperus* species amongst the perennial species. In the case of dicotyledonous weed species, the spectrum of action extends to species such as, for example, *Galium, Viola, Veronica, Lamium, Stellaria, Amaranthus, Sinapis, Ipomoea, Sida, Matricaria* and *Abutilon* from the annual group, and *Convolvulus, Cirsium, Rumex* and *Artemisia* among the perennial weeds. Harmful plants which are found under the specific culture conditions of rice, such as, for example, *Echinochloa, Sagittaria, Alisma, Eleocharis, Scirpus* and *Cyperus* are also controlled outstandingly well by the active substances according to the invention. If the compounds according to the invention are applied to the soil surface prior to germination, then either emergence of the weed seedlings is prevented completely, or the weeds grow until they have reached the cotyledon stage but growth then comes to a standstill and, after a period of three to four weeks, the plants eventually die completely. When the active substances are applied post-emergence to the green parts of the plants, growth also stops drastically very soon after the treatment, and the weeds remain at the growth stage of the time of application, or, after a certain period of time, they die completely so that competition by the weeds, which is detrimental for the crop plants, is thus eliminated at a very early stage and in a sustained manner. In particular, the compounds according to the invention have an outstanding action against *Apera spica venti, Chenopodium album, Lamium purpureum, Polygonum convolvulus, Stellaria media, Veronica hederifolia, Veronica persica* and *Viola tricolor.*

Although the compounds according to the invention have an outstanding herbicidal activity against monocotyledonous and dicotyledonous weeds, crop plants of economically important crops such as, for example, wheat, barley, rye, rice, corn, sugar beet, cotton and soybeans, only suffer negligible damage, if any. In particular, they are outstandingly well tolerated in cereals, such as wheat, barley and corn, in particular wheat. This is why the present compounds are highly suitable for the selective control of undesired vegetation in stands of agricultural useful plants or of ornamentals.

Owing to their herbicidal properties, the active substances can also be employed for controlling harmful plants in crops of known plants or genetically modified plants which are yet to be developed. As a rule, the transgenic plants are distinguished by particularly advantageous properties, for example by resistances to certain pesticides, especially certain herbicides, by resistances to plant diseases or causative organisms of plant diseases, such as certain insects or microorganisms such as fungi, bacteria or viruses. Other particular properties concern for example the harvested material with regard to quantity, quality, shelf life, composition and specific constituents. Thus, transgenic plants are known which have an increased starch content or whose starch quality has been modified, or whose fatty acid composition in the harvested material is different.

The compounds of the formula (I) according to the invention or their salts are preferably employed in economically important transgenic crops of useful plants and ornamentals, for example cereals such as wheat, barley, rye, oats, millet, rice, cassava and corn, or else crops of sugar beet, cotton, soybeans, oilseed rape, potato, tomato, pea and other vegetables. The compounds of the formula (I) can preferably be employed as herbicides in crops of useful plants which are resistant, or have been genetically modified to be resistant, to the phytotoxic effects of the herbicides.

Conventional routes for the generation of novel plants which have modified properties compared with existing plants are, for example, traditional breeding methods and the generation of mutants. Alternatively, novel plants with modified properties can be generated with the aid of recombinant methods (see, for example, EP-A-0221044, EP-A-0131624). For example, several cases of the following have been described:

- recombinant modifications of crop plants for the purposes of modifying the starch synthesized in the plants (for example WO 92/11376, WO 92/14827, WO 91/19806),
- transgenic crop plants which exhibit resistances to certain herbicides of the glufosinate type (cf. e.g. EP-A-0242236, EP-A-242246), glyphosate type (WO 92/00377) or of the sulfonylurea type (EP-A-0257993, U.S. Pat. No. 5,013, 659)
- transgenic crop plants, for example cotton, with the ability to produce *Bacillus thuringiensis* toxins (Bt toxins), which make the plants resistant to certain pests (EP-A-0142924, EP-A-0193259),
- transgenic crop plants with a modified fatty acid composition (WO 91/13972).

A large number of techniques in molecular biology, with the aid of which novel transgenic plants with modified properties can be generated, are known in principle; see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; or Winnacker "Gene und Klone" [Genes and Clones], VCH Weinheim 2nd Edition 1996 or Christou, "Trends in Plant Science" 1 (1996) 423-431.

To carry out such recombinant manipulations, nucleic acid molecules can be introduced into plasmids which permit a mutagenesis or a sequence alteration by recombination of DNA sequences. With the aid of the abovementioned standard methods, it is possible, for example, to carry out base substitutions, to remove part sequences or to add natural or synthetic sequences. The fragments can be provided with adapters or linkers to link the DNA fragments to each other.

Plant cells with a reduced activity of a gene product can be obtained, for example, by expressing at least one corresponding antisense RNA, a sense RNA for achieving a cosuppression effect, or by expressing at least one suitably constructed ribozyme which specifically cleaves transcripts of the abovementioned gene product.

To this end, it is possible, on the one hand, to use DNA molecules which encompass all of the coding sequence of a gene product including any flanking sequences which may be present, but also DNA molecules which only encompass portions of the coding sequence, it being necessary for these portions to be so long as to cause an antisense effect in the cells. Another possibility is the use of DNA sequences which have a high degree of homology with the coding sequences of a gene product, but are not completely identical.

When expressing nucleic acid molecules in plants, the protein synthesized may be localized in any desired compartment of the plant cell. However, to achieve localization in a particular compartment, the coding region can, for example, be linked to DNA sequences which ensure localization in a particular compartment. Such sequences are known to the skilled worker (see, for example, Braun et al., EMBO J. 11 (1992), 3219-3227; Wolter et al., Proc. Natl. Acad. Sci. USA 85 (1988), 846-850; Sonnewald et al., Plant J. 1 (1991), 95-106).

The transgenic plant cells can be regenerated by known techniques to give intact plants. In principle, the transgenic plants can be plants of any desired plant species, i.e. both monocotyledonous and dicotyledonous plants. Thus, transgenic plants can be obtained which exhibit modified properties owing to the overexpression, suppression or inhibition of homologous (=natural) genes or gene sequences or expression of heterologous (=foreign) genes or gene sequences.

When using the active substances according to the invention in transgenic crops, effects are frequently observed in addition to the effects against harmful plants to be observed in other crops, which are specific for the application in the transgenic crop in question, for example a modified or specifically widened weed spectrum which can be controlled, modified application rates which may be employed for the application, preferably good combining ability with the herbicides to which the transgenic crop is resistant, and an effect on the growth and yield of the transgenic crop plants. The invention therefore also relates to the use of the compounds according to the invention as herbicides for controlling harmful plants in transgenic crop plants.

The substances according to the invention additionally have outstanding growth-regulatory properties in crop plants. They engage in the plants' metabolism in a regulatory fashion and can thus be employed for the targeted control of plant constituents and for facilitating harvesting, such as, for example, by triggering desiccation and stunted growth. Moreover, they are also suitable for generally controlling and inhibiting undesired vegetative growth without destroying the plants in the process. Inhibiting the vegetative growth plays an important role in many monocotyledonous and dicotyledonous crops since lodging can be reduced, or prevented completely, hereby.

The compounds according to the invention can be employed in the form of wettable powders, emulsifiable concentrates, sprayable solutions, dusts or granules in the customary preparations. The invention therefore furthermore relates to herbicidal compositions comprising compounds of the formula (I). The compounds of the formula (I) can be formulated in various ways, depending on the prevailing biological and/or chemico-physical parameters. Examples of suitable formulations which are possible are: wettable powders (WP), water-soluble powders (SP), water-soluble concentrates, emulsifiable concentrates (EC), emulsions (EW), such as oil-in-water and water-in-oil emulsions, sprayable solutions, suspension concentrates (SC), oil- or water-based dispersions, oil-miscible solutions, capsule suspensions (CS), dusts (DP), seed-dressing products, granules for spreading and soil application, granules (GR) in the form of microgranules, spray granules, coated granules and adsorption granules, water-dispersible granules (WG), water-soluble granules (SG), ULV formulations, microcapsules and waxes. These individual formulation types are known in principle and are described, for example, in Winnacker-Küchler, "Chemische Technologie" [Chemical Engineering], Volume 7, C. Hauser Verlag Munich, 4th Ed. 1986, Wade van Valkenburg, "Pesticide Formulations", Marcel Dekker, N.Y., 1973; K. Martens, "Spray Drying" Handbook, 3rd Ed. 1979, G. Goodwin Ltd. London.

The formulation auxiliaries required, such as inert materials, surfactants, solvents and further additives, are likewise known and are described, for example, in: Watkins, "Handbook of Insecticide Dust Diluents and Carriers", 2nd Ed., Darland Books, Caldwell N.J., H.v. Olphen, "Introduction to Clay Colloid Chemistry"; 2nd Ed., J. Wiley & Sons, N.Y.; C. Marsden, "Solvents Guide"; 2nd Ed., Interscience, N.Y. 1963; McCutcheon's "Detergents and Emulsifiers Annual", MC Publ. Corp., Ridgewood N.J.; Sisley and Wood, "Encyclopedia of Surface Active Agents", Chem. Publ. Co. Inc., N.Y. 1964; Schönfeldt, "Grenzflächenaktive Äthylenoxidaddukte" [Surface-active ethylene oxide adducts], Wiss. Verlagsgesell., Stuttgart 1976; Winnacker-Küchler, "Chemische Technologie", Volume 7, C. Hauser Verlag Munich, 4th Ed. 1986.

Wettable powders are preparations which are uniformly dispersible in water and which, in addition to the active substance, also contain ionic and/or nonionic surfactants (wetters, dispersants), for example polyoxyethylated alkylphenols, polyoxyethylated fatty alcohols, polyoxyethylated fatty amines, fatty alcohol polyglycol ether sulfates, alkanesulfonates, alkylbenzenesulfonates, sodium 2,2'-dinaphthylmethane-6,6'-disulfonate, sodium lignosulfonate, sodium dibutylnaphthalenesulfonate or else sodium oleoylmethyltaurate, in addition to a diluent or inert substance. To prepare the wettable powders, the herbicidal active substances are ground finely, for example in customary equipment such as hammer mills, blowing mills and air-jet mills, and simultaneously or subsequently mixed with the formulation auxiliaries.

Emulsifiable concentrates are prepared by dissolving the active substance in an organic solvent, e.g. butanol, cyclohexanone, dimethylformamide, xylene or else higher-boiling aromatics or hydrocarbons or mixtures of the organic solvents with addition of one or more ionic and/or nonionic surfactants (emulsifiers). Examples of emulsifiers which can be used are: calcium alkylarylsulfonate salts such as calcium dodecylbenzenesulfonate, or nonionic emulsifiers such as fatty acid polyglycol esters, alkylaryl polyglycol ethers, fatty alcohol polyglycol ethers, propylene oxide/ethylene oxide condensates, alkyl polyethers, sorbitan esters such as, for example, sorbitan fatty acid esters or polyoxyethylene sorbitan esters such as, for example, polyoxyethylene sorbitan fatty acid esters.

Dusts are obtained by grinding the active substance with finely divided solid materials, for example talc, natural clays such as kaolin, bentonite and pyrophyllite, or diatomaceous earth.

Suspension concentrates can be water-based or oil-based. They can be prepared for example by wet-grinding by means of customary bead mills, if appropriate with addition of surfactants, as have already been mentioned for example above in the case of the other formulation types.

Emulsions, for example oil-in-water emulsions (EW), can be prepared for example by means of stirrers, colloid mills and/or static mixers using aqueous organic solvents and, if appropriate, surfactants as have already been mentioned for example above in the case of the other formulation types.

Granules can be prepared either by spraying the active substance onto adsorptive, granulated inert material or by applying active substance concentrates to the surface of carriers such as sand, kaolinites or granulated inert material with the aid of adhesives, for example polyvinyl alcohol, sodium polyacrylate or else mineral oils. Suitable active substances can also be granulated in the fashion which is conventional for the production of fertilizer granules, if desired as a mixture with fertilizers.

Water-dispersible granules are generally prepared by customary methods such as spray drying, fluidized-bed granulation, disk granulation, mixing with high-speed stirrers and extrusion without solid inert material.

To prepare disk granules, fluidized-bed granules, extruder granules and spray granules, see, for example methods in "Spray-Drying Handbook" 3rd ed. 1979, G. Goodwin Ltd., London; J. E. Browning, "Agglomeration", Chemical and

Engineering 1967, pages 147 et seq.; "Perry's Chemical Engineer's Handbook", 5th Ed., McGraw-Hill, New York 1973, pp. 8-57.

For further details on the formulation of crop protection agents see, for example, G. C. Klingman, "Weed Control as a Science", John Wiley and Sons, Inc., New York, 1961, pages 81-96 and J. D. Freyer, S. A. Evans, "Weed Control Handbook", 5th Ed., Blackwell Scientific Publications, Oxford, 1968, pages 101-103.

As a rule, the agrochemical preparations comprise 0.1 to 99% by weight, in particular 0.1 to 95% by weight, of active substance of the formula (I). In wettable powders, the active substance concentration is, for example, approximately 10 to 90% by weight, the remainder to 100% by weight being composed of customary formulation constituents. In the case of emulsifiable concentrates, the active substance concentration can amount to approximately 1 to 90, preferably 5 to 80% by weight. Formulations in the form of dusts comprise 1 to 30% by weight of active substance, preferably in most cases 5 to 20% by weight of active substance, and sprayable solutions comprise approximately 0.05 to 80, preferably 2 to 50% by weight of active substance. In the case of water-dispersible granules, the active substance content depends partly on whether the active compound is in liquid or solid form and on the granulation auxiliaries, fillers and the like which are being used. In the case of the water-dispersible granules, for example, the active substance content is between 1 and 95% by weight, preferably between 10 and 80% by weight.

In addition, the active substance formulations mentioned comprise, if appropriate, the tackifiers, wetters, dispersants, emulsifiers, penetrants, preservatives, antifreeze agents, solvents, fillers, carriers, colorants, antifoams, evaporation inhibitors, and pH and viscosity regulators which are conventional in each case.

Based on these formulations, it is also possible to prepare combinations with other pesticidally active substances such as, for example, insecticides, acaricides, herbicides, fungicides, and with safeners, fertilizers and/or growth regulators, for example in the form of a readymix or a tank mix.

Active substances which can be employed in combination with the active substances according to the invention in mixed formulations or in the tank mix are, for example, known active substances as are described, for example, in Weed Research 26, 441-445 (1986) or "The Pesticide Manual", 14th edition, The British Crop Protection Council and the Royal Soc. of Chemistry, 2006 and literature cited therein. Known herbicides which must be mentioned, and can be combined with the compounds of the formula (I), are, for example, the following active substances (note: the compounds are either designated by the common name according to the International Organization for Standardization (ISO) or using the chemical name, if appropriate together with a customary code number):

acetochlor; acifluorfen; aclonifen; AKH 7088, i.e. [[[1-[5-[2-chloro-4-(trifluoromethyl)-phenoxy]-2-nitrophenyl]-2-methoxyethylidene]amino]oxy]acetic acid and its methyl ester; alachlor; alloxydim; ametryn; amidosulfuron; amitrol; AMS, i.e. ammonium sulfamate; anilofos; asulam; atrazine; azimsulfurone (DPX-A8947); aziprotryn; barban; BAS 516 H, i.e. 5-fluorine-2-phenyl-4H-3,1-benzoxazin-4-one; benazolin; benfluralin; benfuresate; bensulfuron-methyl; bensulide; bentazone; benzofenap; benzofluor; benzoylprop-ethyl; benzthiazuron; bialaphos; bifenox; bromacil; bromobutide; bromofenoxim; bromoxynil; bromuron; buminafos; busoxinone; butachlor; butamifos; butenachlor; buthidazole; butralin; butylate; cafenstrole (CH-900); carbetamide; cafentrazone; CDAA, i.e. 2-chloro-N,N-di-2-propenylacetamide; CDEC, i.e. 2-chloroallyl diethyldithiocarbamate; chlomethoxyfen; chloramben; chlorazifop-butyl, chlorbromuron; chlorbufam; chlorfenac; chlorflurecol-methyl; chloridazon; chlorimuron ethyl; chlornitrofen; chlorotoluron; chloroxuron; chlorpropham; chlorsulfuron; chlorthal-dimethyl; chlorthiamid; cinmethylin; cinosulfuron; clethodim; clodinafop and its ester derivatives (for example clodinafop-propargyl); clomazone; clomeprop; cloproxydim; clopyralid; cumyluron (JC 940); cyanazine; cycloate; cyclosulfamuron (AC 104); cycloxydim; cycluron; cyhalofop and its ester derivatives (for example butylester, DEH-112); cyperquat; cyprazine; cyprazole; daimuron; 2,4-DB; dalapon; desmedipham; desmetryn; di-allate; dicamba; dichlobenil; dichlorprop; diclofop and its esters such as diclofop-methyl; diethatyl; difenoxuron; difenzoquat; diflufenican; dimefuron; dimethachlor; dimethametryn; dimethenamid (SAN-582H); dimethazone, clomazon; dimethipin; dimetrasulfuron, dinitramine; dinoseb; dinoterb; diphenamid; dipropetryn; diquat; dithiopyr; diuron; DNOC; eglinazine-ethyl; EL 77, i.e. 5-cyano-1-(1,1-dimethylethyl)-N-methyl-1H-pyrazole-4-carboxamide; endothal; EPTC; esprocarb; ethalfluralin; ethametsulfuron-methyl; ethidimuron; ethiozin; ethofumesate; F5231, i.e. N-[2-chloro-4-fluoro-5-[4-(3-fluoropropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]phenyl]ethanesulfonamide; ethoxyfen and its esters (for example ethylester, HN-252); etobenzanid (HW 52); fenoprop; fenoxan, fenoxaprop and fenoxaprop-P and their esters, for example fenoxaprop-P-ethyl and fenoxaprop-ethyl; fenoxydim; fenuron; flamprop-methyl; flazasulfuron; fluazifop and fluazifop-P and their esters, for example fluazifop-butyl and fluazifop-P-butyl; fluchloralin; flucarbazoue; flufenacet; flumetsulam; flumeturon; flumiclorac and its esters (for example pentylester, S-23031); flumioxazin (S-482); flumipropyn; flupoxam (KNW-739); fluorodifen; fluoroglycofen-ethyl; flupropacil (UBIC-4243); fluridone; flurochloridone; fluroxypyr; flurtamone; fomesafen; foramsulfuron; fosamine; furyloxyfen; glufosinate; glyphosate; halosafen; halosulfuron and its esters (for example methylester, NC-319); haloxyfop and its esters; haloxyfop-P (=R-haloxyfop) and its esters; hexazinone; imazapyr; imazamethabenz-methyl; imazaquin and salts such as the ammonium salt; ioxynil; imazethamethapyr; imazethapyr; imazosulfuron; iodosulfuron-methyl-sodium; isocarbamid; isopropalin; isoproturon; isouron; isoxaben; isoxapyrifop; karbutilate; lactofen; lenacil; linuron; MCPA; MCPB; mecoprop; mefenacet; mefluidid; mesosulfuron; mesotrione; metamitron; metazachlor; metham; methabenzthiazuron; methazole; methoxyphenone; methyldymron; metabenzuron, methobenzuron; metobromuron; metolachlor; metosulam (XRD 511); metoxuron; metribuzin; metsulfuron-methyl; MH; molinate; monalide; monolinuron; monuron; monocarbamide dihydrogensulfate; MT 128, i.e. 6-chloro-N-(3-chloro-2-propenyl)-5-methyl-N-phenyl-3-pyridazinamine; MT 5950, i.e. N-[3-chloro-4-(1-methylethyl)phenyl]-2-methylpentanamide; naproanilide; napropamide; naptalam; NC 310, i.e. 4-(2,4-dichlorobenzoyl)-1-methyl-5-benzyloxypyrazole; neburon; nicosulfuron; nipyraclophen; nitralin; nitrofen; nitrofluorfen; norflurazon; orbencarb; oryzalin; oxadiargyl (RP-020630); oxadiazon; oxyfluorfen; paraquat; pebulate; pendinethalin; perfluidone; phenisopham; phenmedipham; picloram; pinoxaden; piperophos; piributicarb; pirifenop-butyl; pretilachlor; primisulfuron-methyl; procyazine; prodiamine; profluralin; proglinazine-ethyl; prometon; prometryn; propachlor; propanil; propaquizafop and its esters; propazine; propham; propisochlor; propoxycarbazone; propyzamide; prosulfalin; prosulfocarb; prosulfuron (CGA-152005); prynachlor; pyrazolinate; pyra-

zon; pyrasulfotole; pyrazosulfuron-ethyl; pyrazoxyfen; pyridate; pyrithiobac (KIH-2031); pyroxofop and its esters (for example propargyl ester); quinclorac; quinmerac; quinofop and its ester derivatives, quizalofop and quizalofop-P and their ester derivatives for example quizalofop-ethyl; quizalofop-P-tefuryl and -ethyl; renriduron; rimsulfuron (DPX-E 9636); S 275, i.e. 2-[4-chloro-2-fluoro-5-(2-propynyloxy) phenyl]-4,5,6,7-tetrahydro-2H-indazole; secbumeton; sethoxydim; siduron; simazine; simetryn; SN 106279, i.e. 2-[[7-[2-chloro-4-(trifluoromethyl)phenoxy]-2-naphthalenyl]oxy] propanoic acid and its methyl ester; sulcotrione; sulfentrazon (FMC-97285, F-6285); sulfazuron; sulfometuron-methyl; sulfosate (ICI-A0224); TCA; tebutam (GCP-5544); tebuthiuron; tembotrione; terbacil; terbucarb; terbuchlor; terbumeton; terbuthylazine; terbutryn; TFH 450, i.e. N,N-diethyl-3-[(2-ethyl-6-methylphenyl)sulfonyl]-1H-1,2,4-triazole-1-carboxamide; thenylchlor (NSK-850); thiazafluron; thiencarbazone; thiazopyr (Mon-13200); thidiazimin (SN-24085); thiobencarb; thifensulfuron-methyl; tiocarbazil; tralkoxydim; tri-allate; triasulfuron; triazofenamide; tribenuron-methyl; triclopyr; tridiphane; trietazine; trifluralin; triflusulfuron and esters (for example methyl ester, DPX-66037); trimeturon; tsitodef; vernolate; WL 110547, i.e. 5-phenoxy-1-[3-(trifluoromethyl)phenyl]-1H-tetrazole; UBH-509; D-489; LS 82-556; KPP-300; NC-324; NC-330; KH-218; DPX-N8189; SC-0774; DOWCO-535; DK-8910; V-53482; PP-600; MBH-001; KIH-9201; ET-751; KIH-6127 and KIH-2023

For use, the formulations, which are present in commercially available form, are if appropriate diluted in the customary manner, for example using water in the case of wettable powders, emulsifiable concentrates, dispersions and water-dispersible granules. Preparations in the form of dusts, soil granules, granules for spreading and sprayable solutions are usually not diluted any further with other inert substances prior to use.

The application rate required of the compounds of the formula (I) varies with the external conditions such as, inter alia, temperature, humidity and the nature of the herbicide used. It can vary within wide limits, for example between 0.001 and 1.0 kg/ha or more of active substance, but it is preferably between 0.005 and 750 g/ha.

The examples which follow illustrate the invention.

A. CHEMICAL EXAMPLES

Preparation of 3-cyclopropyl-4-(3-cyclopropylmethylthio-2-methyl-4-methylsulfonylbenzoyl)-5-hydroxy-1-methylpyrazole (Example No. 1-38)

Step 1: 3-Mercapto-2-methyl-4-methylsulfonylbenzoic acid

11.0 g (48.0 mmol) of 3-amino-2-methyl-4-methylsulfonylbenzoic acid (synthesis described by T. L. Siddall et al. in Pest Management Science (2002), 58 (12), 1175-1186) was added to a solution of 2.03 g (50.9 mmol) of NaOH in 60 ml of water. 3.31 g (48.0 mmol) of sodium nitrite were then added. At 5-8° C., the solution was added dropwise to a mixture of concentrated HCl and ice. The mixture was stirred at this temperature for 15 minutes and then neutralized with sodium acetate. The content was then added dropwise to a solution, kept at 70-80° C., of 21.54 g (134.3 mmol) of potassium ethyl xanthogenate in 80 ml of water. The mixture was stirred at 80° C. for 15 minutes and then, at RT, acidified for work-up with 1M HCl. After five minutes, the mixture was decanted and 85 ml of 10% strength aqueous sodium hydroxide solution were added to the residue. The mixture was heated and distillate formed was removed with the aid of a distillation assembly, so that an internal temperature of 100° C. could be reached. After the mixture had been heated at this temperature for 1.25 h, HPLC analysis showed that the reaction had gone to completion. 21 ml of a saturated aqueous sodium bisulfite solution were then added, and the mixture was heated at 100° C. for 10 minutes. For work-up, the cooled reaction mixture was acidified with 1M HCl, cooled to 0-5° C. and filtered under an atmosphere of nitrogen. What was isolated were 10 g of a solid; a 1H-NMR spectrum showed the identity of the product.

Step 2: 3-Cyclopropylmethylthio-2-methyl-4-methylsulfonylbenzoic acid

Under an atmosphere of nitrogen, 9.0 g (36.5 mmol) of 3-mercapto-2,4-dimethyl-sulfonylbenzoic acid were dissolved in 70 ml of N,N-dimethylformamide (DMF), and 3.07 g (76.7 mmol, purity 60% by weight) of NaH were then added a little at a time. The mixture was stirred at RT for 15 minutes, and 5.43 g (40.2 mmol) of cyclopropylmethyl bromide were then slowly added dropwise. The mixture was stirred at RT for 16 h. For work-up, the solvent was removed under reduced pressure and the residue was taken up in a mixture of water and methanol. 8 g (200 mmol) of NaOH were added, and the reaction mixture was stirred at RT until HPLC analysis showed no more cyclopropylmethyl ester. The mixture was freed from the solvents, water was added to the residue and the aqueous phase was acidified with 1M HCl and then extracted twice with ethyl acetate (EA). The combined organic phases were dried, filtered and freed from the solvent. The residue was washed with n-heptane. The heptane was decanted and the residue was dried under reduced pressure. What was isolated were 11.1 g of the pure product.

Step 3: 3-Cyclopropyl-4-(3-cyclopropylmethylthio-2-methyl-4-methylsulfonylbenzoyl)-5-hydroxy-1-methylpyrazole

190 mg (0.63 mmol) of 3-cyclopropylmethylthio-2-methyl-4-methylsulfonylbenzoic acid were initially charged in 15 ml of dry dichloromethane, and 121 mg (0.95 mmol) of oxalyl chloride and a few drops of DMF were added. The mixture was heated at reflux for 15 min, after which no more evolution of gas could be observed. The content was cooled to RT and concentrated. The acid chloride obtained in this manner was dissolved in 15 ml of acetonitrile, and 96 mg (0.70 mmol) of 3-cyclopropyl-5-hydroxy-1-methylpyrazole were added. 128 mg (1.27 mmol) of triethylamine were then slowly added dropwise, and the reaction mixture was stirred at RT for 16 h. Ten drops of acetone cyanohydrin and a spatula tip of KCN were added to the enol ester obtained in this manner. The mixture was stirred at RT for 16 h and then concentrated. 15 ml of dichloromethane and then 2 ml of 1M HCl were added to the residue. After phase separation, the organic phase was freed from the solvent. The residue was purified chromatographically, and 65.7 mg of pure product were isolated.

Preparation of 3-cyclopropyl-4-(3-cyclopropylmethylsulfonyl-2-methyl-4-methylsulfonylbenzoyl)-5-hydroxy-1-methylpyrazole (Example No. 1-50)

Step 1: 3-Cyclopropylmethylsulfonyl-2-methyl-4-methylsulfonylbenzoic acid

952 mg (3.17 mmol) of 3-cyclopropylmethylthio-2-methyl-4-methylsulfonylbenzoic acid were dissolved in 15 ml of

glacial acetic acid. 31 mg (0.095 mmol) of sodium tungstate (VI) dihydrate were added, and the mixture was then heated to 60° C. At this temperature, 1.44 g (30% strength, 12.7 mmol) of an aqueous hydrogen peroxide solution were carefully added dropwise. The mixture was stirred at this temperature for two days. The mixture was then cooled and, for work-up, poured into water. The mixture was extracted twice with EA, the combined organic phases were washed with an aqueous, saturated sodium bisulfite solution, and, after analytical confirmation of the absence of peroxides, the mixture was dried, filtered and freed under reduced pressure from the solvents. 744 g of the product were isolated.

Step 2: Synthesis of 3-cyclopropyl-4-(3-cyclopropyl-methylsulfonyl-2-methyl-4-methylsulfonylbenzoyl)-5-hydroxy-1-methylpyrazole

149 mg (0.45 mmol) of 3-cyclopropylmethylsulfonyl-2-methyl-4-methylsulfonyl-benzoic acid were initially charged in 15 ml of dry CH_2Cl_2, and 114 mg (0.90 mmol) of oxalyl chloride and a few drops of DMF were added. The mixture was heated at reflux for 15 min, after which no more evolution of gas could be observed. The content was cooled to RT and concentrated. The acid chloride obtained in this manner was dissolved in 15 ml of dry dichloromethane, and 68 mg (0.49 mmol) of 3-cyclopropyl-5-hydroxy-1-methylpyrazole were added. 91 mg (0.90 mmol) of triethylamine were then slowly added dropwise, and the reaction mixture was stirred at RT for 16 h. For work-up, 2 ml of 1M HCl were added, and after phase separation the organic phase was freed from the solvent. The enol ester obtained in this manner was taken up in 15 ml of acetonitrile, and 10 drops of acetone cyanohydrin and a spatula tip of KCN were added. The mixture was stirred at RT for 16 h and then concentrated. 15 ml of CH_2Cl_2 and then 2 ml of 1M HCl were added. After phase separation, the organic phase was freed from the solvent. The residue was purified chromatographically, and 103 mg of pure product were isolated.

Preparation of 4-(2-chloro-3-(2-methoxyethyl)thio-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole (Example No. 1-3)

Step 1: Synthesis of 2-chloro-3-(2'-methoxyethyl) thio-4-methylsulfonylbenzoic acid

5.0 g (19.8 mmol) of 2-chloro-3-fluoro-4-methylsulfonyl-benzoic acid (synthesis described in WO 98/42648) were taken up in 40 ml of DMF. 871 mg (21.8 mmol, purity 60% by weight) of NaH were added. The mixture was stirred at RT for 30 minutes. A reaction mixture containing the sodium salt of 2-methoxyethanethiol (prepared from a solution of 2.19 g (23.7 mmol) of 2-methoxyethanethiol in 10 ml of DMF which had been added dropwise to a suspension of 950 mg (23.7 mmol, purity 60% by weight) of NaH in 30 ml of DMF, followed by stirring at RT for 30 minutes) was then added a little at a time. During the addition, the temperature was kept below 30° C. The reaction mixture was stirred at RT for 16 h, for work-up diluted with water and washed with diethyl ether. The aqueous phase was acidified with 1M HCl and extracted with tert-butyl methyl ether. The organic phase was dried and filtered. The aqueous phase was additionally extracted with EA, and the organic phase was also dried and filtered. The filtrates of the organic phases were combined and freed from the solvent. The residue was dried under reduced pressure and purified chromatographically. This gave 4.8 g of the pure product.

Step 2: Synthesis of 4-(2-chloro-3-(2-methoxyethyl) thio-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole

550 mg (1.69 mmol) of 2-chloro-3-(2-methoxyethyl)thio-4-methylsulfonylbenzoic acid were initially charged in 20 ml of dry CH_2Cl_2, and 430 mg (3.39 mmol) of oxalyl chloride and two drops of DMF were added. The mixture was heated at reflux for 15 minutes. The content was cooled to RT and concentrated. The acid chloride obtained in this manner was dissolved in 20 ml of dry CH_2Cl_2, and 257 mg (1.86 mmol) of 3-cyclopropyl-5-hydroxy-1-methylpyrazole were added. 343 mg (3.39 mmol) of triethylamine were then slowly added dropwise, and the reaction mixture was stirred at RT for 16 h. For work-up, 5 ml of 1M HCl were added, and, after phase separation, the organic phase was freed from the solvent. The residue was purified chromatographically, and the enol ester obtained in this manner was taken up in 20 ml of acetonitrile, and 343 mg (3.39 mmol) of triethylamine, eight drops of acetone cyanohydrin and a spatula tip of KCN were added. The mixture was stirred at RT for 16 h and then concentrated. 20 ml of CH_2Cl_2 and then 5 ml of 1M HCl were added to the residue. After phase separation, the organic phase was freed from the solvent. The residue was purified chromatographically, and 579 mg of pure product were isolated.

Preparation of 4-(2-chloro-3-(2-methoxyethyl)sulfynyl-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole (Example No. 1-9) and 4-(2-chloro-3-(2-methoxyethyl)sulfonyl-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methyl pyrazole (Example No. 1-15)

193 mg (0.43 mmol) of 4-(2-chloro-3-(2-methoxyethyl) thio-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole were dissolved in 20 ml of CH_2Cl_2, and 321 mg (purity 70% by weight, 1.30 mmol) of meta-chloroperbenzoic acid were then added. The mixture was then stirred at RT for 16 h. For work-up, the mixture was diluted with CH_2Cl_2 and washed with 10% strength aqueous sodium bisulfite solution. During this step, the pH of the aqueous phase was kept in the acidic range using 1M HCl. After phase separation and the analytical confirmation of the absence of peroxides, the organic phase was then dried, filtered and freed from solvent. The residue was separated chromatographically, which gave 9.6 mg of pure 4-(2-chloro-3-(2-methoxyethyl)sulfynyl-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole and 71.6 mg of pure 4-(2-chloro-3-(2-methoxyethyl)sulfonyl-4-methylsulfonylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole.

Preparation of 3-cyclopropyl-5-hydroxy-4-(3-(2-methoxyethyl)thio-2-methyl-4-trifluoromethylbenzoyl)-1-methylpyrazole (Example No. 1-2091)

Step 1: Synthesis of 3-fluoro-2-methyl-4-trifluoromethylbenzoic acid

25.0 g (120.1 mmol) of 3-fluoro-4-trifluoromethylbenzoic acid were dissolved in 250 ml of dry THF, and 100.9 ml (2.5M in hexane, 252.3 mmol) of n-butyllithium were added dropwise at a temperature of −40° C. The mixture was stirred for 3.5 h, and a solution of 51.2 g (360.4 mmol) of iodomethane in 50 ml of dry THF was then added. The mixture was stirred for 16 h, and after half an hour the temperature slowly increased to RT. For work-up, 150 ml of 1M HCl were added carefully. The mixture was extracted with diethyl ether, and

the organic phase was then extracted with 1M NaOH. The aqueous phase was acidified and then extracted with diethyl ether. The organic phase was washed with water, dried and concentrated. The residue was triturated with n-heptane, and the solid was collected by filtration. What was isolated were 13.5 g of the pure product.

Step 2: Synthesis of 3-(2-methoxyethyl)thio-2-methyl-4-trifluoromethylbenzoic acid

1.45 g (6.53 mmol) of 3-fluoro-2-methyl-4-trifluoromethylbenzoic acid were initially charged in 40 ml of DMF. 809 mg (20.2 mmol) of NaH were added a little at a time. After the evolution of gas had ceased, 1.20 g (13.1 mmol) of 2-methoxyethanethiol were added a little at a time. The mixture was stirred at RT for 10 minutes and then heated at 80° C. for 15 h. The reaction mixture was cooled and concentrated under reduced pressure, and for work-up water was added and the mixture was acidified with 1M HCl. The product precipitated and was removed by filtration. The product was then washed with water and n-heptane. What was isolated were 1.7 g of the pure product.

Step 3: Synthesis of 3-cyclopropyl-5-hydroxy-4-(3-(2-methoxyethyl)thio-2-methyl-4-trifluoromethylbenzoyl)-1-methylpyrazole

520 mg (1.77 mmol) of 3-(2-methoxyethyl)thio-2-methyl-4-trifluoromethylbenzoic acid were initially charged in 20 ml of dry CH_2Cl_2, and 449 mg (3.53 mmol) of oxalyl chloride and two drops of DMF were added. The mixture was heated at reflux for 15 min, after which no more evolution of gas could be observed. The content was cooled to RT and concentrated. The acid chloride obtained in this manner was dissolved in 20 ml of dry CH_2Cl_2, and 269 mg (1.94 mmol) of 3-cyclopropyl-5-hydroxy-1-methylpyrazole were added. 358 mg (3.53 mmol) of triethylamine were then slowly added dropwise, and the reaction mixture was stirred at RT for 16 h. For work-up, 5 ml of 1M HCl were added, and, after phase separation, the solvent was removed. The enol ester obtained in this manner was, after chromatographic purification, taken up in 20 ml of acetonitrile, and 358 mg (3.53 mmol) of triethylamine were added. Eight drops of acetone cyanohydrin and a spatula tip of KCN were then added. The mixture was stirred at RT for 16 h and then concentrated. 20 ml of CH_2Cl_2 and then 5 ml of 1M HCl were added to the residue. After phase separation, the mixture was freed from the solvent. The residue was purified chromatographically, and 354 mg of pure product were isolated.

Preparation of 4-(4-chloro-3'-cyclopropylmethylthio-2-methylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole (Example No. 1-1406)

Step 1: Synthesis of methyl 4-chloro-3-(dimethylaminothiocarbonyloxy)-2-methylbenzoate

Under an atmosphere of nitrogen, 12.3 g (109.7 mmol) of 1,4-diazabicyclo[2.2.2]-octane and then 13.6 g (109.7 mmol) of dimethylaminothiocarbonyl chloride were added to 11.0 g (54.8 mmol) of methyl 4-chloro-3-hydroxy-2-methylbenzoate (synthesis described in DE 10039723) in 200 ml of DMF. The mixture was stirred at RT for 16 h and, for work-up, poured into ice-water. The product precipitated and was removed by filtration. The residue was washed with 1M HCl. This gave 14.7 g of pure product.

Step 2: Synthesis of methyl 4-chloro-3-(dimethylaminocarbonylthio)-2-methyl-benzoate

Under an atmosphere of nitrogen, 12.1 g (42.0 mmol) of methyl 4-chloro-3-(dimethylaminothiocarbonyloxy)-2-methylbenzoate in 30 ml of 1,3-dimethoxy-benzene were heated at 220° C. for 6 h. For work-up, the reaction mixture was cooled and concentrated under reduced pressure. After chromatographic purification of the residue, 5.2 g of pure product were isolated.

Step 3: Synthesis of 4-chloro-3-mercapto-2-methylbenzoic acid

6.61 g (purity 85% by weight, 100.1 mmol) of KOH were added to 4.80 g (16.7 mmol) of methyl 4-chloro-3-(dimethylaminocarbonylthio)-2-methylbenzoate in 150 ml of methanol, and the mixture was stirred under reflux for two days. The reaction mixture was freed from solvent, water was added to the residue, which was then acidified with 1M HCl, and the solid was collected by filtration. This gave 3.2 g of pure product.

Step 4: Synthesis of methyl 4-chloro-3-mercapto-2-methylbenzoate

Under an atmosphere of nitrogen, 3.60 g (17.8 mmol) of 4-chloro-3-mercapto-2-methylbenzoic acid in 50 ml of absolute methanol and 1 ml of concentrated sulfuric acid were heated under reflux for 17 h. The mixture was freed from solvent, and the residue was taken up in water. After two extractions with ethyl acetate, the combined organic phases were dried, filtered under an atmosphere of nitrogen and freed from the solvent. What was isolated were 3.2 g of pure product.

Step 5: Synthesis of methyl 4-chloro-3-cyclopropylmethylthio-2-methylbenzoate

1.66 g (5.09 mmol) of cesium carbonate in 20 ml of acetonitrile were added to 1.05 g (4.85 mmol) of methyl 4-chloro-3-mercapto-2-methylbenzoate. 687 mg (5.09 mmol) of cyclopropylmethyl bromide were slowly added dropwise, and the reaction mixture was stirred at RT for 16 h. For work-up, the solvent was removed, and water was added to the residue. The mixture was extracted three times with ethyl acetate, the combined organic phases were dried and filtered and the solvent was removed. What was isolated were 1.2 g of pure product.

Step 6: Synthesis of 4-chloro-3-cyclopropylmethylthio-2-methylbenzoic acid

3 ml of 20% strength aqueous sodium hydroxide solution were added to 1.20 g (4.43 mmol) of methyl 4-chloro-3-cyclopropylmethylthio-2-methylbenzoate in 30 ml of methanol, and the mixture was stirred at RT for 16 h. For work-up, the mixture was concentrated on a rotary evaporator, and the residue was taken up in water. The mixture was acidified with 1M HCl, and the product was then filtered off as a solid. This gave 1.1 g of pure product.

Step 7: Synthesis of 4-(4'-chloro-3'-cyclopropylmethylthio-2'-methylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole

161 mg (1.17 mmol) of 3-cyclopropyl-5-hydroxy-1-methylpyrazole and a few drops of N,N-dimethylaminopyridine

were added to 272 mg (1.06 mmol) of 4-chloro-3-cyclopropylmethylthio-2-methylbenzoic acid. 244 mg (1.27 mmol) of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride were added, and the mixture was stirred at RT for 16 h. For work-up, 3 ml of 1M HCl were added, and the organic phase was freed from the solvent. 214 mg (2.12 mmol) of triethylamine, 10 drops of acetone cyanohydrin and a spatula tip of KCN were added to the residue in 15 ml of acetonitrile. This reaction mixture was stirred at RT for 16 h and then freed from the solvent. 2 ml of 1M HCl were added to the residue in 15 ml of CH_2Cl_2. The organic phase was freed from the solvent, and the residue was then purified chromatographically. This gave 154 mg of pure product.

Preparation of 4-(4-chloro-3-cyclopropylmethylsulfonyl-2-methylbenzoyl)-3-cyclo-propyl-5-hydroxy-1-methylpyrazole (Example No. 1-1418)

128 mg (purity 70% by weight, 0.52 mmol) of meta-chloroperbenzoic acid were added to 78 mg (0.21 mmol) of 4-(4-chloro-3-cyclopropylmethylthio-2-methylbenzoyl)-3-cyclopropyl-5-hydroxy-1-methylpyrazole in 20 ml of CH_2Cl_2. This mixture was then stirred at RT for 5 h. For work-up, the mixture was washed with 10% strength aqueous sodium bisulfite solution. During this step, the pH of the aqueous phase was kept in the acidic range, otherwise the mixture was acidified with 1M HCl. Subsequently, after phase separation and after analytical confirmation of the absence of peroxides, the organic phase was dried, filtered and freed from the solvent. The residue was purified chromatographically, which gave 29.1 mg of pure product.

The examples given in the tables which follow were prepared analogously to the methods mentioned above, or can be obtained analogously to the methods mentioned above. These compounds are very particularly preferred.

The Abbreviations Used Denote:

Bu=Butyl Et=Ethyl Me=Methyl Pr=Propyl
c=cyclo i=iso Ph=Phenyl

TABLE A

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1	Cl	c-Pr	0	SO_2Me	
1-2	Cl	CH_2-c-Pr	0	SO_2Me	
1-3	Cl	$(CH_2)_2OMe$	0	SO_2Me	8.23 (d, 1H), 7.51 (d, 1H), 3.64 (t, 2H), 3.62 (s, 3H), 3.49 (s, 3H), 3.29 (s, 3H), 3.24 (t, 2H), 0.91 (m, 1H), 0.76 (m, 2H), 0.44 (m, 2H)
1-4	Cl	$(CH_2)_3OMe$	0	SO_2Me	
1-5	Cl	$(CH_2)_2OEt$	0	SO_2Me	
1-6	Cl	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-7	Cl	c-Pr	1	SO_2Me	
1-8	Cl	CH_2-c-Pr	1	SO_2Me	
1-9	Cl	$(CH_2)_2OMe$	1	SO_2Me	8.22 (d, 1H), 7.62 (d, 1H), 4.09-4.01 (m, 2H), 3.91-3.85 (m, 1H), 3.62 (s, 3H), 3.50-3.42 (m, 7H), 0.92 (m, 1H), 0.78 (m, 2H), 0.47 (m, 2H)
1-10	Cl	$(CH_2)_3OMe$	1	SO_2Me	
1-11	Cl	$(CH_2)_2OEt$	1	SO_2Me	
1-12	Cl	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-13	Cl	c-Pr	2	SO_2Me	
1-14	Cl	CH_2-c-Pr	2	SO_2Me	
1-15	Cl	$(CH_2)_2OMe$	2	SO_2Me	8.43 (d, 1H), 7.72 (d, 1H), 4.02 (t, 2H), 3.92 (t, 2H), 3.62 (ss, 6H), 3.29 (s, 3H), 0.92 (m, 1H), 0.78 (m, 2H), 0.65-0.42 (m, 2H)
1-16	Cl	$(CH_2)_3OMe$	2	SO_2Me	
1-17	Cl	$(CH_2)_2OEt$	2	SO_2Me	
1-18	Cl	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-19	Br	c-Pr	0	SO_2Me	
1-20	Br	CH_2-c-Pr	0	SO_2Me	
1-21	Br	$(CH_2)_2OMe$	0	SO_2Me	
1-22	Br	$(CH_2)_3OMe$	0	SO_2Me	
1-23	Br	$(CH_2)_2OEt$	0	SO_2Me	
1-24	Br	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-25	Br	c-Pr	1	SO_2Me	
1-26	Br	CH_2-c-Pr	1	SO_2Me	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-27	Br	$(CH_2)_2OMe$	1	SO_2Me	
1-28	Br	$(CH_2)_3OMe$	1	SO_2Me	
1-29	Br	$(CH_2)_2OEt$	1	SO_2Me	
1-30	Br	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-31	Br	c-Pr	2	SO_2Me	
1-32	Br	CH_2-c-Pr	2	SO_2Me	
1-33	Br	$(CH_2)_2OMe$	2	SO_2Me	
1-34	Br	$(CH_2)_3OMe$	2	SO_2Me	
1-35	Br	$(CH_2)_2OEt$	2	SO_2Me	
1-36	Br	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-37	Me	c-Pr	0	SO_2Me	
1-38	Me	CH_2-c-Pr	0	SO_2Me	8.17 (d, 1H), 7.47 (d, 1H), 3.62 (s, 3H), 3.48 (s, 3H), 2.83 (d, 2H), 2.67 (s, 3H), 1.02 (m, 1H), 0.90-0.82 (m, 1H), 0.77 (m, 2H), 0.57 (m, 2H), 0.48 (m, 2H), 0.23 (m, 2H)
1-39	Me	$(CH_2)_2OMe$	0	SO_2Me	8.19 (d, 1H), 7.48 (d, 1H), 3.63-3.60 (s + t, 5H), 3.47 (s, 3H), 3.34 (s, 3H), 3.12 (t, 2H), 2.63 (s, 3H), 0.91-0.84 (m, 1H), 0.76 (m, 2H), 0.48 (m, 2H)
1-40	Me	$(CH_2)_3OMe$	0	SO_2Me	8.17 (d, 1H), 7.47 (d, 1H), 3.61 (s, 3H), 3.47 (t, 2H), 3.46 (s, 3H), 3.32 (s, 3H), 2.96 (t, 2H), 2.64 (s, 3H), 1.92 (quint., 2H), 0.89-0.82 (m, 1H), 0.77 (m, 2H), 0.47 (m, 2H)
1-41	Me	$(CH_2)_2OEt$	0	SO_2Me	8.18 (d, 1H), 7.48 (d, 1H), 3.62 (t, 2H), 3.61 (s, 3H), 3.48 (s, 3H), 3.47 (q, 2H), 3.10 (t, 2H), 2.65 (s, 3H), 1.18 (t, 3H), 0.86 (m, 1H), 0.77 (m, 2H), 0.48 (m, 2H)
1-42	Me	$(CH_2)_3OMe$	0	SO_2Me	
1-43	Me	c-Pr	1	SO_2Me	
1-44	Me	CH_2-c-Pr	1	SO_2Me	
1-45	Me	$(CH_2)_2OMe$	1	SO_2Me	8.10 (d, 1H), 7.59 (d, 1H), 4.04-4.00 (m, 1H), 3.91-3.86 (m, 1H), 3.75-3.45 (m, 2H), 3.61 (s, 3H), 3.43 (s, 3H), 3.38 (s, 3H), 2.78 (s, 3H), 0.90-0.71 (m, 3H), 0.56 (m, 1H), 0.43 (m, 1H),
1-46	Me	$(CH_2)_3OMe$	1	SO_2Me	8.08 (d, 1H), 7.57 (d, 1H), 3.62-3.56 (m, 6H), 3.38-3.25 (m, 1H), 3.37 (s, 3H), 3.35 (s, 3H), 2.81 (s, 3H), 2.28-2.16 (m, 2H), 0.90-0.72 (m, 3H), 0.55 (m, 1H), 0.45 (m, 1H)
1-47	Me	$(CH_2)_2OEt$	1	SO_2Me	8.11 (d, 1H), 7.57 (d, 1H), 4.02 (m, 1H), 3.92 (m, 1H), 3.66-3.53 (m, 4H), 3.60 (s, 3H), 3.38 (s, 3H), 2.78 (s, 3H), 1.22 (t, 3H), 0.90-0.72 (m, 3H), 0.55 (m, 1H), 0.45 (m, 1H)

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-48	Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-49	Me	c-Pr	2	SO_2Me	
1-50	Me	CH_2-c-Pr	2	SO_2Me	8.37 (d, 1H), 7.67 (d, 1H), 3.65-3.61 (s + d, 5H), 3.57 (s, 3H), 2.80 (s, 3H), 1.30 (m, 1H), 0.88-0.70 (m, 5H), 0.52 (m, 2H), 0.42 (m, 2H)
1-51	Me	$(CH_2)_2OMe$	2	SO_2Me	8.37 (d, 1H), 7.66 (d, 1H), 4.06-3.90 (m, 4H), 3.62 (s, 3H), 3.56 (s, 3H), 3.33 (s, 3H), 2.74 (s, 3H), 0.89-0.80 (m, 1H), 0.76 (m, 2H), 0.52 (m, 2H)
1-52	Me	$(CH_2)_3OMe$	2	SO_2Me	8.37 (d, 1H), 7.67 (d, 1H), 3.71 (t, 2H), 3.61 (s, 3H), 3.57 (s + t, 5H), 3.33 (s, 3H), 2.73 (s, 3H), 2.27 (quint., 2H), 0.86-0.76 (m, 3H), 0.55-0.50 (m, 2H)
1-53	Me	$(CH_2)_2OEt$	2	SO_2Me	8.36 (d, 1H), 7.67 (d, 1H), 4.02 (t, 2H), 3.92 (t, 2H), 3.61 (s, 3H), 3.56 (s, 3H), 3.50 (q, 2H), 2.76 (s, 3H), 1.10 (t, 3H), 0.85-0.75 (m, 3H), 0.52 (m, 2H)
1-54	Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-55	Et	c-Pr	0	SO_2Me	
1-56	Et	CH_2-c-Pr	0	SO_2Me	
1-57	Et	$(CH_2)_2OMe$	0	SO_2Me	
1-58	Et	$(CH_2)_3OMe$	0	SO_2Me	
1-59	Et	$(CH_2)_2OEt$	0	SO_2Me	
1-60	Et	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-61	Et	c-Pr	1	SO_2Me	
1-62	Et	CH_2-c-Pr	1	SO_2Me	
1-63	Et	$(CH_2)_2OMe$	1	SO_2Me	
1-64	Et	$(CH_2)_3OMe$	1	SO_2Me	
1-65	Et	$(CH_2)_2OEt$	1	SO_2Me	
1-66	Et	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-67	Et	c-Pr	2	SO_2Me	
1-68	Et	CH_2-c-Pr	2	SO_2Me	
1-69	Et	$(CH_2)_2OMe$	2	SO_2Me	
1-70	Et	$(CH_2)_3OMe$	2	SO_2Me	
1-71	Et	$(CH_2)_2OEt$	2	SO_2Me	
1-72	Et	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-73	CF_3	c-Pr	0	SO_2Me	
1-74	CF_3	CH_2-c-Pr	0	SO_2Me	
1-75	CF_3	$(CH_2)_2OMe$	0	SO_2Me	
1-76	CF_3	$(CH_2)_3OMe$	0	SO_2Me	
1-77	CF_3	$(CH_2)_2OEt$	0	SO_2Me	
1-78	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-79	CF_3	c-Pr	1	SO_2Me	
1-80	CF_3	CH_2-c-Pr	1	SO_2Me	
1-81	CF_3	$(CH_2)_2OMe$	1	SO_2Me	
1-82	CF_3	$(CH_2)_3OMe$	1	SO_2Me	
1-83	CF_3	$(CH_2)_2OEt$	1	SO_2Me	
1-84	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-85	CF_3	c-Pr	2	SO_2Me	
1-86	CF_3	CH_2-c-Pr	2	SO_2Me	
1-87	CF_3	$(CH_2)_2OMe$	2	SO_2Me	
1-88	CF_3	$(CH_2)_3OMe$	2	SO_2Me	
1-89	CF_3	$(CH_2)_2OEt$	2	SO_2Me	
1-90	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-91	OMe	c-Pr	0	SO_2Me	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-92	OMe	CH_2-c-Pr	0	SO_2Me	
1-93	OMe	$(CH_2)_2OMe$	0	SO_2Me	
1-94	OMe	$(CH_2)_3OMe$	0	SO_2Me	
1-95	OMe	$(CH_2)_2OEt$	0	SO_2Me	
1-96	OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-97	OMe	c-Pr	1	SO_2Me	
1-98	OMe	CH_2-c-Pr	1	SO_2Me	
1-99	OMe	$(CH_2)_2OMe$	1	SO_2Me	
1-100	OMe	$(CH_2)_3OMe$	1	SO_2Me	
1-101	OMe	$(CH_2)_2OEt$	1	SO_2Me	
1-102	OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-103	OMe	c-Pr	2	SO_2Me	
1-104	OMe	CH_2-c-Pr	2	SO_2Me	
1-105	OMe	$(CH_2)_2OMe$	2	SO_2Me	
1-106	OMe	$(CH_2)_3OMe$	2	SO_2Me	
1-107	OMe	$(CH_2)_2OEt$	2	SO_2Me	
1-108	OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-109	OEt	c-Pr	0	SO_2Me	
1-110	OEt	CH_2-c-Pr	0	SO_2Me	
1-111	OEt	$(CH_2)_2OMe$	0	SO_2Me	
1-112	OEt	$(CH_2)_3OMe$	0	SO_2Me	
1-113	OEt	$(CH_2)_2OEt$	0	SO_2Me	
1-114	OEt	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-115	OEt	c-Pr	1	SO_2Me	
1-116	OEt	CH_2-c-Pr	1	SO_2Me	
1-117	OEt	$(CH_2)_2OMe$	1	SO_2Me	
1-118	OEt	$(CH_2)_3OMe$	1	SO_2Me	
1-119	OEt	$(CH_2)_2OEt$	1	SO_2Me	
1-120	OEt	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-121	OEt	c-Pr	2	SO_2Me	
1-122	OEt	CH_2-c-Pr	2	SO_2Me	
1-123	OEt	$(CH_2)_2OMe$	2	SO_2Me	
1-124	OEt	$(CH_2)_3OMe$	2	SO_2Me	
1-125	OEt	$(CH_2)_2OEt$	2	SO_2Me	
1-126	OEt	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-127	NO_2	c-Pr	0	SO_2Me	
1-128	NO_2	CH_2-c-Pr	0	SO_2Me	
1-129	NO_2	$(CH_2)_2OMe$	0	SO_2Me	
1-130	NO_2	$(CH_2)_3OMe$	0	SO_2Me	
1-131	NO_2	$(CH_2)_2OEt$	0	SO_2Me	
1-132	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-133	NO_2	c-Pr	1	SO_2Me	
1-134	NO_2	CH_2-c-Pr	1	SO_2Me	
1-135	NO_2	$(CH_2)_2OMe$	1	SO_2Me	
1-136	NO_2	$(CH_2)_3OMe$	1	SO_2Me	
1-137	NO_2	$(CH_2)_2OEt$	1	SO_2Me	
1-138	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-139	NO_2	c-Pr	2	SO_2Me	
1-140	NO_2	CH_2-c-Pr	2	SO_2Me	
1-141	NO_2	$(CH_2)_2OMe$	2	SO_2Me	
1-142	NO_2	$(CH_2)_3OEt$	2	SO_2Me	
1-143	NO_2	$(CH_2)_2OEt$	2	SO_2Me	
1-144	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-145	SO_2Me	c-Pr	0	SO_2Me	
1-146	SO_2Me	CH_2-c-Pr	0	SO_2Me	
1-147	SO_2Me	$(CH_2)_2OMe$	0	SO_2Me	
1-148	SO_2Me	$(CH_2)_3OMe$	0	SO_2Me	
1-149	SO_2Me	$(CH_2)_2OEt$	0	SO_2Me	
1-150	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-151	SO_2Me	c-Pr	1	SO_2Me	
1-152	SO_2Me	CH_2-c-Pr	1	SO_2Me	
1-153	SO_2Me	$(CH_2)_2OMe$	1	SO_2Me	
1-154	SO_2Me	$(CH_2)_3OMe$	1	SO_2Me	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-155	SO_2Me	$(CH_2)_2OEt$	1	SO_2Me	
1-156	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-157	SO_2Me	c-Pr	2	SO_2Me	
1-158	SO_2Me	CH_2-c-Pr	2	SO_2Me	
1-159	SO_2Me	$(CH_2)_2OMe$	2	SO_2Me	
1-160	SO_2Me	$(CH_2)_3OMe$	2	SO_2Me	
1-161	SO_2Me	$(CH_2)_2OEt$	2	SO_2Me	
1-162	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-163	CH_2OMe	c-Pr	0	SO_2Me	
1-164	CH_2OMe	CH_2-c-Pr	0	SO_2Me	
1-165	CH_2OMe	$(CH_2)_2OMe$	0	SO_2Me	
1-166	CH_2OMe	$(CH_2)_3OMe$	0	SO_2Me	
1-167	CH_2OMe	$(CH_2)_2OEt$	0	SO_2Me	
1-168	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-169	CH_2OMe	c-Pr	1	SO_2Me	
1-170	CH_2OMe	CH_2-c-Pr	1	SO_2Me	
1-171	CH_2OMe	$(CH_2)_2OMe$	1	SO_2Me	
1-172	CH_2OMe	$(CH_2)_3OMe$	1	SO_2Me	
1-173	CH_2OMe	$(CH_2)_2OEt$	1	SO_2Me	
1-174	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-175	CH_2OMe	c-Pr	2	SO_2Me	
1-176	CH_2OMe	CH_2-c-Pr	2	SO_2Me	
1-177	CH_2OMe	$(CH_2)_2OMe$	2	SO_2Me	
1-178	CH_2OMe	$(CH_2)_3OMe$	2	SO_2Me	
1-179	CH_2OMe	$(CH_2)_2OEt$	2	SO_2Me	
1-180	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-181	CH_2SO_2Me	c-Pr	0	SO_2Me	
1-182	CH_2SO_2Me	CH_2-c-Pr	0	SO_2Me	
1-183	CH_2SO_2Me	$(CH_2)_2OMe$	0	SO_2Me	
1-184	CH_2SO_2Me	$(CH_2)_3OMe$	0	SO_2Me	
1-185	CH_2SO_2Me	$(CH_2)_2OEt$	0	SO_2Me	
1-186	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-187	CH_2SO_2Me	c-Pr	1	SO_2Me	
1-188	CH_2SO_2Me	CH_2-c-Pr	1	SO_2Me	
1-189	CH_2SO_2Me	$(CH_2)_2OMe$	1	SO_2Me	
1-190	CH_2SO_2Me	$(CH_2)_3OMe$	1	SO_2Me	
1-191	CH_2SO_2Me	$(CH_2)_2OEt$	1	SO_2Me	
1-192	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-193	CH_2SO_2Me	c-Pr	2	SO_2Me	
1-194	CH_2SO_2Me	CH_2-c-Pr	2	SO_2Me	
1-195	CH_2SO_2Me	$(CH_2)_2OMe$	2	SO_2Me	
1-196	CH_2SO_2Me	$(CH_2)_3OMe$	2	SO_2Me	
1-197	CH_2SO_2Me	$(CH_2)_2OEt$	2	SO_2Me	
1-198	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-199	$CH_2O(CH_2)_2OMe$	c-Pr	0	SO_2Me	
1-200	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	SO_2Me	
1-201	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	SO_2Me	
1-202	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	SO_2Me	
1-203	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	SO_2Me	
1-204	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-205	$CH_2O(CH_2)_2OMe$	c-Pr	1	SO_2Me	
1-206	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	SO_2Me	
1-207	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	SO_2Me	
1-208	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	SO_2Me	
1-209	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	SO_2Me	
1-210	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-211	$CH_2O(CH_2)_2OMe$	c-Pr	2	SO_2Me	
1-212	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	SO_2Me	
1-213	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	SO_2Me	
1-214	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	SO_2Me	
1-215	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	SO_2Me	
1-216	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-217	$CH_2O(CH_2)_2OEt$	c-Pr	0	SO_2Me	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-218	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	SO_2Me	
1-219	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	SO_2Me	
1-220	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	SO_2Me	
1-221	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	SO_2Me	
1-222	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-223	$CH_2O(CH_2)_2OEt$	c-Pr	1	SO_2Me	
1-224	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	SO_2Me	
1-225	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	SO_2Me	
1-226	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	SO_2Me	
1-227	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	SO_2Me	
1-228	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-229	$CH_2O(CH_2)_2OEt$	c-Pr	2	SO_2Me	
1-230	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	SO_2Me	
1-231	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	SO_2Me	
1-232	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	SO_2Me	
1-233	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	SO_2Me	
1-234	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-235	$CH_2O(CH_2)_3OMe$	c-Pr	0	SO_2Me	
1-236	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	SO_2Me	
1-237	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	SO_2Me	
1-238	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	SO_2Me	
1-239	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	SO_2Me	
1-240	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-241	$CH_2O(CH_2)_3OMe$	c-Pr	1	SO_2Me	
1-242	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	SO_2Me	
1-243	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	SO_2Me	
1-244	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	SO_2Me	
1-245	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	SO_2Me	
1-246	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-247	$CH_2O(CH_2)_3OMe$	c-Pr	2	SO_2Me	
1-248	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	SO_2Me	
1-249	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	SO_2Me	
1-250	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	SO_2Me	
1-251	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	SO_2Me	
1-252	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-253	CH_2OCH_2OMe	c-Pr	0	SO_2Me	
1-254	CH_2OCH_2OMe	CH_2-c-Pr	0	SO_2Me	
1-255	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	SO_2Me	
1-256	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	SO_2Me	
1-257	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	SO_2Me	
1-258	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-259	CH_2OCH_2OMe	c-Pr	1	SO_2Me	
1-260	CH_2OCH_2OMe	CH_2-c-Pr	1	SO_2Me	
1-261	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	SO_2Me	
1-262	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	SO_2Me	
1-263	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	SO_2Me	
1-264	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-265	CH_2OCH_2OMe	c-Pr	2	SO_2Me	
1-266	CH_2OCH_2OMe	CH_2-c-Pr	2	SO_2Me	
1-267	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	SO_2Me	
1-268	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	SO_2Me	
1-269	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	SO_2Me	
1-270	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-271	CH_2OCH_2OEt	c-Pr	0	SO_2Me	
1-272	CH_2OCH_2OEt	CH_2-c-Pr	0	SO_2Me	
1-273	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	SO_2Me	
1-274	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	SO_2Me	
1-275	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	SO_2Me	
1-276	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-277	CH_2OCH_2OEt	c-Pr	1	SO_2Me	
1-278	CH_2OCH_2OEt	CH_2-c-Pr	1	SO_2Me	
1-279	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	SO_2Me	
1-280	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	SO_2Me	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-281	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	SO_2Me	
1-282	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-283	CH_2OCH_2OEt	c-Pr	2	SO_2Me	
1-284	CH_2OCH_2OEt	CH_2-c-Pr	2	SO_2Me	
1-285	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	SO_2Me	
1-286	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	SO_2Me	
1-287	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	SO_2Me	
1-288	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-289	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	SO_2Me	
1-290	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	SO_2Me	
1-291	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	SO_2Me	
1-292	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	SO_2Me	
1-293	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	SO_2Me	
1-294	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-295	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	SO_2Me	
1-296	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	SO_2Me	
1-297	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	SO_2Me	
1-298	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	SO_2Me	
1-299	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	SO_2Me	
1-300	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-301	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	SO_2Me	
1-302	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	SO_2Me	
1-303	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	SO_2Me	
1-304	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	SO_2Me	
1-305	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	SO_2Me	
1-306	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-307	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	SO_2Me	
1-308	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	SO_2Me	
1-309	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	SO_2Me	
1-310	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	SO_2Me	
1-311	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	SO_2Me	
1-312	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-313	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	SO_2Me	
1-314	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	SO_2Me	
1-315	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	SO_2Me	
1-316	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	SO_2Me	
1-317	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	SO_2Me	
1-318	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-319	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	SO_2Me	
1-320	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	SO_2Me	
1-321	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	SO_2Me	
1-322	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	SO_2Me	
1-323	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	SO_2Me	
1-324	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-325	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	SO_2Me	
1-326	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	SO_2Me	
1-327	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	SO_2Me	
1-328	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	SO_2Me	
1-329	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	SO_2Me	
1-330	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Me	
1-331	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	SO_2Me	
1-332	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	SO_2Me	
1-333	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	SO_2Me	
1-334	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	SO_2Me	
1-335	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	SO_2Me	
1-336	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Me	
1-337	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	SO_2Me	
1-338	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	SO_2Me	
1-339	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	SO_2Me	
1-340	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	SO_2Me	
1-341	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	SO_2Me	
1-342	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Me	
1-343	Cl	c-Pr	0	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-344	Cl	CH_2-c-Pr	0	SO_2Et	
1-345	Cl	$(CH_2)_2OMe$	0	SO_2Et	
1-346	Cl	$(CH_2)_3OMe$	0	SO_2Et	
1-347	Cl	$(CH_2)_2OEt$	0	SO_2Et	
1-348	Cl	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-349	Cl	c-Pr	1	SO_2Et	
1-350	Cl	CH_2-c-Pr	1	SO_2Et	
1-351	Cl	$(CH_2)_2OMe$	1	SO_2Et	
1-352	Cl	$(CH_2)_3OMe$	1	SO_2Et	
1-353	Cl	$(CH_2)_2OEt$	1	SO_2Et	
1-354	Cl	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-355	Cl	c-Pr	2	SO_2Et	
1-356	Cl	CH_2-c-Pr	2	SO_2Et	
1-357	Cl	$(CH_2)_2OMe$	2	SO_2Et	
1-358	Cl	$(CH_2)_3OMe$	2	SO_2Et	
1-359	Cl	$(CH_2)_2OEt$	2	SO_2Et	
1-360	Cl	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-361	Br	c-Pr	0	SO_2Et	
1-362	Br	CH_2-c-Pr	0	SO_2Et	
1-363	Br	$(CH_2)_2OMe$	0	SO_2Et	
1-364	Br	$(CH_2)_3OMe$	0	SO_2Et	
1-365	Br	$(CH_2)_2OEt$	0	SO_2Et	
1-366	Br	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-367	Br	c-Pr	1	SO_2Et	
1-368	Br	CH_2-c-Pr	1	SO_2Et	
1-369	Br	$(CH_2)_2OMe$	1	SO_2Et	
1-370	Br	$(CH_2)_3OMe$	1	SO_2Et	
1-371	Br	$(CH_2)_2OEt$	1	SO_2Et	
1-372	Br	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-373	Br	c-Pr	2	SO_2Et	
1-374	Br	CH_2-c-Pr	2	SO_2Et	
1-375	Br	$(CH_2)_2OMe$	2	SO_2Et	
1-376	Br	$(CH_2)_3OMe$	2	SO_2Et	
1-377	Br	$(CH_2)_2OEt$	2	SO_2Et	
1-378	Br	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-379	Me	c-Pr	0	SO_2Et	
1-380	Me	CH_2-c-Pr	0	SO_2Et	
1-381	Me	$(CH_2)_2OMe$	0	SO_2Et	
1-382	Me	$(CH_2)_3OMe$	0	SO_2Et	
1-383	Me	$(CH_2)_2OEt$	0	SO_2Et	
1-384	Me	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-385	Me	c-Pr	1	SO_2Et	
1-386	Me	CH_2-c-Pr	1	SO_2Et	
1-387	Me	$(CH_2)_2OMe$	1	SO_2Et	
1-388	Me	$(CH_2)_3OMe$	1	SO_2Et	
1-389	Me	$(CH_2)_2OEt$	1	SO_2Et	
1-390	Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-391	Me	c-Pr	2	SO_2Et	
1-392	Me	CH_2-c-Pr	2	SO_2Et	
1-393	Me	$(CH_2)_2OMe$	2	SO_2Et	8.30 (d, 1H), 7.64 (d, 1H), 4.02-3.87 (m, 4H), 3.81 (q, 2H), 3.62 (s, 3H), 3.33 (s, 3H), 2.77 (s, 3H), 1.37 (t, 3H), 0.86-0.70 (m, 3H), 0.55-0.44 (m, 2H)
1-394	Me	$(CH_2)_3OMe$	2	SO_2Et	
1-395	Me	$(CH_2)_2OEt$	2	SO_2Et	
1-396	Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-397	Et	c-Pr	0	SO_2Et	
1-398	Et	CH_2-c-Pr	0	SO_2Et	
1-399	Et	$(CH_2)_2OMe$	0	SO_2Et	
1-400	Et	$(CH_2)_3OMe$	0	SO_2Et	
1-401	Et	$(CH_2)_2OEt$	0	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-402	Et	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-403	Et	c-Pr	1	SO_2Et	
1-404	Et	CH_2-c-Pr	1	SO_2Et	
1-405	Et	$(CH_2)_2OMe$	1	SO_2Et	
1-406	Et	$(CH_2)_3OMe$	1	SO_2Et	
1-407	Et	$(CH_2)_2OEt$	1	SO_2Et	
1-408	Et	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-409	Et	c-Pr	2	SO_2Et	
1-410	Et	CH_2-c-Pr	2	SO_2Et	
1-411	Et	$(CH_2)_2OMe$	2	SO_2Et	
1-412	Et	$(CH_2)_3OMe$	2	SO_2Et	
1-413	Et	$(CH_2)_2OEt$	2	SO_2Et	
1-414	Et	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-415	CF_3	c-Pr	0	SO_2Et	
1-416	CF_3	CH_2-c-Pr	0	SO_2Et	
1-417	CF_3	$(CH_2)_2OMe$	0	SO_2Et	
1-418	CF_3	$(CH_2)_3OMe$	0	SO_2Et	
1-419	CF_3	$(CH_2)_2OEt$	0	SO_2Et	
1-420	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-421	CF_3	c-Pr	1	SO_2Et	
1-422	CF_3	CH_2-c-Pr	1	SO_2Et	
1-423	CF_3	$(CH_2)_2OMe$	1	SO_2Et	
1-424	CF_3	$(CH_2)_3OMe$	1	SO_2Et	
1-425	CF_3	$(CH_2)_2OEt$	1	SO_2Et	
1-426	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-427	CF_3	c-Pr	2	SO_2Et	
1-428	CF_3	CH_2-c-Pr	2	SO_2Et	
1-429	CF_3	$(CH_2)_2OMe$	2	SO_2Et	
1-430	CF_3	$(CH_2)_3OMe$	2	SO_2Et	
1-431	CF_3	$(CH_2)_2OEt$	2	SO_2Et	
1-432	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-433	OMe	c-Pr	0	SO_2Et	
1-434	OMe	CH_2-c-Pr	0	SO_2Et	
1-435	OMe	$(CH_2)_2OMe$	0	SO_2Et	
1-436	OMe	$(CH_2)_3OMe$	0	SO_2Et	
1-437	OMe	$(CH_2)_2OEt$	0	SO_2Et	
1-438	OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-439	OMe	c-Pr	1	SO_2Et	
1-440	OMe	CH_2-c-Pr	1	SO_2Et	
1-441	OMe	$(CH_2)_2OMe$	1	SO_2Et	
1-442	OMe	$(CH_2)_3OMe$	1	SO_2Et	
1-443	OMe	$(CH_2)_2OEt$	1	SO_2Et	
1-444	OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-445	OMe	c-Pr	2	SO_2Et	
1-446	OMe	CH_2-c-Pr	2	SO_2Et	
1-447	OMe	$(CH_2)_2OMe$	2	SO_2Et	
1-448	OMe	$(CH_2)_3OMe$	2	SO_2Et	
1-449	OMe	$(CH_2)_2OEt$	2	SO_2Et	
1-450	OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-451	OEt	c-Pr	0	SO_2Et	
1-452	OEt	CH_2-c-Pr	0	SO_2Et	
1-453	OEt	$(CH_2)_2OMe$	0	SO_2Et	
1-454	OEt	$(CH_2)_3OMe$	0	SO_2Et	
1-455	OEt	$(CH_2)_2OEt$	0	SO_2Et	
1-456	OEt	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-457	OEt	c-Pr	1	SO_2Et	
1-458	OEt	CH_2-c-Pr	1	SO_2Et	
1-459	OEt	$(CH_2)_2OMe$	1	SO_2Et	
1-460	OEt	$(CH_2)_3OMe$	1	SO_2Et	
1-461	OEt	$(CH_2)_2OEt$	1	SO_2Et	
1-462	OEt	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-463	OEt	c-Pr	2	SO_2Et	
1-464	OEt	CH_2-c-Pr	2	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-465	OEt	$(CH_2)_2OMe$	2	SO_2Et	
1-466	OEt	$(CH_2)_3OMe$	2	SO_2Et	
1-467	OEt	$(CH_2)_2OEt$	2	SO_2Et	
1-468	OEt	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-469	NO_2	c-Pr	0	SO_2Et	
1-470	NO_2	CH_2-c-Pr	0	SO_2Et	
1-471	NO_2	$(CH_2)_2OMe$	0	SO_2Et	
1-472	NO_2	$(CH_2)_3OMe$	0	SO_2Et	
1-473	NO_2	$(CH_2)_2OEt$	0	SO_2Et	
1-474	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-475	NO_2	c-Pr	1	SO_2Et	
1-476	NO_2	CH_2-c-Pr	1	SO_2Et	
1-477	NO_2	$(CH_2)_2OMe$	1	SO_2Et	
1-478	NO_2	$(CH_2)_3OMe$	1	SO_2Et	
1-479	NO_2	$(CH_2)_2OEt$	1	SO_2Et	
1-480	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-481	NO_2	c-Pr	2	SO_2Et	
1-482	NO_2	CH_2-c-Pr	2	SO_2Et	
1-483	NO_2	$(CH_2)_2OMe$	2	SO_2Et	
1-484	NO_2	$(CH_2)_3OMe$	2	SO_2Et	
1-485	NO_2	$(CH_2)_2OEt$	2	SO_2Et	
1-486	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-487	SO_2Me	c-Pr	0	SO_2Et	
1-488	SO_2Me	CH_2-c-Pr	0	SO_2Et	
1-489	SO_2Me	$(CH_2)_2OMe$	0	SO_2Et	
1-490	SO_2Me	$(CH_2)_3OMe$	0	SO_2Et	
1-491	SO_2Me	$(CH_2)_2OEt$	0	SO_2Et	
1-492	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-493	SO_2Me	c-Pr	1	SO_2Et	
1-494	SO_2Me	CH_2-c-Pr	1	SO_2Et	
1-495	SO_2Me	$(CH_2)_2OMe$	1	SO_2Et	
1-496	SO_2Me	$(CH_2)_3OMe$	1	SO_2Et	
1-497	SO_2Me	$(CH_2)_2OEt$	1	SO_2Et	
1-498	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-499	SO_2Me	c-Pr	2	SO_2Et	
1-500	SO_2Me	CH_2-c-Pr	2	SO_2Et	
1-501	SO_2Me	$(CH_2)_2OMe$	2	SO_2Et	
1-502	SO_2Me	$(CH_2)_3OMe$	2	SO_2Et	
1-503	SO_2Me	$(CH_2)_2OEt$	2	SO_2Et	
1-504	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-505	CH_2OMe	c-Pr	0	SO_2Et	
1-506	CH_2OMe	CH_2-c-Pr	0	SO_2Et	
1-507	CH_2OMe	$(CH_2)_2OMe$	0	SO_2Et	
1-508	CH_2OMe	$(CH_2)_3OMe$	0	SO_2Et	
1-509	CH_2OMe	$(CH_2)_2OEt$	0	SO_2Et	
1-510	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-511	CH_2OMe	c-Pr	1	SO_2Et	
1-512	CH_2OMe	CH_2-c-Pr	1	SO_2Et	
1-513	CH_2OMe	$(CH_2)_2OMe$	1	SO_2Et	
1-514	CH_2OMe	$(CH_2)_3OMe$	1	SO_2Et	
1-515	CH_2OMe	$(CH_2)_2OEt$	1	SO_2Et	
1-516	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-517	CH_2OMe	c-Pr	2	SO_2Et	
1-518	CH_2OMe	CH_2-c-Pr	2	SO_2Et	
1-519	CH_2OMe	$(CH_2)_2OMe$	2	SO_2Et	
1-520	CH_2OMe	$(CH_2)_3OMe$	2	SO_2Et	
1-521	CH_2OMe	$(CH_2)_2OEt$	2	SO_2Et	
1-522	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-523	CH_2SO_2Me	c-Pr	0	SO_2Et	
1-524	CH_2SO_2Me	CH_2-c-Pr	0	SO_2Et	
1-525	CH_2SO_2Me	$(CH_2)_2OMe$	0	SO_2Et	
1-526	CH_2SO_2Me	$(CH_2)_3OMe$	0	SO_2Et	
1-527	CH_2SO_2Me	$(CH_2)_2OEt$	0	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-528	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-529	CH_2SO_2Me	c-Pr	1	SO_2Et	
1-530	CH_2SO_2Me	CH_2-c-Pr	1	SO_2Et	
1-531	CH_2SO_2Me	$(CH_2)_2OMe$	1	SO_2Et	
1-532	CH_2SO_2Me	$(CH_2)_3OMe$	1	SO_2Et	
1-533	CH_2SO_2Me	$(CH_2)_2OEt$	1	SO_2Et	
1-534	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-535	CH_2SO_2Me	c-Pr	2	SO_2Et	
1-536	CH_2SO_2Me	CH_2-c-Pr	2	SO_2Et	
1-537	CH_2SO_2Me	$(CH_2)_2OMe$	2	SO_2Et	
1-538	CH_2SO_2Me	$(CH_2)_3OMe$	2	SO_2Et	
1-539	CH_2SO_2Me	$(CH_2)_2OEt$	2	SO_2Et	
1-540	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-541	$CH_2O(CH_2)_2OMe$	c-Pr	0	SO_2Et	
1-542	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	SO_2Et	
1-543	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	SO_2Et	
1-544	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	SO_2Et	
1-545	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	SO_2Et	
1-546	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-547	$CH_2O(CH_2)_2OMe$	c-Pr	1	SO_2Et	
1-548	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	SO_2Et	
1-549	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	SO_2Et	
1-550	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	SO_2Et	
1-551	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	SO_2Et	
1-552	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-553	$CH_2O(CH_2)_2OMe$	c-Pr	2	SO_2Et	
1-554	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	SO_2Et	
1-555	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	SO_2Et	
1-556	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	SO_2Et	
1-557	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	SO_2Et	
1-558	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-559	$CH_2O(CH_2)_2OEt$	c-Pr	0	SO_2Et	
1-560	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	SO_2Et	
1-561	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	SO_2Et	
1-562	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	SO_2Et	
1-563	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	SO_2Et	
1-564	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-565	$CH_2O(CH_2)_2OEt$	c-Pr	1	SO_2Et	
1-566	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	SO_2Et	
1-567	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	SO_2Et	
1-568	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	SO_2Et	
1-569	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	SO_2Et	
1-570	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-571	$CH_2O(CH_2)_2OEt$	c-Pr	2	SO_2Et	
1-572	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	SO_2Et	
1-573	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	SO_2Et	
1-574	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	SO_2Et	
1-575	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	SO_2Et	
1-576	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-577	$CH_2O(CH_2)_3OMe$	c-Pr	0	SO_2Et	
1-578	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	SO_2Et	
1-579	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	SO_2Et	
1-580	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	SO_2Et	
1-581	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	SO_2Et	
1-582	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-583	$CH_2O(CH_2)_3OMe$	c-Pr	1	SO_2Et	
1-584	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	SO_2Et	
1-585	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	SO_2Et	
1-586	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	SO_2Et	
1-587	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	SO_2Et	
1-588	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-589	$CH_2O(CH_2)_3OMe$	c-Pr	2	SO_2Et	
1-590	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-591	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	SO_2Et	
1-592	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	SO_2Et	
1-593	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	SO_2Et	
1-594	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-595	CH_2OCH_2OMe	c-Pr	0	SO_2Et	
1-596	CH_2OCH_2OMe	CH_2-c-Pr	0	SO_2Et	
1-597	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	SO_2Et	
1-598	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	SO_2Et	
1-599	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	SO_2Et	
1-600	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-601	CH_2OCH_2OMe	c-Pr	1	SO_2Et	
1-602	CH_2OCH_2OMe	CH_2-c-Pr	1	SO_2Et	
1-603	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	SO_2Et	
1-604	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	SO_2Et	
1-605	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	SO_2Et	
1-606	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-607	CH_2OCH_2OMe	c-Pr	2	SO_2Et	
1-608	CH_2OCH_2OMe	CH_2-c-Pr	2	SO_2Et	
1-609	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	SO_2Et	
1-610	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	SO_2Et	
1-611	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	SO_2Et	
1-612	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-613	CH_2OCH_2OEt	c-Pr	0	SO_2Et	
1-614	CH_2OCH_2OEt	CH_2-c-Pr	0	SO_2Et	
1-615	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	SO_2Et	
1-616	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	SO_2Et	
1-617	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	SO_2Et	
1-618	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-619	CH_2OCH_2OEt	c-Pr	1	SO_2Et	
1-620	CH_2OCH_2OEt	CH_2-c-Pr	1	SO_2Et	
1-621	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	SO_2Et	
1-622	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	SO_2Et	
1-623	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	SO_2Et	
1-624	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-625	CH_2OCH_2OEt	c-Pr	2	SO_2Et	
1-626	CH_2OCH_2OEt	CH_2-c-Pr	2	SO_2Et	
1-627	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	SO_2Et	
1-628	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	SO_2Et	
1-629	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	SO_2Et	
1-630	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-631	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	SO_2Et	
1-632	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	SO_2Et	
1-633	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	SO_2Et	
1-634	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	SO_2Et	
1-635	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	SO_2Et	
1-636	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-637	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	SO_2Et	
1-638	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	SO_2Et	
1-639	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	SO_2Et	
1-640	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	SO_2Et	
1-641	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	SO_2Et	
1-642	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-643	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	SO_2Et	
1-644	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	SO_2Et	
1-645	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	SO_2Et	
1-646	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	SO_2Et	
1-647	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	SO_2Et	
1-648	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-649	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	SO_2Et	
1-650	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	SO_2Et	
1-651	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	SO_2Et	
1-652	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	SO_2Et	
1-653	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	SO_2Et	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-654	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-655	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	SO_2Et	
1-656	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	SO_2Et	
1-657	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	SO_2Et	
1-658	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	SO_2Et	
1-659	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	SO_2Et	
1-660	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-661	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	SO_2Et	
1-662	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	SO_2Et	
1-663	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	SO_2Et	
1-664	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	SO_2Et	
1-665	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	SO_2Et	
1-666	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-667	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	SO_2Et	
1-668	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	SO_2Et	
1-669	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	SO_2Et	
1-670	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	SO_2Et	
1-671	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	SO_2Et	
1-672	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	SO_2Et	
1-673	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	SO_2Et	
1-674	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	SO_2Et	
1-675	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	SO_2Et	
1-676	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	SO_2Et	
1-677	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	SO_2Et	
1-678	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	SO_2Et	
1-679	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	SO_2Et	
1-680	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	SO_2Et	
1-681	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	SO_2Et	
1-682	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	SO_2Et	
1-683	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	SO_2Et	
1-684	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	SO_2Et	
1-685	Cl	c-Pr	0	OMe	
1-686	Cl	CH_2-c-Pr	0	OMe	
1-687	Cl	$(CH_2)_2OMe$	0	OMe	
1-688	Cl	$(CH_2)_3OMe$	0	OMe	
1-689	Cl	$(CH_2)_2OEt$	0	OMe	
1-690	Cl	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-691	Cl	c-Pr	1	OMe	
1-692	Cl	CH_2-c-Pr	1	OMe	
1-693	Cl	$(CH_2)_2OMe$	1	OMe	
1-694	Cl	$(CH_2)_3OMe$	1	OMe	
1-695	Cl	$(CH_2)_2OEt$	1	OMe	
1-696	Cl	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-697	Cl	c-Pr	2	OMe	
1-698	Cl	CH_2-c-Pr	2	OMe	
1-699	Cl	$(CH_2)_2OMe$	2	OMe	
1-700	Cl	$(CH_2)_3OMe$	2	OMe	
1-701	Cl	$(CH_2)_2OEt$	2	OMe	
1-702	Cl	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-703	Br	c-Pr	0	OMe	
1-704	Br	CH_2-c-Pr	0	OMe	
1-705	Br	$(CH_2)_2OMe$	0	OMe	
1-706	Br	$(CH_2)_3OMe$	0	OMe	
1-707	Br	$(CH_2)_2OEt$	0	OMe	
1-708	Br	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-709	Br	c-Pr	1	OMe	
1-710	Br	CH_2-c-Pr	1	OMe	
1-711	Br	$(CH_2)_2OMe$	1	OMe	
1-712	Br	$(CH_2)_3OMe$	1	OMe	
1-713	Br	$(CH_2)_2OEt$	1	OMe	
1-714	Br	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-715	Br	c-Pr	2	OMe	
1-716	Br	CH_2-c-Pr	2	OMe	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-717	Br	$(CH_2)_2OMe$	2	OMe	
1-718	Br	$(CH_2)_3OMe$	2	OMe	
1-719	Br	$(CH_2)_2OEt$	2	OMe	
1-720	Br	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-721	Me	c-Pr	0	OMe	
1-722	Me	CH_2-c-Pr	0	OMe	
1-723	Me	$(CH_2)_2OMe$	0	OMe	
1-724	Me	$(CH_2)_3OMe$	0	OMe	
1-725	Me	$(CH_2)_2OEt$	0	OMe	
1-726	Me	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-727	Me	c-Pr	1	OMe	
1-728	Me	CH_2-c-Pr	1	OMe	
1-729	Me	$(CH_2)_2OMe$	1	OMe	
1-730	Me	$(CH_2)_3OMe$	1	OMe	
1-731	Me	$(CH_2)_2OEt$	1	OMe	
1-732	Me	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-733	Me	c-Pr	2	OMe	
1-734	Me	CH_2-c-Pr	2	OMe	
1-735	Me	$(CH_2)_2OMe$	2	OMe	
1-736	Me	$(CH_2)_3OMe$	2	OMe	
1-737	Me	$(CH_2)_2OEt$	2	OMe	
1-738	Me	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-739	Et	c-Pr	0	OMe	
1-740	Et	CH_2-c-Pr	0	OMe	
1-741	Et	$(CH_2)_2OMe$	0	OMe	
1-742	Et	$(CH_2)_3OMe$	0	OMe	
1-743	Et	$(CH_2)_2OEt$	0	OMe	
1-744	Et	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-745	Et	c-Pr	1	OMe	
1-746	Et	CH_2-c-Pr	1	OMe	
1-747	Et	$(CH_2)_2OMe$	1	OMe	
1-748	Et	$(CH_2)_3OMe$	1	OMe	
1-749	Et	$(CH_2)_2OEt$	1	OMe	
1-750	Et	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-751	Et	c-Pr	2	OMe	
1-752	Et	CH_2-c-Pr	2	OMe	
1-753	Et	$(CH_2)_2OMe$	2	OMe	
1-754	Et	$(CH_2)_3OMe$	2	OMe	
1-755	Et	$(CH_2)_2OEt$	2	OMe	
1-756	Et	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-757	CF_3	c-Pr	0	OMe	
1-758	CF_3	CH_2-c-Pr	0	OMe	
1-759	CF_3	$(CH_2)_2OMe$	0	OMe	
1-760	CF_3	$(CH_2)_3OMe$	0	OMe	
1-761	CF_3	$(CH_2)_2OEt$	0	OMe	
1-762	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-763	CF_3	c-Pr	1	OMe	
1-764	CF_3	CH_2-c-Pr	1	OMe	
1-765	CF_3	$(CH_2)_2OMe$	1	OMe	
1-766	CF_3	$(CH_2)_3OMe$	1	OMe	
1-767	CF_3	$(CH_2)_2OEt$	1	OMe	
1-768	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-769	CF_3	c-Pr	2	OMe	
1-770	CF_3	CH_2-c-Pr	2	OMe	
1-771	CF_3	$(CH_2)_2OMe$	2	OMe	
1-772	CF_3	$(CH_2)_3OMe$	2	OMe	
1-773	CF_3	$(CH_2)_2OEt$	2	OMe	
1-774	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-775	OMe	c-Pr	0	OMe	
1-776	OMe	CH_2-c-Pr	0	OMe	
1-777	OMe	$(CH_2)_2OMe$	0	OMe	
1-778	OMe	$(CH_2)_3OMe$	0	OMe	
1-779	OMe	$(CH_2)_2OEt$	0	OMe	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-780	OMe	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-781	OMe	c-Pr	1	OMe	
1-782	OMe	CH_2-c-Pr	1	OMe	
1-783	OMe	$(CH_2)_2OMe$	1	OMe	
1-784	OMe	$(CH_2)_3OMe$	1	OMe	
1-785	OMe	$(CH_2)_2OEt$	1	OMe	
1-786	OMe	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-787	OMe	c-Pr	2	OMe	
1-788	OMe	CH_2-c-Pr	2	OMe	
1-789	OMe	$(CH_2)_2OMe$	2	OMe	
1-790	OMe	$(CH_2)_3OMe$	2	OMe	
1-791	OMe	$(CH_2)_2OEt$	2	OMe	
1-792	OMe	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-793	OEt	c-Pr	0	OMe	
1-794	OEt	CH_2-c-Pr	0	OMe	
1-795	OEt	$(CH_2)_2OMe$	0	OMe	
1-796	OEt	$(CH_2)_3OMe$	0	OMe	
1-797	OEt	$(CH_2)_2OEt$	0	OMe	
1-798	OEt	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-799	OEt	c-Pr	1	OMe	
1-800	OEt	CH_2-c-Pr	1	OMe	
1-801	OEt	$(CH_2)_2OMe$	1	OMe	
1-802	OEt	$(CH_2)_3OMe$	1	OMe	
1-803	OEt	$(CH_2)_2OEt$	1	OMe	
1-804	OEt	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-805	OEt	c-Pr	2	OMe	
1-806	OEt	CH_2-c-Pr	2	OMe	
1-807	OEt	$(CH_2)_2OMe$	2	OMe	
1-808	OEt	$(CH_2)_3OMe$	2	OMe	
1-809	OEt	$(CH_2)_2OEt$	2	OMe	
1-810	OEt	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-811	NO_2	c-Pr	0	OMe	
1-812	NO_2	CH_2-c-Pr	0	OMe	
1-813	NO_2	$(CH_2)_2OMe$	0	OMe	
1-814	NO_2	$(CH_2)_3OMe$	0	OMe	
1-815	NO_2	$(CH_2)_2OEt$	0	OMe	
1-816	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-817	NO_2	c-Pr	1	OMe	
1-818	NO_2	CH_2-c-Pr	1	OMe	
1-819	NO_2	$(CH_2)_2OMe$	1	OMe	
1-820	NO_2	$(CH_2)_3OMe$	1	OMe	
1-821	NO_2	$(CH_2)_2OEt$	1	OMe	
1-822	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-823	NO_2	c-Pr	2	OMe	
1-824	NO_2	CH_2-c-Pr	2	OMe	
1-825	NO_2	$(CH_2)_2OMe$	2	OMe	
1-826	NO_2	$(CH_2)_3OMe$	2	OMe	
1-827	NO_2	$(CH_2)_2OEt$	2	OMe	
1-828	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-829	SO_2Me	c-Pr	0	OMe	
1-830	SO_2Me	CH_2-c-Pr	0	OMe	
1-831	SO_2Me	$(CH_2)_2OMe$	0	OMe	
1-832	SO_2Me	$(CH_2)_3OMe$	0	OMe	
1-833	SO_2Me	$(CH_2)_2OEt$	0	OMe	
1-834	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-835	SO_2Me	c-Pr	1	OMe	
1-836	SO_2Me	CH_2-c-Pr	1	OMe	
1-837	SO_2Me	$(CH_2)_2OMe$	1	OMe	
1-838	SO_2Me	$(CH_2)_3OMe$	1	OMe	
1-839	SO_2Me	$(CH_2)_2OEt$	1	OMe	
1-840	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-841	SO_2Me	c-Pr	2	OMe	
1-842	SO_2Me	CH_2-c-Pr	2	OMe	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-843	SO_2Me	$(CH_2)_2OMe$	2	OMe	
1-844	SO_2Me	$(CH_2)_3OMe$	2	OMe	
1-845	SO_2Me	$(CH_2)_2OEt$	2	OMe	
1-846	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-847	CH_2OMe	c-Pr	0	OMe	
1-848	CH_2OMe	CH_2-c-Pr	0	OMe	
1-849	CH_2OMe	$(CH_2)_2OMe$	0	OMe	
1-850	CH_2OMe	$(CH_2)_3OMe$	0	OMe	
1-851	CH_2OMe	$(CH_2)_2OEt$	0	OMe	
1-852	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-853	CH_2OMe	c-Pr	1	OMe	
1-854	CH_2OMe	CH_2-c-Pr	1	OMe	
1-855	CH_2OMe	$(CH_2)_2OMe$	1	OMe	
1-856	CH_2OMe	$(CH_2)_3OMe$	1	OMe	
1-857	CH_2OMe	$(CH_2)_2OEt$	1	OMe	
1-858	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-859	CH_2OMe	c-Pr	2	OMe	
1-860	CH_2OMe	CH_2-c-Pr	2	OMe	
1-861	CH_2OMe	$(CH_2)_2OMe$	2	OMe	
1-862	CH_2OMe	$(CH_2)_3OMe$	2	OMe	
1-863	CH_2OMe	$(CH_2)_2OEt$	2	OMe	
1-864	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-865	CH_2SO_2Me	c-Pr	0	OMe	
1-866	CH_2SO_2Me	CH_2-c-Pr	0	OMe	
1-867	CH_2SO_2Me	$(CH_2)_2OMe$	0	OMe	
1-868	CH_2SO_2Me	$(CH_2)_3OMe$	0	OMe	
1-869	CH_2SO_2Me	$(CH_2)_2OEt$	0	OMe	
1-870	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-871	CH_2SO_2Me	c-Pr	1	OMe	
1-872	CH_2SO_2Me	CH_2-c-Pr	1	OMe	
1-873	CH_2SO_2Me	$(CH_2)_2OMe$	1	OMe	
1-874	CH_2SO_2Me	$(CH_2)_3OMe$	1	OMe	
1-875	CH_2SO_2Me	$(CH_2)_2OEt$	1	OMe	
1-876	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-877	CH_2SO_2Me	c-Pr	2	OMe	
1-878	CH_2SO_2Me	CH_2-c-Pr	2	OMe	
1-879	CH_2SO_2Me	$(CH_2)_2OMe$	2	OMe	
1-880	CH_2SO_2Me	$(CH_2)_3OMe$	2	OMe	
1-881	CH_2SO_2Me	$(CH_2)_2OEt$	2	OMe	
1-882	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-883	$CH_2O(CH_2)_2OMe$	c-Pr	0	OMe	
1-884	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	OMe	
1-885	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	OMe	
1-886	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	OMe	
1-887	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	OMe	
1-888	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-889	$CH_2O(CH_2)_2OMe$	c-Pr	1	OMe	
1-890	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	OMe	
1-891	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	OMe	
1-892	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	OMe	
1-893	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	OMe	
1-894	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-895	$CH_2O(CH_2)_2OMe$	c-Pr	2	OMe	
1-896	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	OMe	
1-897	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	OMe	
1-898	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	OMe	
1-899	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	OMe	
1-900	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-901	$CH_2O(CH_2)_2OEt$	c-Pr	0	OMe	
1-902	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	OMe	
1-903	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	OMe	
1-904	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	OMe	
1-905	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	OMe	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-906	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-907	$CH_2O(CH_2)_2OEt$	c-Pr	1	OMe	
1-908	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	OMe	
1-909	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	OMe	
1-910	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	OMe	
1-911	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	OMe	
1-912	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-913	$CH_2O(CH_2)_2OEt$	c-Pr	2	OMe	
1-914	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	OMe	
1-915	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	OMe	
1-916	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	OMe	
1-917	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	OMe	
1-918	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-919	$CH_2O(CH_2)_3OMe$	c-Pr	0	OMe	
1-920	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	OMe	
1-921	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	OMe	
1-922	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	OMe	
1-923	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	OMe	
1-924	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-925	$CH_2O(CH_2)_3OMe$	c-Pr	1	OMe	
1-926	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	OMe	
1-927	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	OMe	
1-928	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	OMe	
1-929	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	OMe	
1-930	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-931	$CH_2O(CH_2)_3OMe$	c-Pr	2	OMe	
1-932	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	OMe	
1-933	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	OMe	
1-934	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	OMe	
1-935	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	OMe	
1-936	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-937	CH_2OCH_2OMe	c-Pr	0	OMe	
1-938	CH_2OCH_2OMe	CH_2-c-Pr	0	OMe	
1-939	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	OMe	
1-940	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	OMe	
1-941	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	OMe	
1-942	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-943	CH_2OCH_2OMe	c-Pr	1	OMe	
1-944	CH_2OCH_2OMe	CH_2-c-Pr	1	OMe	
1-945	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	OMe	
1-946	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	OMe	
1-947	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	OMe	
1-948	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-949	CH_2OCH_2OMe	c-Pr	2	OMe	
1-950	CH_2OCH_2OMe	CH_2-c-Pr	2	OMe	
1-951	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	OMe	
1-952	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	OMe	
1-953	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	OMe	
1-954	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-955	CH_2OCH_2OEt	c-Pr	0	OMe	
1-956	CH_2OCH_2OEt	CH_2-c-Pr	0	OMe	
1-957	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	OMe	
1-958	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	OMe	
1-959	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	OMe	
1-960	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-961	CH_2OCH_2OEt	c-Pr	1	OMe	
1-962	CH_2OCH_2OEt	CH_2-c-Pr	1	OMe	
1-963	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	OMe	
1-964	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	OMe	
1-965	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	OMe	
1-966	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-967	CH_2OCH_2OEt	c-Pr	2	OMe	
1-968	CH_2OCH_2OEt	CH_2-c-Pr	2	OMe	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-969	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	OMe	
1-970	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	OMe	
1-971	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	OMe	
1-972	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-973	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	OMe	
1-974	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	OMe	
1-975	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	OMe	
1-976	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	OMe	
1-977	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	OMe	
1-978	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-979	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	OMe	
1-980	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	OMe	
1-981	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	OMe	
1-982	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	OMe	
1-983	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	OMe	
1-984	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-985	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	OMe	
1-986	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	OMe	
1-987	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	OMe	
1-988	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	OMe	
1-989	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	OMe	
1-990	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-991	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	OMe	
1-992	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	OMe	
1-993	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	OMe	
1-994	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	OMe	
1-995	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	OMe	
1-996	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-997	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	OMe	
1-998	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	OMe	
1-999	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	OMe	
1-1000	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	OMe	
1-1001	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	OMe	
1-1002	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-1003	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	OMe	
1-1004	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	OMe	
1-1005	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	OMe	
1-1006	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	OMe	
1-1007	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	OMe	
1-1008	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-1009	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	OMe	
1-1010	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	OMe	
1-1011	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	OMe	
1-1012	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	OMe	
1-1013	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	OMe	
1-1014	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	OMe	
1-1015	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	OMe	
1-1016	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	OMe	
1-1017	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	OMe	
1-1018	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	OMe	
1-1019	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	OMe	
1-1020	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	OMe	
1-1021	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	OMe	
1-1022	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	OMe	
1-1023	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	OMe	
1-1024	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	OMe	
1-1025	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	OMe	
1-1026	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	OMe	
1-1027	Cl	c-Pr	0	F	
1-1028	Cl	CH_2-c-Pr	0	F	
1-1029	Cl	$(CH_2)_2OMe$	0	F	
1-1030	Cl	$(CH_2)_3OMe$	0	F	
1-1031	Cl	$(CH_2)_2OEt$	0	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1032	Cl	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1033	Cl	c-Pr	1	F	
1-1034	Cl	CH_2-c-Pr	1	F	
1-1035	Cl	$(CH_2)_2OMe$	1	F	
1-1036	Cl	$(CH_2)_3OMe$	1	F	
1-1037	Cl	$(CH_2)_2OEt$	1	F	
1-1038	Cl	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1039	Cl	c-Pr	2	F	
1-1040	Cl	CH_2-c-Pr	2	F	
1-1041	Cl	$(CH_2)_2OMe$	2	F	
1-1042	Cl	$(CH_2)_3OMe$	2	F	
1-1043	Cl	$(CH_2)_2OEt$	2	F	
1-1044	Cl	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1045	Br	c-Pr	0	F	
1-1046	Br	CH_2-c-Pr	0	F	
1-1047	Br	$(CH_2)_2OMe$	0	F	
1-1048	Br	$(CH_2)_3OMe$	0	F	
1-1049	Br	$(CH_2)_2OEt$	0	F	
1-1050	Br	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1051	Br	c-Pr	1	F	
1-1052	Br	CH_2-c-Pr	1	F	
1-1053	Br	$(CH_2)_2OMe$	1	F	
1-1054	Br	$(CH_2)_3OMe$	1	F	
1-1055	Br	$(CH_2)_2OEt$	1	F	
1-1056	Br	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1057	Br	c-Pr	2	F	
1-1058	Br	CH_2-c-Pr	2	F	
1-1059	Br	$(CH_2)_2OMe$	2	F	
1-1060	Br	$(CH_2)_3OMe$	2	F	
1-1061	Br	$(CH_2)_2OEt$	2	F	
1-1062	Br	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1063	Me	c-Pr	0	F	
1-1064	Me	CH_2-c-Pr	0	F	
1-1065	Me	$(CH_2)_2OMe$	0	F	
1-1066	Me	$(CH_2)_3OMe$	0	F	
1-1067	Me	$(CH_2)_2OEt$	0	F	
1-1068	Me	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1069	Me	c-Pr	1	F	
1-1070	Me	CH_2-c-Pr	1	F	
1-1071	Me	$(CH_2)_2OMe$	1	F	
1-1072	Me	$(CH_2)_3OMe$	1	F	
1-1073	Me	$(CH_2)_2OEt$	1	F	
1-1074	Me	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1075	Me	c-Pr	2	F	
1-1076	Me	CH_2-c-Pr	2	F	
1-1077	Me	$(CH_2)_2OMe$	2	F	
1-1078	Me	$(CH_2)_3OMe$	2	F	
1-1079	Me	$(CH_2)_2OEt$	2	F	
1-1080	Me	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1081	Et	c-Pr	0	F	
1-1082	Et	CH_2-c-Pr	0	F	
1-1083	Et	$(CH_2)_2OMe$	0	F	
1-1084	Et	$(CH_2)_3OMe$	0	F	
1-1085	Et	$(CH_2)_2OEt$	0	F	
1-1086	Et	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1087	Et	c-Pr	1	F	
1-1088	Et	CH_2-c-Pr	1	F	
1-1089	Et	$(CH_2)_2OMe$	1	F	
1-1090	Et	$(CH_2)_3OMe$	1	F	
1-1091	Et	$(CH_2)_2OEt$	1	F	
1-1092	Et	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1093	Et	c-Pr	2	F	
1-1094	Et	CH_2-c-Pr	2	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1095	Et	$(CH_2)_2OMe$	2	F	
1-1096	Et	$(CH_2)_3OMe$	2	F	
1-1097	Et	$(CH_2)_2OEt$	2	F	
1-1098	Et	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1099	CF_3	c-Pr	0	F	
1-1100	CF_3	CH_2-c-Pr	0	F	
1-1101	CF_3	$(CH_2)_2OMe$	0	F	
1-1102	CF_3	$(CH_2)_3OMe$	0	F	
1-1103	CF_3	$(CH_2)_2OEt$	0	F	
1-1104	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1105	CF_3	c-Pr	1	F	
1-1106	CF_3	CH_2-c-Pr	1	F	
1-1107	CF_3	$(CH_2)_2OMe$	1	F	
1-1108	CF_3	$(CH_2)_3OMe$	1	F	
1-1109	CF_3	$(CH_2)_2OEt$	1	F	
1-1110	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1111	CF_3	c-Pr	2	F	
1-1112	CF_3	CH_2-c-Pr	2	F	
1-1113	CF_3	$(CH_2)_2OMe$	2	F	
1-1114	CF_3	$(CH_2)_3OMe$	2	F	
1-1115	CF_3	$(CH_2)_2OEt$	2	F	
1-1116	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1117	OMe	c-Pr	0	F	
1-1118	OMe	CH_2-c-Pr	0	F	
1-1119	OMe	$(CH_2)_2OMe$	0	F	
1-1120	OMe	$(CH_2)_3OMe$	0	F	
1-1121	OMe	$(CH_2)_2OEt$	0	F	
1-1122	OMe	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1123	OMe	c-Pr	1	F	
1-1124	OMe	CH_2-c-Pr	1	F	
1-1125	OMe	$(CH_2)_2OMe$	1	F	
1-1126	OMe	$(CH_2)_3OMe$	1	F	
1-1127	OMe	$(CH_2)_2OEt$	1	F	
1-1128	OMe	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1129	OMe	c-Pr	2	F	
1-1130	OMe	CH_2-c-Pr	2	F	
1-1131	OMe	$(CH_2)_2OMe$	2	F	
1-1132	OMe	$(CH_2)_3OMe$	2	F	
1-1133	OMe	$(CH_2)_2OEt$	2	F	
1-1134	OMe	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1135	OEt	c-Pr	0	F	
1-1136	OEt	CH_2-c-Pr	0	F	
1-1137	OEt	$(CH_2)_2OMe$	0	F	
1-1138	OEt	$(CH_2)_3OMe$	0	F	
1-1139	OEt	$(CH_2)_2OEt$	0	F	
1-1140	OEt	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1141	OEt	c-Pr	1	F	
1-1142	OEt	CH_2-c-Pr	1	F	
1-1143	OEt	$(CH_2)_2OMe$	1	F	
1-1144	OEt	$(CH_2)_3OMe$	1	F	
1-1145	OEt	$(CH_2)_2OEt$	1	F	
1-1146	OEt	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1147	OEt	c-Pr	2	F	
1-1148	OEt	CH_2-c-Pr	2	F	
1-1149	OEt	$(CH_2)_2OMe$	2	F	
1-1150	OEt	$(CH_2)_3OMe$	2	F	
1-1151	OEt	$(CH_2)_2OEt$	2	F	
1-1152	OEt	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1153	NO_2	c-Pr	0	F	
1-1154	NO_2	CH_2-c-Pr	0	F	
1-1155	NO_2	$(CH_2)_2OMe$	0	F	
1-1156	NO_2	$(CH_2)_3OMe$	0	F	
1-1157	NO_2	$(CH_2)_2OEt$	0	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1158	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1159	NO_2	c-Pr	1	F	
1-1160	NO_2	CH_2-c-Pr	1	F	
1-1161	NO_2	$(CH_2)_2OMe$	1	F	
1-1162	NO_2	$(CH_2)_3OMe$	1	F	
1-1163	NO_2	$(CH_2)_2OEt$	1	F	
1-1164	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1165	NO_2	c-Pr	2	F	
1-1166	NO_2	CH_2-c-Pr	2	F	
1-1167	NO_2	$(CH_2)_2OMe$	2	F	
1-1168	NO_2	$(CH_2)_3OMe$	2	F	
1-1169	NO_2	$(CH_2)_2OEt$	2	F	
1-1170	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1171	SO_2Me	c-Pr	0	F	
1-1172	SO_2Me	CH_2-c-Pr	0	F	
1-1173	SO_2Me	$(CH_2)_2OMe$	0	F	
1-1174	SO_2Me	$(CH_2)_3OMe$	0	F	
1-1175	SO_2Me	$(CH_2)_2OEt$	0	F	
1-1176	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1177	SO_2Me	c-Pr	1	F	
1-1178	SO_2Me	CH_2-c-Pr	1	F	
1-1179	SO_2Me	$(CH_2)_2OMe$	1	F	
1-1180	SO_2Me	$(CH_2)_3OMe$	1	F	
1-1181	SO_2Me	$(CH_2)_2OEt$	1	F	
1-1182	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1183	SO_2Me	c-Pr	2	F	
1-1184	SO_2Me	CH_2-c-Pr	2	F	
1-1185	SO_2Me	$(CH_2)_2OMe$	2	F	
1-1186	SO_2Me	$(CH_2)_3OMe$	2	F	
1-1187	SO_2Me	$(CH_2)_2OEt$	2	F	
1-1188	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1189	CH_2OMe	c-Pr	0	F	
1-1190	CH_2OMe	CH_2-c-Pr	0	F	
1-1191	CH_2OMe	$(CH_2)_2OMe$	0	F	
1-1192	CH_2OMe	$(CH_2)_3OMe$	0	F	
1-1193	CH_2OMe	$(CH_2)_2OEt$	0	F	
1-1194	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1195	CH_2OMe	c-Pr	1	F	
1-1196	CH_2OMe	CH_2-c-Pr	1	F	
1-1197	CH_2OMe	$(CH_2)_2OMe$	1	F	
1-1198	CH_2OMe	$(CH_2)_3OMe$	1	F	
1-1199	CH_2OMe	$(CH_2)_2OEt$	1	F	
1-1200	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1201	CH_2OMe	c-Pr	2	F	
1-1202	CH_2OMe	CH_2-c-Pr	2	F	
1-1203	CH_2OMe	$(CH_2)_2OMe$	2	F	
1-1204	CH_2OMe	$(CH_2)_3OMe$	2	F	
1-1205	CH_2OMe	$(CH_2)_2OEt$	2	F	
1-1206	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1207	CH_2SO_2Me	c-Pr	0	F	
1-1208	CH_2SO_2Me	CH_2-c-Pr	0	F	
1-1209	CH_2SO_2Me	$(CH_2)_2OMe$	0	F	
1-1210	CH_2SO_2Me	$(CH_2)_3OMe$	0	F	
1-1211	CH_2SO_2Me	$(CH_2)_2OEt$	0	F	
1-1212	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1213	CH_2SO_2Me	c-Pr	1	F	
1-1214	CH_2SO_2Me	CH_2-c-Pr	1	F	
1-1215	CH_2SO_2Me	$(CH_2)_2OMe$	1	F	
1-1216	CH_2SO_2Me	$(CH_2)_3OMe$	1	F	
1-1217	CH_2SO_2Me	$(CH_2)_2OEt$	1	F	
1-1218	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1219	CH_2SO_2Me	c-Pr	2	F	
1-1220	CH_2SO_2Me	CH_2-c-Pr	2	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1221	CH_2SO_2Me	$(CH_2)_2OMe$	2	F	
1-1222	CH_2SO_2Me	$(CH_2)_3OMe$	2	F	
1-1223	CH_2SO_2Me	$(CH_2)_2OEt$	2	F	
1-1224	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1225	$CH_2O(CH_2)_2OMe$	c-Pr	0	F	
1-1226	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	F	
1-1227	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	F	
1-1228	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	F	
1-1229	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	F	
1-1230	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1231	$CH_2O(CH_2)_2OMe$	c-Pr	1	F	
1-1232	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	F	
1-1233	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	F	
1-1234	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	F	
1-1235	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	F	
1-1236	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1237	$CH_2O(CH_2)_2OMe$	c-Pr	2	F	
1-1238	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	F	
1-1239	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	F	
1-1240	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	F	
1-1241	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	F	
1-1242	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1243	$CH_2O(CH_2)_2OEt$	c-Pr	0	F	
1-1244	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	F	
1-1245	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	F	
1-1246	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	F	
1-1247	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	F	
1-1248	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1249	$CH_2O(CH_2)_2OEt$	c-Pr	1	F	
1-1250	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	F	
1-1251	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	F	
1-1252	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	F	
1-1253	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	F	
1-1254	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1255	$CH_2O(CH_2)_2OEt$	c-Pr	2	F	
1-1256	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	F	
1-1257	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	F	
1-1258	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	F	
1-1259	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	F	
1-1260	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1261	$CH_2O(CH_2)_3OMe$	c-Pr	0	F	
1-1262	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	F	
1-1263	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	F	
1-1264	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	F	
1-1265	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	F	
1-1266	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1267	$CH_2O(CH_2)_3OMe$	c-Pr	1	F	
1-1268	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	F	
1-1269	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	F	
1-1270	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	F	
1-1271	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	F	
1-1272	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1273	$CH_2O(CH_2)_3OMe$	c-Pr	2	F	
1-1274	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	F	
1-1275	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	F	
1-1276	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	F	
1-1277	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	F	
1-1278	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1279	CH_2OCH_2OMe	c-Pr	0	F	
1-1280	CH_2OCH_2OMe	CH_2-c-Pr	0	F	
1-1281	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	F	
1-1282	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	F	
1-1283	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1284	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1285	CH_2OCH_2OMe	c-Pr	1	F	
1-1286	CH_2OCH_2OMe	CH_2-c-Pr	1	F	
1-1287	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	F	
1-1288	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	F	
1-1289	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	F	
1-1290	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1291	CH_2OCH_2OMe	c-Pr	2	F	
1-1292	CH_2OCH_2OMe	CH_2-c-Pr	2	F	
1-1293	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	F	
1-1294	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	F	
1-1295	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	F	
1-1296	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1297	CH_2OCH_2OEt	c-Pr	0	F	
1-1298	CH_2OCH_2OEt	CH_2-c-Pr	0	F	
1-1299	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	F	
1-1300	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	F	
1-1301	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	F	
1-1302	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1303	CH_2OCH_2OEt	c-Pr	1	F	
1-1304	CH_2OCH_2OEt	CH_2-c-Pr	1	F	
1-1305	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	F	
1-1306	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	F	
1-1307	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	F	
1-1308	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1309	CH_2OCH_2OEt	c-Pr	2	F	
1-1310	CH_2OCH_2OEt	CH_2-c-Pr	2	F	
1-1311	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	F	
1-1312	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	F	
1-1313	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	F	
1-1314	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1315	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	F	
1-1316	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	F	
1-1317	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	F	
1-1318	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	F	
1-1319	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	F	
1-1320	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1321	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	F	
1-1322	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	F	
1-1323	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	F	
1-1324	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	F	
1-1325	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	F	
1-1326	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1327	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	F	
1-1328	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	F	
1-1329	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	F	
1-1330	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	F	
1-1331	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	F	
1-1332	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1333	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	F	
1-1334	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	F	
1-1335	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	F	
1-1336	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	F	
1-1337	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	F	
1-1338	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1339	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	F	
1-1340	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	F	
1-1341	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	F	
1-1342	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	F	
1-1343	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	F	
1-1344	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1345	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	F	
1-1346	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	F	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1347	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	F	
1-1348	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	F	
1-1349	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	F	
1-1350	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1351	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	F	
1-1352	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	F	
1-1353	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	F	
1-1354	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	F	
1-1355	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	F	
1-1356	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	F	
1-1357	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	F	
1-1358	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	F	
1-1359	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	F	
1-1360	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	F	
1-1361	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	F	
1-1362	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	F	
1-1363	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	F	
1-1364	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	F	
1-1365	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	F	
1-1366	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	F	
1-1367	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	F	
1-1368	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	F	
1-1369	Cl	c-Pr	0	Cl	
1-1370	Cl	CH_2-c-Pr	0	Cl	7.48 (d, 1H), 7.25 (d, 1H), 3.60 (s, 3H), 2.84 (d, 2H), 1.02-0.95 (m, 2H), 0.77 (m, 2H), 0.52-0.45 (m, 4H), 0.15 (m, 2H)
1-1371	Cl	$(CH_2)_2OMe$	0	Cl	
1-1372	Cl	$(CH_2)_3OMe$	0	Cl	
1-1373	Cl	$(CH_2)_2OEt$	0	Cl	
1-1374	Cl	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1375	Cl	c-Pr	1	Cl	
1-1376	Cl	CH_2-c-Pr	1	Cl	
1-1377	Cl	$(CH_2)_2OMe$	1	Cl	
1-1378	Cl	$(CH_2)_3OMe$	1	Cl	
1-1379	Cl	$(CH_2)_2OEt$	1	Cl	
1-1380	Cl	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1381	Cl	c-Pr	2	Cl	
1-1382	Cl	CH_2-c-Pr	2	Cl	7.62 (d, 1H), 7.44 (d, 1H), 3.61 (s, 3H), 3.38 (d, 2H), 1.15 (m, 1H), 0.97 (m, 1H), 0.79 (m, 2H), 0.68-0.52 (m, 4H), 0.28 (m, 2H)
1-1383	Cl	$(CH_2)_2OMe$	2	Cl	
1-1384	Cl	$(CH_2)_3OMe$	2	Cl	
1-1385	Cl	$(CH_2)_2OEt$	2	Cl	
1-1386	Cl	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1387	Br	c-Pr	0	Cl	
1-1388	Br	CH_2-c-Pr	0	Cl	
1-1389	Br	$(CH_2)_2OMe$	0	Cl	
1-1390	Br	$(CH_2)_3OMe$	0	Cl	
1-1391	Br	$(CH_2)_2OEt$	0	Cl	
1-1392	Br	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1393	Br	c-Pr	1	Cl	
1-1394	Br	CH_2-c-Pr	1	Cl	
1-1395	Br	$(CH_2)_2OMe$	1	Cl	
1-1396	Br	$(CH_2)_3OMe$	1	Cl	
1-1397	Br	$(CH_2)_2OEt$	1	Cl	
1-1398	Br	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1399	Br	c-Pr	2	Cl	
1-1400	Br	CH_2-c-Pr	2	Cl	
1-1401	Br	$(CH_2)_2OMe$	2	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1402	Br	$(CH_2)_3OMe$	2	Cl	
1-1403	Br	$(CH_2)_2OEt$	2	Cl	
1-1404	Br	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1405	Me	c-Pr	0	Cl	
1-1406	Me	CH_2-c-Pr	0	Cl	7.40 (d, 1H), 7.21 (d, 1H), 3.58 (s, 3H), 2.75 (d, 2H), 2.62 (s, 3H), 0.99-0.90 (m, 2H), 0.77 (m, 2H), 0.51 (m, 4H), 0.13 (m, 2H)
1-1407	Me	$(CH_2)_2OMe$	0	Cl	7.41 (d, 1H), 7.22 (d, 1H), 3.59 (s, 3H), 3.47 (t, 2H), 3.31 (s, 3H), 3.02 (t, 2H), 2.60 (s, 3H), 0.94 (m, 1H), 0.77 (m, 2H), 0.52 (m, 2H)
1-1408	Me	$(CH_2)_3OMe$	0	Cl	
1-1409	Me	$(CH_2)_2OEt$	0	Cl	
1-1410	Me	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1411	Me	c-Pr	1	Cl	
1-1412	Me	CH_2-c-Pr	1	Cl	
1-1413	Me	$(CH_2)_2OMe$	1	Cl	7.33 (s, 2H), 3.92 (m, 1H), 3.76 (m, 1H), 3.60-3.54 (m, 1H), 3.59 (s, 3H), 3.39 (s, 3H), 3.32 (m, 1H), 2.64 (s, 3H), 0.94 (m, 1H), 0.79 (m, 2H), 0.57 (m, 2H)
1-1414	Me	$(CH_2)_3OMe$	1	Cl	
1-1415	Me	$(CH_2)_2OEt$	1	Cl	
1-1416	Me	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1417	Me	c-Pr	2	Cl	
1-1418	Me	CH_2-c-Pr	2	Cl	7.51 (d, 1H), 7.41 (d, 1H), 3.60 (s, 3H), 3.37 (d, 2H), 2.77 (s, 3H), 1.08 (m, 1H), 0.88 (m, 1H), 0.78 (m, 2H), 0.62-0.51 (m, 4H), 0.26 (m, 2H)
1-1419	Me	$(CH_2)_2OMe$	2	Cl	7.51 (d, 1H), 7.39 (d, 1H), 3.83 (t, 2H), 3.71 (t, 2H), 3.59 (s, 3H), 3.22 (s, 3H), 2.72 (s, 3H), 0.88 (m, 1H), 0.78 (m, 2H), 0.54 (m, 2H)
1-1420	Me	$(CH_2)_3OMe$	2	Cl	
1-1421	Me	$(CH_2)_2OEt$	2	Cl	
1-1422	Me	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1423	Et	c-Pr	0	Cl	
1-1424	Et	CH_2-c-Pr	0	Cl	
1-1425	Et	$(CH_2)_2OMe$	0	Cl	
1-1426	Et	$(CH_2)_3OMe$	0	Cl	
1-1427	Et	$(CH_2)_2OEt$	0	Cl	
1-1428	Et	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1429	Et	c-Pr	1	Cl	
1-1430	Et	CH_2-c-Pr	1	Cl	
1-1431	Et	$(CH_2)_2OMe$	1	Cl	
1-1432	Et	$(CH_2)_3OMe$	1	Cl	
1-1433	Et	$(CH_2)_2OEt$	1	Cl	
1-1434	Et	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1435	Et	c-Pr	2	Cl	
1-1436	Et	CH_2-c-Pr	2	Cl	
1-1437	Et	$(CH_2)_2OMe$	2	Cl	
1-1438	Et	$(CH_2)_3OMe$	2	Cl	
1-1439	Et	$(CH_2)_2OEt$	2	Cl	
1-1440	Et	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1441	CF_3	c-Pr	0	Cl	
1-1442	CF_3	CH_2-c-Pr	0	Cl	
1-1443	CF_3	$(CH_2)_2OMe$	0	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1444	CF_3	$(CH_2)_3OMe$	0	Cl	
1-1445	CF_3	$(CH_2)_2OEt$	0	Cl	
1-1446	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1447	CF_3	c-Pr	1	Cl	
1-1448	CF_3	CH_2-c-Pr	1	Cl	
1-1449	CF_3	$(CH_2)_2OMe$	1	Cl	
1-1450	CF_3	$(CH_2)_3OMe$	1	Cl	
1-1451	CF_3	$(CH_2)_2OEt$	1	Cl	
1-1452	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1453	CF_3	c-Pr	2	Cl	
1-1454	CF_3	CH_2-c-Pr	2	Cl	
1-1455	CF_3	$(CH_2)_2OMe$	2	Cl	
1-1456	CF_3	$(CH_2)_3OMe$	2	Cl	
1-1457	CF_3	$(CH_2)_2OEt$	2	Cl	
1-1458	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1459	OMe	c-Pr	0	Cl	
1-1460	OMe	CH_2-c-Pr	0	Cl	
1-1461	OMe	$(CH_2)_2OMe$	0	Cl	
1-1462	OMe	$(CH_2)_3OMe$	0	Cl	
1-1463	OMe	$(CH_2)_2OEt$	0	Cl	
1-1464	OMe	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1465	OMe	c-Pr	1	Cl	
1-1466	OMe	CH_2-c-Pr	1	Cl	
1-1467	OMe	$(CH_2)_2OMe$	1	Cl	
1-1468	OMe	$(CH_2)_3OMe$	1	Cl	
1-1469	OMe	$(CH_2)_2OEt$	1	Cl	
1-1470	OMe	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1471	OMe	c-Pr	2	Cl	
1-1472	OMe	CH_2-c-Pr	2	Cl	
1-1473	OMe	$(CH_2)_2OMe$	2	Cl	
1-1474	OMe	$(CH_2)_3OMe$	2	Cl	
1-1475	OMe	$(CH_2)_2OEt$	2	Cl	
1-1476	OMe	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1477	OEt	c-Pr	0	Cl	
1-1478	OEt	CH_2-c-Pr	0	Cl	
1-1479	OEt	$(CH_2)_2OMe$	0	Cl	
1-1480	OEt	$(CH_2)_3OMe$	0	Cl	
1-1481	OEt	$(CH_2)_2OEt$	0	Cl	
1-1482	OEt	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1483	OEt	c-Pr	1	Cl	
1-1484	OEt	CH_2-c-Pr	1	Cl	
1-1485	OEt	$(CH_2)_2OMe$	1	Cl	
1-1486	OEt	$(CH_2)_3OMe$	1	Cl	
1-1487	OEt	$(CH_2)_2OEt$	1	Cl	
1-1488	OEt	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1489	OEt	c-Pr	2	Cl	
1-1490	OEt	CH_2-c-Pr	2	Cl	
1-1491	OEt	$(CH_2)_2OMe$	2	Cl	
1-1492	OEt	$(CH_2)_3OMe$	2	Cl	
1-1493	OEt	$(CH_2)_2OEt$	2	Cl	
1-1494	OEt	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1495	NO_2	c-Pr	0	Cl	
1-1496	NO_2	CH_2-c-Pr	0	Cl	
1-1497	NO_2	$(CH_2)_2OMe$	0	Cl	
1-1498	NO_2	$(CH_2)_3OMe$	0	Cl	
1-1499	NO_2	$(CH_2)_2OEt$	0	Cl	
1-1500	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1501	NO_2	c-Pr	1	Cl	
1-1502	NO_2	CH_2-c-Pr	1	Cl	
1-1503	NO_2	$(CH_2)_2OMe$	1	Cl	
1-1504	NO_2	$(CH_2)_3OMe$	1	Cl	
1-1505	NO_2	$(CH_2)_2OEt$	1	Cl	
1-1506	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1507	NO_2	c-Pr	2	Cl	
1-1508	NO_2	CH_2-c-Pr	2	Cl	
1-1509	NO_2	$(CH_2)_2OMe$	2	Cl	
1-1510	NO_2	$(CH_2)_3OMe$	2	Cl	
1-1511	NO_2	$(CH_2)_2OEt$	2	Cl	
1-1512	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1513	SO_2Me	c-Pr	0	Cl	
1-1514	SO_2Me	CH_2-c-Pr	0	Cl	
1-1515	SO_2Me	$(CH_2)_2OMe$	0	Cl	
1-1516	SO_2Me	$(CH_2)_3OMe$	0	Cl	
1-1517	SO_2Me	$(CH_2)_2OEt$	0	Cl	
1-1518	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1519	SO_2Me	c-Pr	1	Cl	
1-1520	SO_2Me	CH_2-c-Pr	1	Cl	
1-1521	SO_2Me	$(CH_2)_2OMe$	1	Cl	
1-1522	SO_2Me	$(CH_2)_3OMe$	1	Cl	
1-1523	SO_2Me	$(CH_2)_2OEt$	1	Cl	
1-1524	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1525	SO_2Me	c-Pr	2	Cl	
1-1526	SO_2Me	CH_2-c-Pr	2	Cl	
1-1527	SO_2Me	$(CH_2)_2OMe$	2	Cl	
1-1528	SO_2Me	$(CH_2)_3OMe$	2	Cl	
1-1529	SO_2Me	$(CH_2)_2OEt$	2	Cl	
1-1530	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1531	CH_2OMe	c-Pr	0	Cl	
1-1532	CH_2OMe	CH_2-c-Pr	0	Cl	
1-1533	CH_2OMe	$(CH_2)_2OMe$	0	Cl	
1-1534	CH_2OMe	$(CH_2)_3OMe$	0	Cl	
1-1535	CH_2OMe	$(CH_2)_2OEt$	0	Cl	
1-1536	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1537	CH_2OMe	c-Pr	1	Cl	
1-1538	CH_2OMe	CH_2-c-Pr	1	Cl	
1-1539	CH_2OMe	$(CH_2)_2OMe$	1	Cl	
1-1540	CH_2OMe	$(CH_2)_3OMe$	1	Cl	
1-1541	CH_2OMe	$(CH_2)_2OEt$	1	Cl	
1-1542	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1543	CH_2OMe	c-Pr	2	Cl	
1-1544	CH_2OMe	CH_2-c-Pr	2	Cl	
1-1545	CH_2OMe	$(CH_2)_2OMe$	2	Cl	
1-1546	CH_2OMe	$(CH_2)_3OMe$	2	Cl	
1-1547	CH_2OMe	$(CH_2)_2OEt$	2	Cl	
1-1548	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1549	CH_2SO_2Me	c-Pr	0	Cl	
1-1550	CH_2SO_2Me	CH_2-c-Pr	0	Cl	
1-1551	CH_2SO_2Me	$(CH_2)_2OMe$	0	Cl	
1-1552	CH_2SO_2Me	$(CH_2)_3OMe$	0	Cl	
1-1553	CH_2SO_2Me	$(CH_2)_2OEt$	0	Cl	
1-1554	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1555	CH_2SO_2Me	c-Pr	1	Cl	
1-1556	CH_2SO_2Me	CH_2-c-Pr	1	Cl	
1-1557	CH_2SO_2Me	$(CH_2)_2OMe$	1	Cl	
1-1558	CH_2SO_2Me	$(CH_2)_3OMe$	1	Cl	
1-1559	CH_2SO_2Me	$(CH_2)_2OEt$	1	Cl	
1-1560	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1561	CH_2SO_2Me	c-Pr	2	Cl	
1-1562	CH_2SO_2Me	CH_2-c-Pr	2	Cl	
1-1563	CH_2SO_2Me	$(CH_2)_2OMe$	2	Cl	
1-1564	CH_2SO_2Me	$(CH_2)_3OMe$	2	Cl	
1-1565	CH_2SO_2Me	$(CH_2)_2OEt$	2	Cl	
1-1566	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1567	$CH_2O(CH_2)_2OMe$	c-Pr	0	Cl	
1-1568	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	Cl	
1-1569	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1570	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	Cl	
1-1571	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	Cl	
1-1572	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1573	$CH_2O(CH_2)_2OMe$	c-Pr	1	Cl	
1-1574	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	Cl	
1-1575	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	Cl	
1-1576	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	Cl	
1-1577	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	Cl	
1-1578	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1579	$CH_2O(CH_2)_2OMe$	c-Pr	2	Cl	
1-1580	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	Cl	
1-1581	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	Cl	
1-1582	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	Cl	
1-1583	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	Cl	
1-1584	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1585	$CH_2O(CH_2)_2OEt$	c-Pr	0	Cl	
1-1586	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	Cl	
1-1587	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	Cl	
1-1588	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	Cl	
1-1589	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	Cl	
1-1590	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1591	$CH_2O(CH_2)_2OEt$	c-Pr	1	Cl	
1-1592	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	Cl	
1-1593	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	Cl	
1-1594	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	Cl	
1-1595	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	Cl	
1-1596	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1597	$CH_2O(CH_2)_2OEt$	c-Pr	2	Cl	
1-1598	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	Cl	
1-1599	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	Cl	
1-1600	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	Cl	
1-1601	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	Cl	
1-1602	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1603	$CH_2O(CH_2)_3OMe$	c-Pr	0	Cl	
1-1604	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	Cl	
1-1605	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	Cl	
1-1606	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	Cl	
1-1607	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	Cl	
1-1608	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1609	$CH_2O(CH_2)_3OMe$	c-Pr	1	Cl	
1-1610	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	Cl	
1-1611	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	Cl	
1-1612	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	Cl	
1-1613	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	Cl	
1-1614	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1615	$CH_2O(CH_2)_3OMe$	c-Pr	2	Cl	
1-1616	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	Cl	
1-1617	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	Cl	
1-1618	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	Cl	
1-1619	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	Cl	
1-1620	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1621	CH_2OCH_2OMe	c-Pr	0	Cl	
1-1622	CH_2OCH_2OMe	CH_2-c-Pr	0	Cl	
1-1623	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	Cl	
1-1624	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	Cl	
1-1625	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	Cl	
1-1626	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1627	CH_2OCH_2OMe	c-Pr	1	Cl	
1-1628	CH_2OCH_2OMe	CH_2-c-Pr	1	Cl	
1-1629	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	Cl	
1-1630	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	Cl	
1-1631	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	Cl	
1-1632	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1633	CH_2OCH_2OMe	c-Pr	2	Cl	
1-1634	CH_2OCH_2OMe	CH_2-c-Pr	2	Cl	
1-1635	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	Cl	
1-1636	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	Cl	
1-1637	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	Cl	
1-1638	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1639	CH_2OCH_2OEt	c-Pr	0	Cl	
1-1640	CH_2OCH_2OEt	CH_2-c-Pr	0	Cl	
1-1641	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	Cl	
1-1642	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	Cl	
1-1643	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	Cl	
1-1644	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1645	CH_2OCH_2OEt	c-Pr	1	Cl	
1-1646	CH_2OCH_2OEt	CH_2-c-Pr	1	Cl	
1-1647	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	Cl	
1-1648	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	Cl	
1-1649	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	Cl	
1-1650	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1651	CH_2OCH_2OEt	c-Pr	2	Cl	
1-1652	CH_2OCH_2OEt	CH_2-c-Pr	2	Cl	
1-1653	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	Cl	
1-1654	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	Cl	
1-1655	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	Cl	
1-1656	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1657	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	Cl	
1-1658	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	Cl	
1-1659	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	Cl	
1-1660	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	Cl	
1-1661	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	Cl	
1-1662	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1663	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	Cl	
1-1664	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	Cl	
1-1665	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	Cl	
1-1666	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	Cl	
1-1667	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	Cl	
1-1668	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1669	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	Cl	
1-1670	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	Cl	
1-1671	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	Cl	
1-1672	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	Cl	
1-1673	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	Cl	
1-1674	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1675	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	Cl	
1-1676	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	Cl	
1-1677	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	Cl	
1-1678	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	Cl	
1-1679	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	Cl	
1-1680	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1681	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	Cl	
1-1682	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	Cl	
1-1683	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	Cl	
1-1684	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	Cl	
1-1685	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	Cl	
1-1686	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1687	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	Cl	
1-1688	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	Cl	
1-1689	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	Cl	
1-1690	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	Cl	
1-1691	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	Cl	
1-1692	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1693	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	Cl	
1-1694	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	Cl	
1-1695	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	Cl	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1696	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	Cl	
1-1697	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	Cl	
1-1698	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	Cl	
1-1699	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	Cl	
1-1700	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	Cl	
1-1701	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	Cl	
1-1702	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	Cl	
1-1703	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	Cl	
1-1704	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	Cl	
1-1705	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	Cl	
1-1706	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	Cl	
1-1707	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	Cl	
1-1708	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	Cl	
1-1709	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	Cl	
1-1710	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	Cl	
1-1711	Cl	c-Pr	0	Br	
1-1712	Cl	CH_2-c-Pr	0	Br	
1-1713	Cl	$(CH_2)_2OMe$	0	Br	
1-1714	Cl	$(CH_2)_3OMe$	0	Br	
1-1715	Cl	$(CH_2)_2OEt$	0	Br	
1-1716	Cl	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1717	Cl	c-Pr	1	Br	
1-1718	Cl	CH_2-c-Pr	1	Br	
1-1719	Cl	$(CH_2)_2OMe$	1	Br	
1-1720	Cl	$(CH_2)_3OMe$	1	Br	
1-1721	Cl	$(CH_2)_2OEt$	1	Br	
1-1722	Cl	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1723	Cl	c-Pr	2	Br	
1-1724	Cl	CH_2-c-Pr	2	Br	
1-1725	Cl	$(CH_2)_2OMe$	2	Br	
1-1726	Cl	$(CH_2)_3OMe$	2	Br	
1-1727	Cl	$(CH_2)_2OEt$	2	Br	
1-1728	Cl	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1729	Br	c-Pr	0	Br	
1-1730	Br	CH_2-c-Pr	0	Br	
1-1731	Br	$(CH_2)_2OMe$	0	Br	
1-1732	Br	$(CH_2)_3OMe$	0	Br	
1-1733	Br	$(CH_2)_2OEt$	0	Br	
1-1734	Br	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1735	Br	c-Pr	1	Br	
1-1736	Br	CH_2-c-Pr	1	Br	
1-1737	Br	$(CH_2)_2OMe$	1	Br	
1-1738	Br	$(CH_2)_3OMe$	1	Br	
1-1739	Br	$(CH_2)_2OEt$	1	Br	
1-1740	Br	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1741	Br	c-Pr	2	Br	
1-1742	Br	CH_2-c-Pr	2	Br	
1-1743	Br	$(CH_2)_2OMe$	2	Br	
1-1744	Br	$(CH_2)_3OMe$	2	Br	
1-1745	Br	$(CH_2)_2OEt$	2	Br	
1-1746	Br	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1747	Me	c-Pr	0	Br	
1-1748	Me	CH_2-c-Pr	0	Br	
1-1749	Me	$(CH_2)_2OMe$	0	Br	
1-1750	Me	$(CH_2)_3OMe$	0	Br	
1-1751	Me	$(CH_2)_2OEt$	0	Br	
1-1752	Me	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1753	Me	c-Pr	1	Br	
1-1754	Me	CH_2-c-Pr	1	Br	
1-1755	Me	$(CH_2)_2OMe$	1	Br	
1-1756	Me	$(CH_2)_3OMe$	1	Br	
1-1757	Me	$(CH_2)_2OEt$	1	Br	
1-1758	Me	$(CH_2)_2OCH_2$-c-Pr	1	Br	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1759	Me	c-Pr	2	Br	
1-1760	Me	CH_2-c-Pr	2	Br	
1-1761	Me	$(CH_2)_2OMe$	2	Br	
1-1762	Me	$(CH_2)_3OMe$	2	Br	
1-1763	Me	$(CH_2)_2OEt$	2	Br	
1-1764	Me	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1765	Et	c-Pr	0	Br	
1-1766	Et	CH_2-c-Pr	0	Br	
1-1767	Et	$(CH_2)_2OMe$	0	Br	
1-1768	Et	$(CH_2)_3OMe$	0	Br	
1-1769	Et	$(CH_2)_2OEt$	0	Br	
1-1770	Et	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1771	Et	c-Pr	1	Br	
1-1772	Et	CH_2-c-Pr	1	Br	
1-1773	Et	$(CH_2)_2OMe$	1	Br	
1-1774	Et	$(CH_2)_3OMe$	1	Br	
1-1775	Et	$(CH_2)_2OEt$	1	Br	
1-1776	Et	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1777	Et	c-Pr	2	Br	
1-1778	Et	CH_2-c-Pr	2	Br	
1-1779	Et	$(CH_2)_2OMe$	2	Br	
1-1780	Et	$(CH_2)_3OMe$	2	Br	
1-1781	Et	$(CH_2)_2OEt$	2	Br	
1-1782	Et	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1783	CF_3	c-Pr	0	Br	
1-1784	CF_3	CH_2-c-Pr	0	Br	
1-1785	CF_3	$(CH_2)_2OMe$	0	Br	
1-1786	CF_3	$(CH_2)_3OMe$	0	Br	
1-1787	CF_3	$(CH_2)_2OEt$	0	Br	
1-1788	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1789	CF_3	c-Pr	1	Br	
1-1790	CF_3	CH_2-c-Pr	1	Br	
1-1791	CF_3	$(CH_2)_2OMe$	1	Br	
1-1792	CF_3	$(CH_2)_3OMe$	1	Br	
1-1793	CF_3	$(CH_2)_2OEt$	1	Br	
1-1794	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1795	CF_3	c-Pr	2	Br	
1-1796	CF_3	CH_2-c-Pr	2	Br	
1-1797	CF_3	$(CH_2)_2OMe$	2	Br	
1-1798	CF_3	$(CH_2)_3OMe$	2	Br	
1-1799	CF_3	$(CH_2)_2OEt$	2	Br	
1-1800	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1801	OMe	c-Pr	0	Br	
1-1802	OMe	CH_2-c-Pr	0	Br	
1-1803	OMe	$(CH_2)_2OMe$	0	Br	
1-1804	OMe	$(CH_2)_3OMe$	0	Br	
1-1805	OMe	$(CH_2)_2OEt$	0	Br	
1-1806	OMe	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1807	OMe	c-Pr	1	Br	
1-1808	OMe	CH_2-c-Pr	1	Br	
1-1809	OMe	$(CH_2)_2OMe$	1	Br	
1-1810	OMe	$(CH_2)_3OMe$	1	Br	
1-1811	OMe	$(CH_2)_2OEt$	1	Br	
1-1812	OMe	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1813	OMe	c-Pr	2	Br	
1-1814	OMe	CH_2-c-Pr	2	Br	
1-1815	OMe	$(CH_2)_2OMe$	2	Br	
1-1816	OMe	$(CH_2)_3OMe$	2	Br	
1-1817	OMe	$(CH_2)_2OEt$	2	Br	
1-1818	OMe	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1819	OEt	c-Pr	0	Br	
1-1820	OEt	CH_2-c-Pr	0	Br	
1-1821	OEt	$(CH_2)_2OMe$	0	Br	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1822	OEt	$(CH_2)_3OMe$	0	Br	
1-1823	OEt	$(CH_2)_2OEt$	0	Br	
1-1824	OEt	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1825	OEt	c-Pr	1	Br	
1-1826	OEt	CH_2-c-Pr	1	Br	
1-1827	OEt	$(CH_2)_2OMe$	1	Br	
1-1828	OEt	$(CH_2)_3OMe$	1	Br	
1-1829	OEt	$(CH_2)_2OEt$	1	Br	
1-1830	OEt	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1831	OEt	c-Pr	2	Br	
1-1832	OEt	CH_2-c-Pr	2	Br	
1-1833	OEt	$(CH_2)_2OMe$	2	Br	
1-1834	OEt	$(CH_2)_3OMe$	2	Br	
1-1835	OEt	$(CH_2)_2OEt$	2	Br	
1-1836	OEt	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1837	NO_2	c-Pr	0	Br	
1-1838	NO_2	CH_2-c-Pr	0	Br	
1-1839	NO_2	$(CH_2)_2OMe$	0	Br	
1-1840	NO_2	$(CH_2)_3OMe$	0	Br	
1-1841	NO_2	$(CH_2)_2OEt$	0	Br	
1-1842	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1843	NO_2	c-Pr	1	Br	
1-1844	NO_2	CH_2-c-Pr	1	Br	
1-1845	NO_2	$(CH_2)_2OMe$	1	Br	
1-1846	NO_2	$(CH_2)_3OMe$	1	Br	
1-1847	NO_2	$(CH_2)_2OEt$	1	Br	
1-1848	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1849	NO_2	c-Pr	2	Br	
1-1850	NO_2	CH_2-c-Pr	2	Br	
1-1851	NO_2	$(CH_2)_2OMe$	2	Br	
1-1852	NO_2	$(CH_2)_3OMe$	2	Br	
1-1853	NO_2	$(CH_2)_2OEt$	2	Br	
1-1854	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1855	SO_2Me	c-Pr	0	Br	
1-1856	SO_2Me	CH_2-c-Pr	0	Br	
1-1857	SO_2Me	$(CH_2)_2OMe$	0	Br	
1-1858	SO_2Me	$(CH_2)_3OMe$	0	Br	
1-1859	SO_2Me	$(CH_2)_2OEt$	0	Br	
1-1860	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1861	SO_2Me	c-Pr	1	Br	
1-1862	SO_2Me	CH_2-c-Pr	1	Br	
1-1863	SO_2Me	$(CH_2)_2OMe$	1	Br	
1-1864	SO_2Me	$(CH_2)_3OMe$	1	Br	
1-1865	SO_2Me	$(CH_2)_2OEt$	1	Br	
1-1866	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1867	SO_2Me	c-Pr	2	Br	
1-1868	SO_2Me	CH_2-c-Pr	2	Br	
1-1869	SO_2Me	$(CH_2)_2OMe$	2	Br	
1-1870	SO_2Me	$(CH_2)_3OMe$	2	Br	
1-1871	SO_2Me	$(CH_2)_2OEt$	2	Br	
1-1872	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1873	CH_2OMe	c-Pr	0	Br	
1-1874	CH_2OMe	CH_2-c-Pr	0	Br	
1-1875	CH_2OMe	$(CH_2)_2OMe$	0	Br	
1-1876	CH_2OMe	$(CH_2)_3OMe$	0	Br	
1-1877	CH_2OMe	$(CH_2)_2OEt$	0	Br	
1-1878	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1879	CH_2OMe	c-Pr	1	Br	
1-1880	CH_2OMe	CH_2-c-Pr	1	Br	
1-1881	CH_2OMe	$(CH_2)_2OMe$	1	Br	
1-1882	CH_2OMe	$(CH_2)_3OMe$	1	Br	
1-1883	CH_2OMe	$(CH_2)_2OEt$	1	Br	
1-1884	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	Br	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1885	CH_2OMe	c-Pr	2	Br	
1-1886	CH_2OMe	CH_2-c-Pr	2	Br	
1-1887	CH_2OMe	$(CH_2)_2OMe$	2	Br	
1-1888	CH_2OMe	$(CH_2)_3OMe$	2	Br	
1-1889	CH_2OMe	$(CH_2)_2OEt$	2	Br	
1-1890	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1891	CH_2SO_2Me	c-Pr	0	Br	
1-1892	CH_2SO_2Me	CH_2-c-Pr	0	Br	
1-1893	CH_2SO_2Me	$(CH_2)_2OMe$	0	Br	
1-1894	CH_2SO_2Me	$(CH_2)_3OMe$	0	Br	
1-1895	CH_2SO_2Me	$(CH_2)_2OEt$	0	Br	
1-1896	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1897	CH_2SO_2Me	c-Pr	1	Br	
1-1898	CH_2SO_2Me	CH_2-c-Pr	1	Br	
1-1899	CH_2SO_2Me	$(CH_2)_2OMe$	1	Br	
1-1900	CH_2SO_2Me	$(CH_2)_3OMe$	1	Br	
1-1901	CH_2SO_2Me	$(CH_2)_2OEt$	1	Br	
1-1902	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1903	CH_2SO_2Me	c-Pr	2	Br	
1-1904	CH_2SO_2Me	CH_2-c-Pr	2	Br	
1-1905	CH_2SO_2Me	$(CH_2)_2OMe$	2	Br	
1-1906	CH_2SO_2Me	$(CH_2)_3OMe$	2	Br	
1-1907	CH_2SO_2Me	$(CH_2)_2OEt$	2	Br	
1-1908	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1909	$CH_2O(CH_2)_2OMe$	c-Pr	0	Br	
1-1910	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	Br	
1-1911	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	Br	
1-1912	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	Br	
1-1913	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	Br	
1-1914	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1915	$CH_2O(CH_2)_2OMe$	c-Pr	1	Br	
1-1916	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	Br	
1-1917	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	Br	
1-1918	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	Br	
1-1919	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	Br	
1-1920	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1921	$CH_2O(CH_2)_2OMe$	c-Pr	2	Br	
1-1922	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	Br	
1-1923	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	Br	
1-1924	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	Br	
1-1925	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	Br	
1-1926	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1927	$CH_2O(CH_2)_2OEt$	c-Pr	0	Br	
1-1928	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	Br	
1-1929	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	Br	
1-1930	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	Br	
1-1931	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	Br	
1-1932	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1933	$CH_2O(CH_2)_2OEt$	c-Pr	1	Br	
1-1934	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	Br	
1-1935	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	Br	
1-1936	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	Br	
1-1937	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	Br	
1-1938	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1939	$CH_2O(CH_2)_2OEt$	c-Pr	2	Br	
1-1940	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	Br	
1-1941	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	Br	
1-1942	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	Br	
1-1943	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	Br	
1-1944	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1945	$CH_2O(CH_2)_3OMe$	c-Pr	0	Br	
1-1946	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	Br	
1-1947	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	Br	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-1948	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	Br	
1-1949	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	Br	
1-1950	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1951	$CH_2O(CH_2)_3OMe$	c-Pr	1	Br	
1-1952	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	Br	
1-1953	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	Br	
1-1954	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	Br	
1-1955	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	Br	
1-1956	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1957	$CH_2O(CH_2)_3OMe$	c-Pr	2	Br	
1-1958	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	Br	
1-1959	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	Br	
1-1960	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	Br	
1-1961	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	Br	
1-1962	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1963	CH_2OCH_2OMe	c-Pr	0	Br	
1-1964	CH_2OCH_2OMe	CH_2-c-Pr	0	Br	
1-1965	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	Br	
1-1966	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	Br	
1-1967	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	Br	
1-1968	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1969	CH_2OCH_2OMe	c-Pr	1	Br	
1-1970	CH_2OCH_2OMe	CH_2-c-Pr	1	Br	
1-1971	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	Br	
1-1972	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	Br	
1-1973	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	Br	
1-1974	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1975	CH_2OCH_2OMe	c-Pr	2	Br	
1-1976	CH_2OCH_2OMe	CH_2-c-Pr	2	Br	
1-1977	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	Br	
1-1978	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	Br	
1-1979	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	Br	
1-1980	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1981	CH_2OCH_2OEt	c-Pr	0	Br	
1-1982	CH_2OCH_2OEt	CH_2-c-Pr	0	Br	
1-1983	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	Br	
1-1984	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	Br	
1-1985	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	Br	
1-1986	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-1987	CH_2OCH_2OEt	c-Pr	1	Br	
1-1988	CH_2OCH_2OEt	CH_2-c-Pr	1	Br	
1-1989	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	Br	
1-1990	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	Br	
1-1991	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	Br	
1-1992	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-1993	CH_2OCH_2OEt	c-Pr	2	Br	
1-1994	CH_2OCH_2OEt	CH_2-c-Pr	2	Br	
1-1995	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	Br	
1-1996	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	Br	
1-1997	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	Br	
1-1998	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-1999	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	Br	
1-2000	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	Br	
1-2001	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	Br	
1-2002	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	Br	
1-2003	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	Br	
1-2004	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-2005	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	Br	
1-2006	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	Br	
1-2007	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	Br	
1-2008	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	Br	
1-2009	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	Br	
1-2010	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	Br	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2011	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	Br	
1-2012	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	Br	
1-2013	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	Br	
1-2014	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	Br	
1-2015	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	Br	
1-2016	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-2017	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	Br	
1-2018	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	Br	
1-2019	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	Br	
1-2020	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	Br	
1-2021	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	Br	
1-2022	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-2023	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	Br	
1-2024	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	Br	
1-2025	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	Br	
1-2026	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	Br	
1-2027	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	Br	
1-2028	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-2029	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	Br	
1-2030	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	Br	
1-2031	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	Br	
1-2032	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	Br	
1-2033	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	Br	
1-2034	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-2035	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	Br	
1-2036	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	Br	
1-2037	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	Br	
1-2038	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	Br	
1-2039	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	Br	
1-2040	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	Br	
1-2041	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	Br	
1-2042	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	Br	
1-2043	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	Br	
1-2044	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	Br	
1-2045	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	Br	
1-2046	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	Br	
1-2047	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	Br	
1-2048	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	Br	
1-2049	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	Br	
1-2050	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	Br	
1-2051	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	Br	
1-2052	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	Br	
1-2053	Cl	c-Pr	0	CF_3	
1-2054	Cl	CH_2-c-Pr	0	CF_3	
1-2055	Cl	$(CH_2)_2OMe$	0	CF_3	
1-2056	Cl	$(CH_2)_3OMe$	0	CF_3	
1-2057	Cl	$(CH_2)_2OEt$	0	CF_3	
1-2058	Cl	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2059	Cl	c-Pr	1	CF_3	
1-2060	Cl	CH_2-c-Pr	1	CF_3	
1-2061	Cl	$(CH_2)_2OMe$	1	CF_3	
1-2062	Cl	$(CH_2)_3OMe$	1	CF_3	
1-2063	Cl	$(CH_2)_2OEt$	1	CF_3	
1-2064	Cl	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2065	Cl	c-Pr	2	CF_3	
1-2066	Cl	CH_2-c-Pr	2	CF_3	
1-2067	Cl	$(CH_2)_2OMe$	2	CF_3	
1-2068	Cl	$(CH_2)_3OMe$	2	CF_3	
1-2069	Cl	$(CH_2)_2OEt$	2	CF_3	
1-2070	Cl	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2071	Br	c-Pr	0	CF_3	
1-2072	Br	CH_2-c-Pr	0	CF_3	
1-2073	Br	$(CH_2)_2OMe$	0	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2074	Br	$(CH_2)_3OMe$	0	CF_3	
1-2075	Br	$(CH_2)_2OEt$	0	CF_3	
1-2076	Br	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2077	Br	c-Pr	1	CF_3	
1-2078	Br	CH_2-c-Pr	1	CF_3	
1-2079	Br	$(CH_2)_2OMe$	1	CF_3	
1-2080	Br	$(CH_2)_3OMe$	1	CF_3	
1-2081	Br	$(CH_2)_2OEt$	1	CF_3	
1-2082	Br	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2083	Br	c-Pr	2	CF_3	
1-2084	Br	CH_2-c-Pr	2	CF_3	
1-2085	Br	$(CH_2)_2OMe$	2	CF_3	
1-2086	Br	$(CH_2)_3OMe$	2	CF_3	
1-2087	Br	$(CH_2)_2OEt$	2	CF_3	
1-2088	Br	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2089	Me	c-Pr	0	CF_3	
1-2090	Me	CH_2-c-Pr	0	CF_3	
1-2091	Me	$(CH_2)_2OMe$	0	CF_3	7.68 (d, 1H), 7.39 (d, 1H), 3.61 (s, 3H), 3.52 (t, 2H), 3.32 (s, 3H), 2.91 (t, 2H), 2.64 (s, 3H), 0.90-0.83 (m, 1H), 0.76 (m, 2H), 0.47 (m, 2H)
1-2092	Me	$(CH_2)_3OMe$	0	CF_3	
1-2093	Me	$(CH_2)_2OEt$	0	CF_3	
1-2094	Me	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2095	Me	c-Pr	1	CF_3	
1-2096	Me	CH_2-c-Pr	1	CF_3	
1-2097	Me	$(CH_2)_2OMe$	1	CF_3	7.72 (d, 1H), 7.51 (d, 1H), 3.95 (dt, 1H), 3.83 (dt, 1H), 3.62-3.58 (m, 1H), 3.61 (s, 3H), 3.41 (s, 3H), 3.13 (m, 1H), 2.82 (s, 3H), 0.91-0.72 (m, 3H), 0.58 (m, 1H), 0.46 (m, 1H)
1-2098	Me	$(CH_2)_3OMe$	1	CF_3	
1-2099	Me	$(CH_2)_2OEt$	1	CF_3	
1-2100	Me	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2101	Me	c-Pr	2	CF_3	
1-2102	Me	CH_2-c-Pr	2	CF_3	
1-2103	Me	$(CH_2)_2OMe$	2	CF_3	
1-2104	Me	$(CH_2)_3OMe$	2	CF_3	
1-2105	Me	$(CH_2)_2OEt$	2	CF_3	
1-2106	Me	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2107	Et	c-Pr	0	CF_3	
1-2108	Et	CH_2-c-Pr	0	CF_3	
1-2109	Et	$(CH_2)_2OMe$	0	CF_3	
1-2110	Et	$(CH_2)_3OMe$	0	CF_3	
1-2111	Et	$(CH_2)_2OEt$	0	CF_3	
1-2112	Et	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2113	Et	c-Pr	1	CF_3	
1-2114	Et	CH_2-c-Pr	1	CF_3	
1-2115	Et	$(CH_2)_2OMe$	1	CF_3	
1-2116	Et	$(CH_2)_3OMe$	1	CF_3	
1-2117	Et	$(CH_2)_2OEt$	1	CF_3	
1-2118	Et	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2119	Et	c-Pr	2	CF_3	
1-2120	Et	CH_2-c-Pr	2	CF_3	
1-2121	Et	$(CH_2)_2OMe$	2	CF_3	
1-2122	Et	$(CH_2)_3OMe$	2	CF_3	
1-2123	Et	$(CH_2)_2OEt$	2	CF_3	
1-2124	Et	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2125	CF_3	c-Pr	0	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2126	CF_3	CH_2-c-Pr	0	CF_3	
1-2127	CF_3	$(CH_2)_2OMe$	0	CF_3	
1-2128	CF_3	$(CH_2)_3OMe$	0	CF_3	
1-2129	CF_3	$(CH_2)_2OEt$	0	CF_3	
1-2130	CF_3	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2131	CF_3	c-Pr	1	CF_3	
1-2132	CF_3	CH_2-c-Pr	1	CF_3	
1-2133	CF_3	$(CH_2)_2OMe$	1	CF_3	
1-2134	CF_3	$(CH_2)_3OMe$	1	CF_3	
1-2135	CF_3	$(CH_2)_2OEt$	1	CF_3	
1-2136	CF_3	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2137	CF_3	c-Pr	2	CF_3	
1-2138	CF_3	CH_2-c-Pr	2	CF_3	
1-2139	CF_3	$(CH_2)_2OMe$	2	CF_3	
1-2140	CF_3	$(CH_2)_3OMe$	2	CF_3	
1-2141	CF_3	$(CH_2)_2OEt$	2	CF_3	
1-2142	CF_3	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2143	OMe	c-Pr	0	CF_3	
1-2144	OMe	CH_2-c-Pr	0	CF_3	
1-2145	OMe	$(CH_2)_2OMe$	0	CF_3	
1-2146	OMe	$(CH_2)_3OMe$	0	CF_3	
1-2147	OMe	$(CH_2)_2OEt$	0	CF_3	
1-2148	OMe	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2149	OMe	c-Pr	1	CF_3	
1-2150	OMe	CH_2-c-Pr	1	CF_3	
1-2151	OMe	$(CH_2)_2OMe$	1	CF_3	
1-2152	OMe	$(CH_2)_3OMe$	1	CF_3	
1-2153	OMe	$(CH_2)_2OEt$	1	CF_3	
1-2154	OMe	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2155	OMe	c-Pr	2	CF_3	
1-2156	OMe	CH_2-c-Pr	2	CF_3	
1-2157	OMe	$(CH_2)_2OMe$	2	CF_3	
1-2158	OMe	$(CH_2)_3OMe$	2	CF_3	
1-2159	OMe	$(CH_2)_2OEt$	2	CF_3	
1-2160	OMe	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2161	OEt	c-Pr	0	CF_3	
1-2162	OEt	CH_2-c-Pr	0	CF_3	
1-2163	OEt	$(CH_2)_2OMe$	0	CF_3	
1-2164	OEt	$(CH_2)_3OMe$	0	CF_3	
1-2165	OEt	$(CH_2)_2OEt$	0	CF_3	
1-2166	OEt	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2167	OEt	c-Pr	1	CF_3	
1-2168	OEt	CH_2-c-Pr	1	CF_3	
1-2169	OEt	$(CH_2)_2OMe$	1	CF_3	
1-2170	OEt	$(CH_2)_3OMe$	1	CF_3	
1-2171	OEt	$(CH_2)_2OEt$	1	CF_3	
1-2172	OEt	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2173	OEt	c-Pr	2	CF_3	
1-2174	OEt	CH_2-c-Pr	2	CF_3	
1-2175	OEt	$(CH_2)_2OMe$	2	CF_3	
1-2176	OEt	$(CH_2)_3OMe$	2	CF_3	
1-2177	OEt	$(CH_2)_2OEt$	2	CF_3	
1-2178	OEt	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2179	NO_2	c-Pr	0	CF_3	
1-2180	NO_2	CH_2-c-Pr	0	CF_3	
1-2181	NO_2	$(CH_2)_2OMe$	0	CF_3	
1-2182	NO_2	$(CH_2)_3OMe$	0	CF_3	
1-2183	NO_2	$(CH_2)_2OEt$	0	CF_3	
1-2184	NO_2	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2185	NO_2	c-Pr	1	CF_3	
1-2186	NO_2	CH_2-c-Pr	1	CF_3	
1-2187	NO_2	$(CH_2)_2OMe$	1	CF_3	
1-2188	NO_2	$(CH_2)_3OMe$	1	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2189	NO_2	$(CH_2)_2OEt$	1	CF_3	
1-2190	NO_2	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2191	NO_2	c-Pr	2	CF_3	
1-2192	NO_2	CH_2-c-Pr	2	CF_3	
1-2193	NO_2	$(CH_2)_2OMe$	2	CF_3	
1-2194	NO_2	$(CH_2)_3OMe$	2	CF_3	
1-2195	NO_2	$(CH_2)_2OEt$	2	CF_3	
1-2196	NO_2	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2197	SO_2Me	c-Pr	0	CF_3	
1-2198	SO_2Me	CH_2-c-Pr	0	CF_3	
1-2199	SO_2Me	$(CH_2)_2OMe$	0	CF_3	
1-2200	SO_2Me	$(CH_2)_3OMe$	0	CF_3	
1-2201	SO_2Me	$(CH_2)_2OEt$	0	CF_3	
1-2202	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2203	SO_2Me	c-Pr	1	CF_3	
1-2204	SO_2Me	CH_2-c-Pr	1	CF_3	
1-2205	SO_2Me	$(CH_2)_2OMe$	1	CF_3	
1-2206	SO_2Me	$(CH_2)_3OMe$	1	CF_3	
1-2207	SO_2Me	$(CH_2)_2OEt$	1	CF_3	
1-2208	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2209	SO_2Me	c-Pr	2	CF_3	
1-2210	SO_2Me	CH_2-c-Pr	2	CF_3	
1-2211	SO_2Me	$(CH_2)_2OMe$	2	CF_3	
1-2212	SO_2Me	$(CH_2)_3OMe$	2	CF_3	
1-2213	SO_2Me	$(CH_2)_2OEt$	2	CF_3	
1-2214	SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2215	CH_2OMe	c-Pr	0	CF_3	
1-2216	CH_2OMe	CH_2-c-Pr	0	CF_3	
1-2217	CH_2OMe	$(CH_2)_2OMe$	0	CF_3	
1-2218	CH_2OMe	$(CH_2)_3OMe$	0	CF_3	
1-2219	CH_2OMe	$(CH_2)_2OEt$	0	CF_3	
1-2220	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2221	CH_2OMe	c-Pr	1	CF_3	
1-2222	CH_2OMe	CH_2-c-Pr	1	CF_3	
1-2223	CH_2OMe	$(CH_2)_2OMe$	1	CF_3	
1-2224	CH_2OMe	$(CH_2)_3OMe$	1	CF_3	
1-2225	CH_2OMe	$(CH_2)_2OEt$	1	CF_3	
1-2226	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2227	CH_2OMe	c-Pr	2	CF_3	
1-2228	CH_2OMe	CH_2-c-Pr	2	CF_3	
1-2229	CH_2OMe	$(CH_2)_2OMe$	2	CF_3	
1-2230	CH_2OMe	$(CH_2)_3OMe$	2	CF_3	
1-2231	CH_2OMe	$(CH_2)_2OEt$	2	CF_3	
1-2232	CH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2233	CH_2SO_2Me	c-Pr	0	CF_3	
1-2234	CH_2SO_2Me	CH_2-c-Pr	0	CF_3	
1-2235	CH_2SO_2Me	$(CH_2)_2OMe$	0	CF_3	
1-2236	CH_2SO_2Me	$(CH_2)_3OMe$	0	CF_3	
1-2237	CH_2SO_2Me	$(CH_2)_2OEt$	0	CF_3	
1-2238	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2239	CH_2SO_2Me	c-Pr	1	CF_3	
1-2240	CH_2SO_2Me	CH_2-c-Pr	1	CF_3	
1-2241	CH_2SO_2Me	$(CH_2)_2OMe$	1	CF_3	
1-2242	CH_2SO_2Me	$(CH_2)_3OMe$	1	CF_3	
1-2243	CH_2SO_2Me	$(CH_2)_2OEt$	1	CF_3	
1-2244	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2245	CH_2SO_2Me	c-Pr	2	CF_3	
1-2246	CH_2SO_2Me	CH_2-c-Pr	2	CF_3	
1-2247	CH_2SO_2Me	$(CH_2)_2OMe$	2	CF_3	
1-2248	CH_2SO_2Me	$(CH_2)_3OMe$	2	CF_3	
1-2249	CH_2SO_2Me	$(CH_2)_2OEt$	2	CF_3	
1-2250	CH_2SO_2Me	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2251	$CH_2O(CH_2)_2OMe$	c-Pr	0	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2252	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	0	CF_3	
1-2253	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	0	CF_3	
1-2254	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	0	CF_3	
1-2255	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	0	CF_3	
1-2256	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2257	$CH_2O(CH_2)_2OMe$	c-Pr	1	CF_3	
1-2258	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	1	CF_3	
1-2259	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	1	CF_3	
1-2260	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	1	CF_3	
1-2261	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	1	CF_3	
1-2262	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2263	$CH_2O(CH_2)_2OMe$	c-Pr	2	CF_3	
1-2264	$CH_2O(CH_2)_2OMe$	CH_2-c-Pr	2	CF_3	
1-2265	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OMe$	2	CF_3	
1-2266	$CH_2O(CH_2)_2OMe$	$(CH_2)_3OMe$	2	CF_3	
1-2267	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OEt$	2	CF_3	
1-2268	$CH_2O(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2269	$CH_2O(CH_2)_2OEt$	c-Pr	0	CF_3	
1-2270	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	0	CF_3	
1-2271	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	0	CF_3	
1-2272	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	0	CF_3	
1-2273	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	0	CF_3	
1-2274	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2275	$CH_2O(CH_2)_2OEt$	c-Pr	1	CF_3	
1-2276	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	1	CF_3	
1-2277	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	1	CF_3	
1-2278	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	1	CF_3	
1-2279	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	1	CF_3	
1-2280	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2281	$CH_2O(CH_2)_2OEt$	c-Pr	2	CF_3	
1-2282	$CH_2O(CH_2)_2OEt$	CH_2-c-Pr	2	CF_3	
1-2283	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OMe$	2	CF_3	
1-2284	$CH_2O(CH_2)_2OEt$	$(CH_2)_3OMe$	2	CF_3	
1-2285	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OEt$	2	CF_3	
1-2286	$CH_2O(CH_2)_2OEt$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2287	$CH_2O(CH_2)_3OMe$	c-Pr	0	CF_3	
1-2288	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	0	CF_3	
1-2289	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	0	CF_3	
1-2290	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	0	CF_3	
1-2291	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	0	CF_3	
1-2292	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2293	$CH_2O(CH_2)_3OMe$	c-Pr	1	CF_3	
1-2294	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	1	CF_3	
1-2295	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	1	CF_3	
1-2296	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	1	CF_3	
1-2297	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	1	CF_3	
1-2298	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2299	$CH_2O(CH_2)_3OMe$	c-Pr	2	CF_3	
1-2300	$CH_2O(CH_2)_3OMe$	CH_2-c-Pr	2	CF_3	
1-2301	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OMe$	2	CF_3	
1-2302	$CH_2O(CH_2)_3OMe$	$(CH_2)_3OMe$	2	CF_3	
1-2303	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OEt$	2	CF_3	
1-2304	$CH_2O(CH_2)_3OMe$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2305	CH_2OCH_2OMe	c-Pr	0	CF_3	
1-2306	CH_2OCH_2OMe	CH_2-c-Pr	0	CF_3	
1-2307	CH_2OCH_2OMe	$(CH_2)_2OMe$	0	CF_3	
1-2308	CH_2OCH_2OMe	$(CH_2)_3OMe$	0	CF_3	
1-2309	CH_2OCH_2OMe	$(CH_2)_2OEt$	0	CF_3	
1-2310	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2311	CH_2OCH_2OMe	c-Pr	1	CF_3	
1-2312	CH_2OCH_2OMe	CH_2-c-Pr	1	CF_3	
1-2313	CH_2OCH_2OMe	$(CH_2)_2OMe$	1	CF_3	
1-2314	CH_2OCH_2OMe	$(CH_2)_3OMe$	1	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2315	CH_2OCH_2OMe	$(CH_2)_2OEt$	1	CF_3	
1-2316	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2317	CH_2OCH_2OMe	c-Pr	2	CF_3	
1-2318	CH_2OCH_2OMe	CH_2-c-Pr	2	CF_3	
1-2319	CH_2OCH_2OMe	$(CH_2)_2OMe$	2	CF_3	
1-2320	CH_2OCH_2OMe	$(CH_2)_3OMe$	2	CF_3	
1-2321	CH_2OCH_2OMe	$(CH_2)_2OEt$	2	CF_3	
1-2322	CH_2OCH_2OMe	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2323	CH_2OCH_2OEt	c-Pr	0	CF_3	
1-2324	CH_2OCH_2OEt	CH_2-c-Pr	0	CF_3	
1-2325	CH_2OCH_2OEt	$(CH_2)_2OMe$	0	CF_3	
1-2326	CH_2OCH_2OEt	$(CH_2)_3OMe$	0	CF_3	
1-2327	CH_2OCH_2OEt	$(CH_2)_2OEt$	0	CF_3	
1-2328	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2329	CH_2OCH_2OEt	c-Pr	1	CF_3	
1-2330	CH_2OCH_2OEt	CH_2-c-Pr	1	CF_3	
1-2331	CH_2OCH_2OEt	$(CH_2)_2OMe$	1	CF_3	
1-2332	CH_2OCH_2OEt	$(CH_2)_3OMe$	1	CF_3	
1-2333	CH_2OCH_2OEt	$(CH_2)_2OEt$	1	CF_3	
1-2334	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2335	CH_2OCH_2OEt	c-Pr	2	CF_3	
1-2336	CH_2OCH_2OEt	CH_2-c-Pr	2	CF_3	
1-2337	CH_2OCH_2OEt	$(CH_2)_2OMe$	2	CF_3	
1-2338	CH_2OCH_2OEt	$(CH_2)_3OMe$	2	CF_3	
1-2339	CH_2OCH_2OEt	$(CH_2)_2OEt$	2	CF_3	
1-2340	CH_2OCH_2OEt	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2341	$CH_2O(CH_2)_2SO_2Me$	c-Pr	0	CF_3	
1-2342	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	0	CF_3	
1-2343	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	CF_3	
1-2344	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	CF_3	
1-2345	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	CF_3	
1-2346	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2347	$CH_2O(CH_2)_2SO_2Me$	c-Pr	1	CF_3	
1-2348	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	1	CF_3	
1-2349	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	CF_3	
1-2350	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	CF_3	
1-2351	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	CF_3	
1-2352	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2353	$CH_2O(CH_2)_2SO_2Me$	c-Pr	2	CF_3	
1-2354	$CH_2O(CH_2)_2SO_2Me$	CH_2-c-Pr	2	CF_3	
1-2355	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	CF_3	
1-2356	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	CF_3	
1-2357	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	CF_3	
1-2358	$CH_2O(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2359	$CH_2SO_2(CH_2)_2OMe$	c-Pr	0	CF_3	
1-2360	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	0	CF_3	
1-2361	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	0	CF_3	
1-2362	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	0	CF_3	
1-2363	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	0	CF_3	
1-2364	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2365	$CH_2SO_2(CH_2)_2OMe$	c-Pr	1	CF_3	
1-2366	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	1	CF_3	
1-2367	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	1	CF_3	
1-2368	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	1	CF_3	
1-2369	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	1	CF_3	
1-2370	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2371	$CH_2SO_2(CH_2)_2OMe$	c-Pr	2	CF_3	
1-2372	$CH_2SO_2(CH_2)_2OMe$	CH_2-c-Pr	2	CF_3	
1-2373	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OMe$	2	CF_3	
1-2374	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_3OMe$	2	CF_3	
1-2375	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OEt$	2	CF_3	
1-2376	$CH_2SO_2(CH_2)_2OMe$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	
1-2377	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	0	CF_3	

TABLE A-continued

Compounds according to the invention of the general formula (I) in which R^1 is methyl, R^4 is hydrogen and q is zero



No.	X	R^3	n	Y	Physical data: ^{1}H-NMR: δ[$CDCl_3$]
1-2378	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	0	CF_3	
1-2379	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	0	CF_3	
1-2380	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	0	CF_3	
1-2381	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	0	CF_3	
1-2382	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	0	CF_3	
1-2383	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	1	CF_3	
1-2384	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	1	CF_3	
1-2385	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	1	CF_3	
1-2386	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	1	CF_3	
1-2387	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	1	CF_3	
1-2388	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	1	CF_3	
1-2389	$CH_2SO_2(CH_2)_2SO_2Me$	c-Pr	2	CF_3	
1-2390	$CH_2SO_2(CH_2)_2SO_2Me$	CH_2-c-Pr	2	CF_3	
1-2391	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OMe$	2	CF_3	
1-2392	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_3OMe$	2	CF_3	
1-2393	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OEt$	2	CF_3	
1-2394	$CH_2SO_2(CH_2)_2SO_2Me$	$(CH_2)_2OCH_2$-c-Pr	2	CF_3	

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is n-propylsulfonyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is phenylsulfonyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is methoxyethylsulfonyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is benzoylmethyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is 4-methylphenylsulfonyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is thien-2-ylsulfonyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is benzoyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is 4-methylbenzoylmethyl.

Very particular preference is also given to all of the compounds of Nos. 1-1 to 1-2394 mentioned above in which R^4 is (ethylthio)carbonyl.

B. FORMULATION EXAMPLES

1. Dust

A dust is obtained by mixing 10 parts by weight of a compound of general formula (I) and 90 parts by weight of talc as inert substance and comminuting the mixture in a hammer mill.

2. Dispersible Powder

A wettable powder which is readily dispersible in water is obtained by mixing 25 parts by weight of a compound of general formula (I), 64 parts by weight of kaolin-containing quartz as inert material, 10 parts by weight of potassium lignosulfonate and 1 part by weight of sodium oleoylmethyltauride as wetter and dispersant, and grinding the mixture in a pinned-disk mill.

3. Dispersion Concentrate

A dispersion concentrate which is readily dispersible in water is obtained by mixing 20 parts by weight of a compound of general formula (I), 6 parts by weight of alkylphenol polyglycol ether (®Triton X 207), 3 parts by weight of isotridecanol polyglycol ether (8 EO) and 71 parts by weight of paraffinic mineral oil (boiling range for example approx. 255 to above 277° C.), and grinding the mixture in a ball mill to a fineness of below 5 microns.

4. Emulsifiable Concentrate

An emulsifiable concentrate is obtained from 15 parts by weight of a compound of general formula (I), 75 parts by weight of cyclohexanone as solvent and 10 parts by weight of oxethylated nonylphenol as emulsifier.

5. Water-Dispersible Granules

Water-dispersible granules are obtained by mixing
75 parts by weight of a compound of general formula (I),
10" calcium lignosulfonate,
5" sodium lauryl sulfate,
3" polyvinyl alcohol and
7" kaolin,

grinding the mixture in a pinned-disk mill and granulating the powder in a fluidized bed by spraying on water as granulation liquid.

Water-dispersible granules are also obtained by homogenizing and precomminuting, in a colloid mill,
25 parts by weight of a compound of general formula (I),
5" sodium 2,2'-dinaphthylmethane-6,6'-disulfonate,
2" sodium oleoylmethyltauride,
1" polyvinyl alcohol,
17" calcium carbonate and
50" water,
subsequently grinding the mixture in a bead mill, and atomizing and drying the resulting suspension in a spray tower by means of a single-substance nozzle.

C. BIOLOGICAL EXAMPLES

1. Pre-Emergence Herbicidal Action Against Harmful Plants

Seeds or rhizome pieces of mono- and dicotyledonous harmful plants are placed in sandy loam in pots of a diameter of 9 to 13 cm and covered with soil. The herbicides, formulated as emulsifiable concentrates or dusts, are applied to the surface of the covering soil in the form of aqueous dispersions or suspensions or emulsions at an application rate of 300 to 800 l of water/ha (converted), at a dosage of 320 grams per hectare. For further cultivation of the plants, the pots are then kept in a greenhouse under optimum conditions. The visual scoring of the damage to the harmful plants is carried out 3-4 weeks after the treatment. Here, the compounds of Nos. 1-3, 1-15, 1-44 and 1-1407 show an activity of at least 90% against *Echinochloa crus galli*. The compounds of Nos. 1-15, 1-45, 1-1407 and 1-1419 show an activity of at least 90% against *Abutilon theophrasti*. The compounds of Nos. 1-3, 1-45, 1-1406 and 1-1418 show an activity of at least 90% against *Amaranthus retroflexus*. The compounds of Nos. 1-44, 1-1406, 1-1407 and 1-1419 show an activity of at least 90% against *Stellaria media*.

2. Post-Emergence Herbicidal Action Against Harmful Plants

Seeds of mono- and dicotyledonous harmful plants are placed in sandy loam in cardboard pots, covered with soil and grown in the greenhouse under good growth conditions. Two to three weeks after sowing, the test plants are treated at the three-leaf stage. The compounds according to the invention, which are formulated as wettable powders or as emulsion concentrates, are sprayed at an application rate of 600 to 800 l of water/ha (converted) in a dosage of 80 grams per hectare onto the surface of the green plant parts. The visual scoring of the damage to the harmful plants is carried out 3-4 weeks after the treatment. Here, the compounds of Nos. 1-39, 1-40, 1-1382 and 1-2091 show an activity of at least 90% against *Echinochloa crus galli*. The compounds of Nos. 1-3, 1-44 and 1-2091 shown an activity of at least 90% against *Abutilon theophrasti*. The compounds of Nos. 1-39, 1-40 and 1-1382 show an activity of at least 90% against *Veronica persica*. The compounds of Nos. 1-3, 1-38, 1-39, 1-1406 and 1-1407 show an activity of at least 90% against *Stellaria media*.

3. Comparative Tests

To demonstrate the superiority of the compounds according to the invention over compounds known from the prior art (WO 97/41106 and WO 00/03993), the herbicidal activity against harmful plants and the damage of crop plants under the conditions mentioned above was compared in the comparative tests by the pre- and post-emergence method. The comparative tests of Tables 1 to 24 below show the superiority of the compounds according to the invention over the compounds known from the prior art.

The Abbreviations Used Denote:

Harmful Plants
ABUTH *Abutilon theophrasti* ALOMY *Alopecurus myosuroides*
AMARE *Amaranthus retroflexus* AVEFA *Avena fatua*
CHEAL *Chenopodium album* ECHCG *Echinochloa crus galli*
GALAP *Galium aparine* LOLMU *Lolium multiflorum*
MATIN *Matricaria inodora* PHBPU *Pharbitis purpureum*
POLCO *Fallopia convolvulus* STEME *Stellaria media*
VERPE *Veronica persica* VIOTR *Viola tricolor*
XANST *Xanthium strumarium*
Crop Plants
GLXMA *Glycine max* (soybeans) TRZAS *Triticum aestivum* (wheat)
ZEAMX *Zea mays* (corn)

TABLE 1

Pre-emergence activity		
Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against VIOTR
 example according to the invention No. 1-45	80	70

TABLE 1-continued

Pre-emergence activity		
Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against VIOTR
 compound known from the prior art	80	60

TABLE 2

Pre-emergence activity				
		Herbicidal activity in % against		
Compound No.	Dosage [g of a.i./ha]	PHBPU	POLCO	XANST
 example according to the invention No. 1-51	320	60	60	70
 compound known from the prior art	320	20	20	0

TABLE 3

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against PHBPU	POLCO	XANST
 example according to the invention No. 1-50	320	50	50	60
 compound known from the prior art	320	20	20	0

TABLE 4

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against MATIN	STEME	VERPE
 example according to the invention N. 1-1407	80	60	90	90
 compound known from the prior art	80	30	60	30

TABLE 5

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ABUTH	MATIN
 example according to the invention No. 1-2091	320	100	60
 compound known from the prior art	320	50	0

TABLE 6

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ABUTH	MATIN
 example according to the invention No. 1-2091	320	100	60
 compound known from the prior art	320	90	0

TABLE 7

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ABUTH	AMARE	MATIN	POLCO	VIOTR
 example according to the invention No. 1-3	320	100	100	60	50	100
 compound known from the prior art	320	70	90	0	0	50

TABLE 8

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ABUTH	AMARE	MATIN	POLCO	VIOTR
 example according to the invention No. 1-3	320	100	100	60	50	100
 compound known from the prior art	320	60	90	0	40	50

TABLE 9

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ECHCG	VIOTR	XANST
 example according to the invention No. 1-39	80	90	90	90
 compound known from the prior art	80	80	70	80

TABLE 10

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ECHCG	VIOTR	XANST
 example according to the invention No. 1-38	80	100	90	90
 compound known from the prior art	80	80	70	60

TABLE 11

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against PHBPU	POLCO	VIOTR
 example according to the invention No. 1-41	80	60	70	80
 compound known from the prior art	80	40	50	70

TABLE 12

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against VERPE	VIOTR	Damage to TRZAS
 example according to the invention No. 1-45	80	100	70	20
 compound known from the prior art	80	80	60	50

TABLE 13

Post-emergence activity							
	Dosage [g of	Herbicidal activity in % against			Damage to		
Compound No.	a.i./ha]	VERPE	VIOTR	GALAP	TRZAS	ZEAMX
 example according to the invention No. 1-51	20	90	70	50	0	0
 compound known from the prior art	20	20	20	20	80	10

TABLE 14

Pre-emergence activity						
	Dosage	Herbicidal activity in %		Damage to		
Compound No.	[g of a.i./ha]	GALAP	CHEAL	TRZAS	GLXMA
 example according to the invention No. 1-50	320	100	100	0	0
 compound known from the prior art	320	90	90	50	50

TABLE 15

Compound No.	Dosage [g of a.i./ha]	Post-emergence activity: Herbicidal activity in % against ECHCG	PHBPU	MATIN	STEME
 example according to the invention No. 1-1406	80	90	70	70	100
 compound known from the prior art	80	80	40	40	90

TABLE 16

Compound No.	Dosage [g of a.i./ha]	Post-emergence activity: Herbicidal activity in % against ECHCG	PHBPU	MATIN	STEME
 example according to the invention No. 1-1407	80	90	80	80	100
 compound known from the prior art	80	80	40	40	90

TABLE 17

Pre-emergence activity

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against AMARE	STEME	VERPE
 example according to the invention No. 1-1406	80	80	90	70
 compound known from the prior art	80	70	80	50

TABLE 18

Post-emergence activity

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ECHCG	ABUTH
 example according to the invention No. 1-2091	20	80	80
 compound known from the prior art	20	60	70

TABLE 19

Post-emergene activity					
		Dosage	Herbicidal activity in % against		
Compound No.		[g of a.i./ha]	ABUTH	MATIN	VIOTR
example according to the invention No. 1-3		80	90	70	70
compound known from the prior art		80	80	0	60

TABLE 20

Post-emergence activity					
		Dosage	Herbicidal activity in % against		
Compound No.		[g of a.i./ha]	ABUTH	MATIN	VIOTR
example according to the invention No. 1-3		80	90	70	70
compound known from the prior art		80	80	30	60

TABLE 21

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against PHBPU	STEME	VERPE
 example according to the invention No. 1-3	80	60	90	100
 compound known from the prior art	80	50	80	80

TABLE 22

Compound No.	Dosage [g of a.i./ha]	Herbicidal activity in % against ABUTH	XANST
 example according to the invention No. 1-1370	20	60	70
 compound known from the prior art	20	40	50

TABLE 23

Compound No.	Dosage [g of a.i./ha]	Post-emergence activity: Herbicidal activity in % against ALOMY	AVEFA	ECHCG	LOLMU	ABUTH
 example according to the invention No. 1-1382	80	70	50	90	60	70
 compound known from the prior art	80	20	20	30	20	60

TABLE 24

Compound No.	Dosage [g of a.i./ha]	Post-emergence activity: Herbicidal activity in % against GALAP	MATIN	STEME	VERPE	XANST
 example according to the invention No. 1-1382	80	70	50	100	90	90
 compound known from the prior art	80	40	0	80	60	70

The invention claimed is:

1. A 3-cyclopropyl-4-(3-thiobenzoyl)pyrazole of formula (I) or a salt thereof



(I)

in which

R^1 is $(C_1$-$C_4)$-alkyl,

R^2 is halogen or $(C_1$-$C_4)$-alkyl,

R^3 is $(C_3$-$C_8)$-cycloalkyl, $(C_3$-$C_8)$-cycloalkyl-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_1$-$C_6)$-haloalkyl, $(C_3$-$C_8)$-halocycloalkyl-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkenyl, $(C_2$-$C_6)$-haloalkynyl, $(C_2$-$C_6)$-nitroalkyl, phenyl, $(C_3$-$C_8)$-cycloalkoxy-$(C_1$-$C_9)$-alkyl, $(C_3$-$C_8)$-cycloalkyl-$(C_1$-$C_9)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_1$-$C_6)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkenyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-alkynyloxy-$(C_1$-$C_9)$-alkyl, $(C_1$-$C_6)$-haloalkoxy-$(C_1$-$C_9)$-alkyl, $(C_3$-$C_8)$-halocycloalkyl-$(C_1$-$C_9)$-alkoxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkenyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-haloalkynyloxy-$(C_1$-$C_9)$-alkyl, $(C_2$-$C_6)$-nitroalkoxy-$(C_1$-$C_9)$-alkyl, phenyloxy-$(C_1$-$C_9)$-alkyl, where the phenyl group may in each case be substituted by m identical or different radicals selected from the group consisting of $(C_1$-$C_3)$-alkyl, halogen, nitro, and $(C_1$-$C_3)$-alkoxy,

R^4 is hydrogen, $(C_1$-$C_6)$-alkylsulfonyl, $(C_1$-$C_4)$-alkoxy-$(C_1$-$C_6)$-alkylsulfonyl, or is phenylsulfonyl, thien-2-ylsulfonyl, (ethylthio)carbonyl, benzoyl, benzoyl-$(C_1$-$C_6)$-alkyl or benzyl, each of which is substituted by m identical or different radicals selected from the group consisting of halogen, $(C_1$-$C_4)$-alkyl and $(C_1$-$C_4)$-alkoxy,

X and Y independently of one another are hydrogen, mercapto, nitro, halogen, cyano, thiocyanato, $(C_1$-$C_6)$-alkyl, $(C_1$-$C_6)$-haloalkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-haloalkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_6)$-haloalkynyl, $(C_3$-$C_6)$-cycloalkyl, OR^5, methylsulfonylethoxymethyl, methylsulfonylethylsulfonylmethyl, methoxyethylsulfonylmethyl, $OCOR^5$, OSO_2R^5, $S(O)_nR^5$, SO_2OR^5, $SO_2N(R^5)_2$, $(C_1$-$C_3)$-alkoxy-$(C_1$-$C_3)$-alkoxy-$(C_1$-$C_3)$-alkyl, $NR^5SO_2R^5$, NR^5COR^5, $(C_1$-$C_6)$-alkyl-$S(O)_nR^5$, $(C_1$-$C_6)$-alkyl-OR^5, $(C_1$-$C_6)$-alkyl-$OCOR^5$, $(C_1$-$C_6)$-alkyl-OSO_2R^5, $(C_1$-$C_6)$-alkyl-SO_2OR^5, $(C_1$-$C_6)$-alkyl-$SO_2N(R^5)_2$ or $(C_1$-$C_6)$-alkyl-NR^5COR^5;

R^5 is hydrogen, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_6)$-cycloalkyl, phenyl or phenyl-$(C_1$-$C_6)$-alkyl, wherein, if R5 is $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl, $(C_2$-$C_6)$-alkynyl, $(C_3$-$C_6)$-cycloalkyl, phenyl or phenyl-$(C_1$-$C_6)$-alkyl, R5 can be substituted by s radicals selected from the group consisting of hydroxyl, mercapto, amino, cyano, nitro, thiocyanato, OR^6, SR^6, $N(R^6)_2$, NOR^6, $OCOR^6$, $SCOR^6$, NR^6COR^6, CO_2R^6, $COSR^6$, $CON(R^6)_2$, $(C_1$-$C_4)$-alkyliminooxy, $(C_1$-$C_4)$-alkoxyamino, $(C_1$-$C_4)$-alkylcarbonyl, $(C_1$-$C_4)$-alkoxy-$(C_2$-$C_6)$-alkoxycarbonyl and $(C_1$-$C_4)$-alkylsulfonyl;

R^6 is hydrogen, $(C_1$-$C_6)$-alkyl, $(C_2$-$C_6)$-alkenyl or $(C_2$-$C_6)$-alkynyl,

m is 0, 1, 2, 3, 4 or 5,

n is 0, 1 or 2,

q is 0, 1, 2, 3, 4 or 5,

s is 0, 1, 2 or 3,

with the proviso that R^3 is not $(C_1$-$C_6)$-haloalkyl if n is 0.

2. The 3-cyclopropyl-4-(3-thiobenzoyl)pyrazole as claimed in claim **1** wherein

R^1 is $(C_1$-$C_4)$-alkyl,

R^2 is halogen, methyl or ethyl,

R^3 is cyclopropyl, cyclopropylmethyl, cyclopropylmethoxyethyl, methoxyethyl, methoxypropyl, or ethoxyethyl,

R^4 is hydrogen, n-propylsulfonyl, phenylsulfonyl, methoxyethylsulfonyl, benzoylmethyl, benzoyl, 4-methylbenzoylmethyl, (ethylthio)carbonyl, 4-methylphenylsulfonyl, or thien-2-ylsulfonyl,

X is nitro, halogen, $(C_1$-$C_4)$-alkyl, trifluoromethyl, $(C_1$-$C_4)$-alkoxy, methylsulfonyl, methoxymethyl, methoxymethoxymethyl, ethoxyethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, methoxypropoxymethyl, methylsulfonylmethyl, methylsulfonylethoxymethyl, methoxyethylsulfonylmethyl, or methylsulfonylethylsulfonylmethyl,

Y is halogen, trifluoromethyl, $(C_1$-$C_4)$-alkoxy, methylsulfonyl or ethylsulfonyl,

n is 0, 1 or 2,

q is 0, 1 or 2.

3. The 3-cyclopropyl-4-(3-thiobenzoyl)pyrazole as claimed in claim **1** wherein

R^1 is methyl or ethyl,

R^3 is cyclopropyl, cyclopropylmethyl, cyclopropylmethoxyethyl, methoxyethyl, methoxypropyl, or ethoxyethyl,

R^4 is hydrogen, n-propylsulfonyl, phenylsulfonyl, methoxyethylsulfonyl, benzoylmethyl, benzoyl, 4-methylbenzoylmethyl, (ethylthio)carbonyl, 4-methylphenylsulfonyl, or thien-2-ylsulfonyl,

X is nitro, bromine, chlorine, fluorine, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methylsulfonyl, methoxymethyl, methoxymethoxymethyl, ethoxyethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, methoxypropoxymethyl, methylsulfonylmethyl, methylsulfonylethoxymethyl, methoxyethylsulfonylmethyl, or methylsulfonylethylsulfonylmethyl,

Y is bromine, chlorine, fluorine, trifluoromethyl, methoxy, methylsulfonyl or ethylsulfonyl,

n is 0, 1 or 2,

q is 0.

4. A herbicidal composition which comprises a herbicidally effective amount of at least one 3-cyclopropyl-4-(3-thiobenzoyl)pyrazole of formula (I) or a salt thereof as claimed in claim **1**.

5. The herbicidal composition as claimed in claim **4** as a mixture with formulation auxiliaries.

6. A method for controlling unwanted plants which comprises applying an effective amount of at least one compound of formula (I) as claimed in claim **1** to a plant or to a site of unwanted plant growth.

7. A herbicidal composition as claimed in claim **4** which is capable of controlling unwanted plants.

8. The composition as claimed in claim **7** a compound of formula (I) is capable of controlling unwanted plants in crops of useful plants.

9. The composition as claimed in claim **8** wherein the useful plants are transgenic useful plants.

* * * * *